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Hydrogen sulfide (H2S) and nitric oxide (NO) are gasotransmitters endogenously 
synthesized in the body, sharing several common roles such as vasodilation. Additionally,  
both are implicated in the disease progression of myocardial infarction (MI), which will 
be examined in this study. Furthermore, several works have investigated their interaction 
in the vascular system, but due to the disparity in outcomes observed, their relationship is 
far from clear. Thus far, the interplay between H2S and NO in the cardiovascular system 
has not been researched on. For this thesis, we aim to elucidate the roles and relationship 
of H2S and NO in MI, and shed light  on the mechanisms involved. 
In the first study, S-allylcysteine (SAC) is proposed to be a novel H2S donor as it exerted 
cardioprotection through a CSE (H2S-synthesizing enzyme)/H2S-related pathway. Pre-
treatment with SAC before MI induction lowered mortality and reduced infarct size. This 
was accompanied by an increase in left ventricular (LV) H2S production and plasma H2S 
concentration. Co-treatment with propargylglycine (PAG; CSE inhibitor) which blocked 
H2S production and lowered plasma H2S concentration was shown to abrogate the 
improvements in survival and infarct. Furthermore, SAC increased NO content in the LV 
and plasma, implicating NO involvement in SAC-mediated cardioprotection. 
In the next study, sildenafil brought about cardioprotection in MI via a NO-related 
pathway with the concomitant involvement of H2S. Sildenafil improved survival and 
attenuated infarct size. This was via a NOS/NO pathway as protein and gene expressions 
of eNOS, nNOS and iNOS were drastically upregulated with an associated enhancement 
in LV and plasma NO levels. Interestingly, sildenafil also stimulated CSE activity by 
ix 
 
increasing H2S production in the heart without affecting CSE’s protein expression, 
providing yet another evidence for the interaction between H2S and NO. 
The third study examined this crosstalk on a common platform using both donors and 
inhibitors of H2S and NO in in vivo MI models. NaHS and molsidomine attenuated 
infarct enlargement and improved survival whilst inhibitors of CSE and NOS exacerbated 
these. Crosstalk is evidently present between H2S and NO. Firstly, NaHS increased LV 
and plasma NO levels due to an upregulation of eNOS and iNOS gene and protein 
expressions. Consistent stimulation of NOS/NO pathway by NaHS may involve HIF as 
NaHS upregulated HIF-1 protein expression drastically. This will be further examined in 
the next study. Secondly, blockade of H2S production with PAG resulted in higher NO 
levels in both LV and plasma. This may be due to an increment in NOS activities as 
protein expressions were unaltered. Thirdly, NOS inhibitor L-NAME increased CSE 
protein expression, which was accompanied by an increase in LV H2S production.  
Transcription factor HIF-1 plays a pivotal role in initiating the transcription of hypoxia-
sensitive genes to improve cellular adaptation to hypoxia. During hypoxia, NaHS 
enhanced HIF-1 protein expression and transcriptional activity in cardiac cells. Moreover, 
following NaHS treatment, HIF-1 activation upregulated downstream target iNOS and 
increased NO production. Additionally, numerous studies have implicated PI3K/Akt 
participation during hypoxia to mediate HIF-1α activation. Hence, its invo lvement was 
determined. NaHS-pretreated hypoxic cells had higher Akt and eNOS phosphorylations, 
which were abrogated when PI3K inhibitors were applied, indicating PI3K/Akt pathway 
involvement in this mode of cardioprotection. Furthermore, it was determined that this 
pathway lies upstream of HIF-1α.  
x 
 
In conclus ion, this study provided evidence for a cardioprotective role of H2S and NO, 
and suppor t for their crosstalk in MI. Furthermore, we elucidated that H2S exerted its 
cardioprotection by enhancing HIF-1α activation and its downstream target iNOS with 
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1.1 GENERAL OVERVIEW 
Cardiovascular diseases (CVDs) is an umbrella term that covers an array of pathological 
conditions that affect the proper functioning of blood vessels and heart. These include 
coronary heart diseases (CHD) such as myocardial infarction (MI), cerebrovascular 
diseases such as stroke, and hypertension. The main causes of CVDs stem from tobacco 
use, physical inactivity and an unhealthy diet. According to the latest World Health 
Organization (WHO) report, CVD is the leading cause of death globally and projections 
as far as 2030 expects it to remain so. In 2005, an estimated 17.5 million people died 
from CVD, which accounts for 30% of all global deaths and CHD is responsible for 43.5% 
(7.6 million) of these deaths. By 2015, a forecasted 20 million people will die from CVDs 
(mainly from heart attacks and strokes) if current trends are maintained (WHO, 2009). As 
such, it is of paramount importance that a greater understanding in this field is pursued 
such that immediate therapeutic interventions can be engaged to reduce the prevalence of 
this chronic, aging-related condition. 
Coronary heart disease (CHD) refers to a subset of CVD that pertains to the heart and its 
vessels. In CHD, atheromatous plaques build up in coronary vessels supplying the 
myocardium, limiting oxygen and nutrients to result in myocardial damage. Of all 
cardiovascular deaths in Europe and in the United States, CHD is the single largest killer, 
accounting for more than 1 in 5 deaths (Klocke et al., 2007). The number of CHD is 
escalating in both developed and developing countries and is claiming more lives than 
cancer does annually (WHO, 2006). In the local context, ischemic heart disease is the 
second leading cause of all mortalities in Singapore, accounting for 20% of all deaths in 





1.2 MYOCARDIAL INFARCTION (MI)  
1.2.1 Pathophysiology and Management of Myocardial Infarction 
Myocardial infarction, otherwise more commonly known as heart attack is the most 
prevalent form of cardiovascular death in developed countries. It is a major cause of 
morbidity and mortality worldwide, affecting more than 7 million people annually (White 
et al., 2008). Nearly all MI deaths arise from a sudden thrombotic blockade of an 
atherosclerotic coronary artery. 
MI occurs when there is a partial or complete epicardial coronary artery occlusion from 
plaques which are vulnerable to rupture or erosion (White et al., 2008). Plaque formation 
is due to a build-up of fatty deposits on the inner walls of coronary vessels. This 
consequently diminishes microcirculatory perfusion as a result of reduced coronary artery 
flow through epicardial stenoses, as well as distal embolisation of thrombus. 
Correspondingly, part of the heart is deprived of oxygenated blood and nutrients, 
inevitably leading to necrosis of the myocardium. MI is thus the progression to 
myocardial necrosis due to the critical imbalance between demand and supply of oxygen 
to the heart (Zhu et al., 2000). 
Management of MI involves a complex interplay between rapid restoration of epicardial 
and microvascular blood flow, thwarting recurrent ischemic events through anti-
thrombotic therapies, and treatments targeted at improving cell survival to alleviate 
myocardial necrosis (White et al., 2008). Currently, the mainstream MI treatments 





et al., 2006) with adjunctive pharmacotherapies such as nitrates, beta-blockers and  
angiotensin-converting enzyme inhibitors (White et al., 2008). 
However, the prompt re-establishment of vessel patency does not warrant the survival of 
ischemic cells. Numerous studies performed in the past two decades have unequivocally 
established that despite revascularization being the only possible alternative to salvage 
ischemic cells, cell death is partly precipitated, paradoxically, by restoration of the flow 
itself (Piper et al., 2004). This phenomenon, known as reperfusion injury leads to 
endothelial cell loss, disrupted endothelial cell junctions as well as increased adhesion of 
both platelets and leukocytes. 
Under such circumstances, there is a need to come up with better MI treatment 
alternatives. It is imperative to identify molecular triggers, cell signaling pathways and 
the underlying mechanisms involved such that a better understanding of the disease can 
be achieved to allow for the development of a novel, more superior, therapeutic 
intervention in the treatment of MI. 
1.2.2 Animal Models of Acute Myocardial Infarction (AMI) 
Several animal models of AMI have contributed to our understanding of the disease. AMI 
can be initiated using several means; (i) thermal, using cyroinjury (Bhindi et al., 2006; 
Ciulla et al., 2004) ; (ii) pharmacologic, using isoproterenol (Geng et al., 2004a; 
Saravanan et al., 2004); (iii) microembolisation (Medvedev et al., 1993), and (iv) surgical 
ligation, which is the most commonly employed  (Zhu et al., 2007; Chuah et al., 2007).  
Firstly, the cyroinjury model is achieved by placing a precooled (-190°C) metal rod over 





myocardial damage.  However, the injury provoked is distinctly different compared to MI 
pathophysiology as the injury wavefront is epicardial inwards in this case, as opposed to 
that induced by ischemic injury. In addition, a transition zone between ischemic and non-
ischemic tissue is absent from this model. Next, administration of catecholamine 
isoproterenol to induce MI has the advantage of simplicity with low mortality. However, 
this model is based on increased myocardial demand, rather than reduced blood flow 
which is the case in ischemia. Thirdly, microembolisation results in global myocardial 
dysfunction as tiny microspheres are injected into the ascending aorta to hinder coronary 
delivery. As such, coronary selectivity cannot be achieved with this protocol (Bhindi et 
al., 2006). On the other hand, surgical induction of MI is widely adopted as it is best able 
to replicate the disease condition in human with respect to structural and functional 
characteristics. In addition, this model allows for the precise timing and location of the 
infarct induction, as well as the extent of the coronary event. This will in turn yield more 
reproducible results (Klocke et al., 2007). In view of its numerous advantages over other 
models, this model was selected for use in the current study. 
1.2.3 Experimental Model of MI: Simulation of Hypoxic Conditions in vitro 
Hypoxia is a state of reduced oxygen tension to below normal physiological levels, thus 
restricting the proper functioning of organs, tissues or cells (Koh et al., 2008). It can arise 
from the reduction in oxygen supply due to a disruption of blood flow, such as in 
myocardial ischemia. Several in vitro hypoxic models have been established which 
include the physical deprivation of cells of oxygen (≤1%) and using chemical hypoxia 





Physical hypoxia can be induced by placing cells in a hypoxic chamber or a hypoxic 
incubator with low oxygen levels. Otherwise, hypoxia can also be triggered by using 
hypoxia mimetic agents such as cobalt chloride (CoCl2) or desferrioxamine (DFX). 
Under normoxic conditions, cobalt can activate hypoxia-mediated signaling pathways by 
stabilizing hypoxia-inducible factor 1α (HIF-1α). CoCl2 inhibits prolyl hydroxylase 
(PHD), a class of enzymes involved in the oxygen-dependent degradation of HIF-1α 
(Epstein et al., 2001). CoCl2 has been engaged as a hypoxia model in several studies 
(Chen et al., 2009b; Shu et al., 2008; Montopoli et al., 2007; Triantafyllou et al., 2006; 
Vassilopoulos et al., 2005). Desferrioxamine (DFX) is an iron chelator which is also able 
to inhibit the degradation of HIF-1α under normoxic conditions. DFX prevents the 
association between iron-dependent PHD and HIF-1α, thus blocking the hydroxylation, 
ubiquitination and subsequent degradation of HIF-1α (Zhu et al., 2008; Schofield et al., 
2005). Considerable studies have used DFX to induce hypoxia (Bartolome et al., 2009; 
Milosevic et al., 2009; van der Kooij et al., 2009; Zhu et al., 2008; Chun et al., 2003). 
1.2.3.1 H9c2 
H9c2 cardiomyoblast is a subclone of the original clonal cell line derived from 13.5-
embryonic day BDIX rat heart muscle tissue by Kimes and Brandt. These cells exhibit 
cardiac cell type-specific L-type Ca2+ currents in addition to its sensitivity to organic Ca2+ 
channel blockers of the dihydropyridine and phenylalkylamine types (Hescheler et al., 
1991) . As cardiomyocytes make up the bulk of the heart tissue, h9c2 is well-suited for 
use as an in vitro model to study MI. In addition, the relative ease of its handling and 





1.2.3.2 Rat Neonatal Cardiomyocytes 
Cardiomyocytes isolated from rat pups were also employed in this investigation. This 
model is more superior compared to the cell line h9c2, as being a primary culture; it 
would resemble the in vivo model more closely. To illustrate, h9c2 cells do not possess 
the spontaneous beating of a heart muscle cell, whereas the isolated myocytes display this 
beating characteristic. Furthermore, h9c2 lack morphological properties of freshly 
prepared cardiomyocytes as the former do not express gap junctions, T tubules or 
myofibrils (Hescheler et al., 1991). This may be due to a de-differentiation of h9c2 as a 
consequence of increased passage number. Nonetheless, the isolation procedure of 
primary cardiomyocyte is time-consuming, and coupled with the low cell yield (vs. cell 
lines) and its difficulty to be passaged makes it necessary to employ both models of 
primary culture and cell line for this study. 
1.3 GASOTRANSMITTERS 
Gasotransmitters are small molecules of endogenously synthesized gases with important 
neurotransmitter-like functions in the biological system. Similar to classical 
neurotransmitters, gasotransmitters take part in diverse cellular signaling processes. In 
contrast to neurotransmitters, these gaseous transmitters are freely permeable across 
membranes and can exert their biological effects without depending on the presence of 
specific membrane receptors. In addition, they are enzymatically produced and their 
generation is well-regulated. Moreover, they have well-defined functions at 





Due to their gaseous nature, gasotransmitters are not synthesized in advance nor stored in 
classic presynaptic vesicles; rather, they are generated and released when the demand 
arises. No storage vesicles have yet been identified, but it has been suggested that protein 
adducts might serve as storage pools for these gases (Kasparek et al., 2008). Upon 
termination of their signaling activity, the gases are rapidly scavenged, or enzymatically 
degraded. At present, three gasotransmitters have been characterized; they are hydrogen 
sulphide (H2S) (Abe et al., 1996), nitric oxide (NO) (Furchgott et al., 1980) and carbon 
monoxide (CO) (Wu et al., 2005). A table detailing their similarities and differences is 
















 Hydrogen Sulphide Nitric Oxide Carbon Monoxide 
Formula H2S NO CO 
Colour colourless colourless colourless 
Odour ‘rotten-egg’ odour mild, sweet odour odourless 
Flammable Yes No No 
Toxicity Yes Yes Yes 
Receptors KATP channels heme protein; K/Ca channels 




Yes. From L-cysteine by 
CSE or CBS 
Yes. From L-arginine by 
NOS; or from reduction 
of nitrite 
Yes. Through heme 
degradation by heme 
oxygenase 
Vascular effects Vasodilation Vasodilation Vasodilation 
Anti-apoptotic 
effects Yes Yes Yes 
Anti-inflammatory 
effects Yes Yes Yes 
    
    
Table 1.1 Properties and characteristics of gasotransmitters H2S, NO and CO. 





1.3.1 Hydrogen Sulfide 
1.3.1.1 Overview of H2S 
Hydrogen sulfide (H2S) is a colourless, flammable gas with a characteristic ‘rotten-egg’ 
odour. It is water-soluble, forming a weak acid in water or plasma, as H2S dissociates to 
form HS- and H+. As predicted by the Henderson-Hasselbach equation, when sodium 
hydrosulfide (NaHS) or H2S is dissolved in a physiological solution of pH 7.4 at 37°C, 
18.5% will exists as H2S and the remaining 81.5% as hydrosulfide ion (HS-). In addition, 
the solubility of H2S in lipophilic solvents is fivefold greater than in water,  and hence, it 
is able to diffuse across all cell types (Li et al., 2008b).  
It has been known for nearly 300 years that H2S is a toxic environmental pollutant 
(Bhatia, 2005). Due to the massive amounts of anaerobic bacterial digestion of organic 
substrates, workers working in sewers and swamps suffer from the occasional fatal H2S 
poisoning, commonly referred to as ‘sulphuratted hydrogen’  intoxication (Mancardi et 
al., 2009). Its toxicity stems from it being a potent inhibitor of mitochondrial cytochrome 
c oxidase (Reiffenstein et al., 1992). Despite early reports demonstrating the basal 
production of H2S in animal tissue more than 80 years ago, its role as a gasotransmitter 
was only recently recognized (Fiorucci et al., 2006; Kamoun, 2004; Wang, 2002; Abe et 
al., 1996; Sluiter, 1930). 
1.3.1.2 Biosynthesis of H2S 
In mammalian tissues, H2S is largely synthesized by two pyridoxal-phosphate dependent 
enzymes, cystathionine-β-synthase (CBS, EC 4.2.1.22) and cystathionine-γ-lyase (CSE, 





distributed in mammalian cells and tissues, and also in several invertebrates and bacteria 
(Kamoun, 2004). The distribution of these enzymes in the body is tissue-specific, with 
CBS found predominantly in the brain and nervous system, and CSE in the 
cardiovascular system and in organs such as pancreas (Szabo, 2007). In some cases, large 
amounts of both enzymes are present in organs such as liver and kidney (Lowicka et al., 
2007). CBS activity is regulated at the transcriptional level by glucocorticoids and cyclic 
AMP, and can be inhibited by NO and CO (Puranik et al., 2006). On the other hand, the 
regulation of CSE is less understood. Earlier work by our group has demonstrated that the 
amino acid sequence of pyridoxal-5’-phosphate binding site of CSE is highly conserved 
among different mammalian species including the rat, mouse, monkey and human. This 
indicates the importance of CSE in mammalian physiology as this protein is well-
conserved throughout the course of evolution. As such, it can be interpreted that CSE-
mediated endogenous H2S production plays a pivotal role in the body. 
It was reported in a study by Zhao and colleagues that the rank order of H2S biosynthesis 
from exogenous cysteine in rat vessels was tail artery > aorta > mesenteric artery (Zhao et 
al., 2003). In tissue homogenates, sulphide is being synthesized at a rate of 1-10pmoles 
per second per mg protein, resulting in low micromolar extracellular concentrations of 
sulphide (Doeller et al., 2005). 
In addition to CBS and CSE, H2S can also be generated from L-methionine through a 
transulfuration pathway with homosyteine as an intermediate in the process. Furthermore, 
non-enzymatic reduction of elemental sulphur using reducing equivalents obtained from 








      
 
 
Figure 1.2 Non-enzymatic production of H2S.  
(adapted from Wang, 2002) 
Figure 1.1 Endogenous enzymatic production of H2S.  





1.3.1.3 Metabolism of H2S 
In the body, majority of the H2S is metabolized either by oxidation in the mitochondria, 
methylation in the cytosol or is scavenged by methemoglobin, metallo- or disulfide-
containing molecules such as oxidized glutathione (Figure 1.3).  
Firstly, in the mitochondria, H2S is oxidized to thiosulfate which is subsequently further 
oxidized to form sulfite and sulfate. It is suggested that the oxidation of H2S to thiosulfate 
does not require enzymatic action and is associated with the mitochondrial respiratory 
electron transport. Sulfite is oxidized by sulfite oxidase to form sulfate, the major end-
product of H2S metabolism. Sulfate, either in the free form or conjugated to another 
molecule, is then excreted by the kidney (Lowicka et al., 2007). Secondly, a portion of 
H2S is metabolized by methylation in the cytoplasm by thiol S-methyltransferase (TSMT) 
to methanethiol and dimethylsulfide (Furne et al., 2001). Thirdly, hemoglobin is 
proposed to serve as a sink for H2S to form green sulfhemoglobin. Hemoglobin is also a 
common sink for both NO and CO in forming nitrosyl hemoglobin and scarlet 
carboxyhemoglobin respectively (Wang, 1998) . As such, the binding of one gas will 
reduce the binding potential of the other gases to hemoglobin, and this will then alter the 











Figure 1.3 Metabolism of H2S in the body. (1) Mitochondrial oxidation, (2) cytosolic 
methylation, (3) binding to methemoglobin. SO, sulfite oxidase; TST, thiosulfate: 
cyanide sulfurtransferase (rhodanese); TSMT, thiol S-methyltransferase 






1.3.1.4 Roles of H2S in the Cardiovascular System 
1.3.1.4.1 Effect of H2S on Vascular Tone 
The role of H2S as a vasodilator has been extensively investigated in numerous studies. In 
whole animals, when an intravenous bolus injection of H2S was given to rats, BP was 
lowered by 12-30mmHg (Zhao et al., 2001). Additionally, administering an exogenous 
H2S donor (NaHS) to spontaneously hypertensive rats (SHR) also served to reduce BP. 
When rats were treated with a CSE inhibitor propargylglycine (PAG) which inhibits H2S 
production, BP was in turn elevated (Yan et al., 2004).  
In isolated organ systems, examples of blood vessels relaxed by H2S include the rat aorta 
and portal vein (Ali et al., 2006; Zhao et al., 2001; Hosoki et al., 1997), rabbit corpus 
cavernosum (Srilatha et al., 2007) and rat mesenteric artery beds (Cheng et al., 2004). 
Thus far, the mechanism of action governing this effect of H2S on blood vessels is shown 
to be via the opening of mitochondrial ATP-sensitive potassium (mitoKATP) channels as 
glibenclamide, a mitoKATP channel antagonist attenuated the H2S-induced vasorelaxant 
effect (Cheng et al., 2004; Zhao et al., 2001). Furthermore, when endogenous H2S 
production was inhibited by PAG, mitoKATP channel current was reduced (Tang et al., 
2005).  
1.3.1.4.2 Effect of H2S on the Ischemic Heart 
H2S involvement has been implicated in CVDs such as hypertension (Xiaohui et al., 2005; 
Yan et al., 2004), stroke (Qu et al., 2006) and MI (Zhu et al., 2007; Geng et al., 2004a)  






In a study performed by Geng and colleagues, NaHS decreased myocardial contractility 
both in vitro and in vivo. They showed that this effect is attenuated, but not completely 
abolished by glibenclamide pretreatment, indicating only partial involvement of KATP 
channels (Geng et al., 2004b).  
Also, our group has reported that both endogenous and exogenous H2S offers protection 
to the heart in a coronary artery ligation model of MI as evaluated by an improvement in 
survival rate and a reduction in infarct size, which is the gold standard employed to assess 
myocardial injury. This protection was linked to the participation of a CSE/H2S pathway 
as CSE was expressed in the infarct area and this was accompanied by an increase in 
plasma H2S concentration. In the same study, NaHS conferred cardioprotection to 
cultured myocardial cells against hypoxia-induced death (Zhu et al., 2007). 
In a separate study using the isoproterenol-induced MI model, NaHS was shown to 
reduce mortality and improve cardiac function. This group further identified that the H2S-
conferred protection involved scavenging of oxygen-free radicals and reduction of lipid 
peroxidation accumulation (Geng et al., 2004a). Next, H2S-mediated cardioprotection 
was also similarly noted in an animal model of regional myocardial ischemia reperfusion 
ex vivo (Johansen et al., 2006) and in vivo (Sivarajah et al., 2006). To further corroborate 
these studies, treatment with PAG in rat models of MI increased infarct size which was in 
agreement with the cardioprotective role of H2S as noted earlier (Zhu et al., 2007; 
Sivarajah et al., 2006). 
Ischemic preconditioning is a phenomenon in which the heart is subjected to several 





severe ischemia. Pharmacological preconditioning with exogenous H2S administered 
before the ischemic insult may confer cardioprotection analogous to that of ischemic 
preconditioning. It was reported that when the isolated rat heart was perfused with NaHS 
(0.1-1µM) before the ischemia insult, the duration and severity of ischemia/reperfusion-
induced arrhythmia was attenuated, similar to that observed with ischemic 
preconditioning. Myocardial infarct size was also reduced in a concentration-dependent 
manner. Additionally, cell viability of cardiomyocytes pretreated with NaHS was also 
improved and protected against death induced by subsequent hypoxia (Bian et al., 2006). 
In a separate study by the same group, it was shown that NaHS pretreatment (10-1000µM) 
also conferred protection against the loss of cell viability during metabolic inhibition in 
cultured rat ventricular myocytes (Pan et al., 2006).  
1.3.1.5 S-allylcysteine (SAC) as a Novel H2S Donor 
1.3.1.5.1 Garlic as a Cardioprotective Agent 
Garlic (Allium Sativum) is used traditionally as an alternative and complementary therapy 
in the treatment of several diseases such as diabetes, several forms of cancer and 
neurodegenerative conditions such as ischemic stroke (Rahman et al., 2006; Banerjee et 
al., 2002). In addition, garlic possess a range of cardiovascular effects such as lowering 
of plasma cholesterol (Ali et al., 1995); inhibition of platelet aggregation as well as 
lowering of arterial blood pressure (Agarwal, 1996). As garlic’s characteristic odor is 
largely attributed to its sulfur-containing compounds, researchers investigating the 
therapeutic potential of garlic have concentrated almost exclusively on these molecules. 







1.3.1.5.2 SAC as a Cardioprotective Agent 
A handful of studies have reported that garlic contains active components that are 
beneficial in metabolic and CVDs (Neil et al., 1994). S-allylcysteine (SAC), a main 
bioactive constituent of garlic is an organosulphur-containing amino acid derived from 
the aqueous garlic extract (Kim et al., 2001). Like garlic extract, SAC is reported to be 
anti-oxidative (Herrera-Mundo et al., 2006; Numagami et al., 2001); anti-cancer (Chu et 
al., 2007; Welch et al., 1992) anti-hepatotoxic (Kodai et al., 2007; Hsu et al., 2006) and 
can also reduce the incidence of stroke (Kim et al., 2006).  
In the cardiac context, Padmanabhan and Prince reported that SAC mediated 
cardioprotection in isoproterenol-induced MI rats via an anti-oxidative pathway. An 
Figure 1.4 Structure of sulfur-containing compounds derived from garlic. 





improvement in the antioxidant status as characterized by a reduction in lipid 
peroxidative products and an increase in antioxidant enzymatic activities were noted 
(Padmanabhan et al., 2006). In a subsequent study using the same MI model, this group 
reported that SAC pretreatment (50-150mg/kg) restored the activities of mitochondrial 
and respiratory chain enzymes. These enzymes participate in the tricarboxylic (TCA) 
cycle, and play a key role in catalyzing the oxidation of various metabolic substrates.  
Hence, this data comfirms the efficacy of SAC in improving isoproterenol-induced MI 
damage (Padmanabhan et al., 2007).  
As H2S is endogenously synthesized from the amino acid L-cysteine, the discovery of 
H2S as a gasotransmitter in the CV system makes it plausible that administration of 
chemically modified cysteine analogues, such as those found in the Allium species (i.e. 
SAC), may affect H2S formation in the heart and vasculature, and be of therapeutic 
potential (Rose et al., 2005). This claim is further substantiated by 3D chemistry 
modeling that SAC binds to the active site of CSE as shown below in Figure 1.5, hence 
serving as a novel CSE substrate. 
 
Figure 1.5 CSE-SAC interaction model. 
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1.3.2 Nitric Oxide 
1.3.2.1 Overview of NO 
Nitric oxide is a soluble diatomic lipophilic gas which is both colourless and odourless.  
Being a free radical, it is highly reactive. NO was previously regarded as an 
environmental pollutant, originating mainly from the exhausts of vehicles and industrial 
plants. NO reacts readily with oxygen in the environment to form smog, increasing the 
risk of asthma. To add on, NO is produced in the troposphere by the action of lightning 
and can be found in large amounts in tobacco smoke (Bruckdorfer, 2005). 
The role of NO as a gasotransmitter was only recognized in the late 1980s. However, it 
has been known for more than 150 years that some nitrogen oxide-containing species 
relieves symptoms associated with coronary artery disease. In 1867, Brunton observed 
that amyl nitrite could alleviate symptoms of chest pain linked to angina pectoris. This 
seminal discovery propelled scientists to experiment on nitrite-containing compounds for 
the next 100 years on various physiological systems with the conclusion that nitrites are 
vasodilators, but without giving much attention to its mechanism of action (Marsh et al., 
2000). The next big break only came in the 1970s, when pharmacologist Ferid Murad and 
his colleagues were examining the action of several vasodilators, including nitroglycerin. 
They discovered NO activation of guanyl cyclase (GC) with a corresponding increase in 
cGMP (Furchgott et al., 1980; Arnold et al., 1977). At the same time, Furchgott reported 
the presence of an endothelium-derived relaxing factor (EDRF) which was able to relax 
blood vessels (Furchgott et al., 1980). Despite it being evident that NO was an effector of 





Ruiz et al., 2009). However, it was only seven years later in 1987 that the identity of this 
EDRF was recognized to be NO. This discovery arose from the work of Ignarro who later 
went on to share a Nobel Prize in Physiology with Murad and Furchgott in 1998 (Marsh 
et al., 2000). 
Since its discovery, NO has become the most ubiquitous of intercellular signaling 
molecules recognized in the 1990s: the involvement of NO in a seemingly limitless range 
of physiological systems continues to expand.  To illustrate, some of the major roles of 
NO include regulation of BP, inhibition of platelet aggregation and leukocyte adhesion 
and its involvement in neurotransmission and immune response. Not forgetting, NO also 
participates in post-translational protein modification which involves the formation of a 
nitrosothiol or thionitrite bond (-S-N=O) in a thiol group (Martinez-Ruiz et al., 2009). In 
1992, NO received an accolade which further escalated its fame when it was chosen as 
the cover story by Science for its ‘Molecule of the Year’ issue (Culotta et al., 1992).  
1.3.2.2 Biosynthesis of NO 
In the body, NO is synthesized by the oxidation of a guanidine nitrogen of the amino acid 
L-arginine with citrulline as a co-product (Li et al., 2009). L-arginine is present in 
abundance in the blood (60-80µM) and extracellular fluid, and at even higher 
concentrations within cells (Bruckdorfer, 2005). This reaction is catalyzed by a family of 
NO synthase (NOS) enzymes, and requires the presence of several co-factors including 
NAPDH, tetrahydrobiopterin (BH4), flavin adenine dinucleotide (FAD), flavin 
mononucleotide (FMN), heme and calmodulin which attach to their specific binding sites 







1.3.2.3 NOS Isoforms 
The NOS family comprises of three members; namely, neuronal NOS (nNOS; also 
known as NOS1), inducible NOS (iNOS; also known as NOS2) and endothelial NOS 
(eNOS; also known as NOS3).  These three isoforms of NOS originate from distinct 
genes and differ in their subcellular localization and mode of regulation. Both nNOS and 
eNOS are constitutively expressed and require calcium for NO production. The amount 
of NO produced is in the nM range (Corson, 2007). Both are regulated predominantly in 
the post-translational stages. In contrast, iNOS is expressed only in response to stimuli 
such as inflammation and infection and is independent of calcium presence. It produces 
NO in large quantities in the µM range (Napoli et al., 2006). 
 nNOS was first identified in the cerebellum of rat brain, and consequently named after 
the tissue it was isolated from. Similarly, eNOS was discovered in bovine aortic 
endothelial cells and named as such. iNOS was first identified when its expression was 
Figure 1.6 Endogenous synthesis of NO from L-arginine in animal cells. 






induced from a mouse macrophage cell line activated by interferon γ and bacterial 
lipopolysaccharide (LPS) (Li et al., 2009). At the cellular level, nNOS is localized mainly 
in the cytoplasm and mitochondria; eNOS in both the cytoplasm and plasma membrane 
and iNOS primarily in the cytoplasm (Jobgen et al., 2006). 
All three NOS isoforms are present in the heart (Ziolo et al., 2008; Massion et al., 2003; 
Barouch et al., 2002). Upon the release of NO, it diffuses through the endothelial cell 
membrane into neighbouring smooth muscle cell and binds to its cytosolic target, GC 
which will then catalyze the formation of cGMP. By serving as the second messenger of 
NO, cGMP in turn activates protein kinase G (PKG) which will open KATP channels on 
the inner mitochondrial membrane. Consequently, this decreases intracellular Ca2+ to 
result in cellular hyperpolarization and the eventual relaxation of smooth muscle cells 
(Kasparek et al., 2008). 
1.3.2.4 NO Metabolism  
In the body, the metabolic pathway of NO is highly dependent on its own concentration, 
its diffusibility and the surrounding concentration of other bioreactants. The charge 
neutrality of NO confers it high diffusion capacity. NO biotransformation occurs via 
several metabolic routes within the body. For instance, NO may react with redox-
activated thiols to form S-nitrosothiols which constitutes an active storage pool for NO. 
Moreover, it can also be converted to other forms by enzymes such as xanthine oxidase 
and superoxide dismutase (SOD) (Kelm, 1999). Furthermore, NO has a very short half-
life of <5s in physiological solutions and the majority of NO is oxidized in a non-





via an auto-oxidation process, or NO can react with superoxide anion to form 
peroxynitrite. NO and the nitrite formed can also undergo further oxidation by 
oxyhemoglobin or oxymyoglobin to form nitrate (Li et al., 2009). Nitrite and nitrate are 
stable metabolic products of NO, and can be employed as a valid indicator of NO 
production in the body. Both are eventually excreted by the kidneys. 
1.3.2.5 Roles of NO in the Cardiovascular System 
Over the past 20 years following the identification of EDRF as NO, numerous studies 
were carried out to investigate the role NO plays in CVD in hope of offering more 
effective therapeutic interventions. At the beginning of this quest, there was a constant 
debate as to whether NO was doing more good than bad to the heart. When a review of 
the existing literature was performed, it is revealed that the vast majority of studies 
concluded that NO is beneficial in myocardial ischemia whilst a shrinking minority 
implicate a deleterious role of NO (Bolli, 2001).  As such, the cardioprotective role of 
NO is currently established and the focus should now be switched to how NO is exerting 
its cardioprotection. 
Within the cardiovascular system, NO plays an important role in the protection against 
the onset and development of CVDs, first and foremost by inducing vasorelaxation. This 
is mediated largely through the stimulation of GC which catalyzes GMP production, 
triggering a cascade of phosphorylation events that lead to vasorelaxation. In addition, 
NO is involved in a myriad of cardiovascular functions such as maintaining vascular 
homeostasis, inhibiting platelet aggregation and preventing the proliferation of vascular 





prostanoids (prostaglandins and thromboxanes) in the injured myocardium, preservation 
of vascular impermeability and angiogenesis (Yamamoto et al., 2000; Kelm, 1999).  
It was demonstrated in several studies that when NO was administered, there was a 
corresponding improvement in myocardial ischemia, with a reduction in infarct size and 
endothelial dysfunction (Bolli, 2001). NO donors such as sodium nitroprusside (SNP) 
also reduced infarct size which is a key prognosis in MI (Pasceri et al., 2005). Several 
studies which increased NO levels showed improvements in cardiac functions after 
myocardial ischemia (Chen et al., 2007; Fu et al., 2007; Smul et al., 2006; Rossoni et al., 
2006; Zhu et al., 2006; Linz et al., 2003; Xi et al., 2000). When MI/R rats were treated 
with NO-aspirin (a novel NO-derivative of aspirin), myocardial injury was attenuated and 
the beneficial effects observed were reported to derive largely from NO with a reduction 
in infarct size and a general improvement in LV function (Fu et al., 2007). 
Correspondingly, when NOS inhibitors such as L-NAME (Williams et al., 1995) or L-
nitroarginine (Hoshida et al., 1995) were given to rabbits prior to coronary occlusion, it 
resulted in significantly larger infarcts compared to untreated animals.  
Several attempts to stimulate endogenous NO production with exogenous 
pharmacological agents have also yielded promising results. To illustrate, when 
investigators administered L-arginine (substrate for NO production via NOS) to animals, 
it was noted that the infarct sizes were reduced and there was an improvement in the 
recovery of post-ischemic left ventricular function in rats (Pabla et al., 1996) and dogs 





In a study by Brunner and colleagues, they generated transgenic mice that exclusively 
overexpressed human eNOS in cardiac myocytes. In these genetically altered mice, left 
ventricular pressure was reduced and basal cardiac cGMP levels were doubled. When L-
NAME was employed to block NOS activity, these changes were reversed, implying NO 
involvement. Compared to their wild-type counterparts, parameters of cardiac function 
such as left ventricular developed pressure and dP/dt after ischemia were significantly 
better preserved in transgenic mice (Brunner et al., 2003). 
Being a free radical, NO can react with O2 as well as O2.- to form potentially deleterious 
oxidants such as peroxynitrite, ONOO.-. Conversely, its property as a radical will also 
allow it to combine with another radical to terminate radical chain propagation (Pryor et 
al., 2006). This is exemplified in several studies in which NO reduced lipid peroxidation, 
a common occurrence in arteriosclerosis (Niziolek et al., 2003; Rubbo et al., 2000; Hogg 
et al., 1999; Rubbo, 1998). Thus, depending on physiological conditions, NO may act 
either as an oxidant, or an antioxidant in the body.  
Next, NO is a potent vascular anti-inflammatory agent (Lowenstein, 2007) although 
several studies have reported a pro-inflammatory role for NO (Ganguly et al., 2007; Tan-
No et al., 2006). Leukocytes are the key cellular mediators of the inflammatory process.    
Exogenous NO donors were reported to limit leukocyte interaction and adherence to 
vessel walls. On the contrary, inhibitors of NO production increased leukocyte rolling 
along the endothelium (Kubes et al., 1991).  In a study by Lefer, it was reported that 
leukocyte adherence to the vessel wall was elevated by 10 and 4-fold in eNOS and nNOS 





reduce inflammation in several animal models of CVD including MI and stroke (Jones et 
al., 1999).   
It is now widely accepted that NO is a powerful cardioprotectant against ischemia injury. 
As summarized above, increased NO bioavailability is a common feature of diverse, 
apparently unrelated interventions that limit tissue injury during myocardial ischemia, 
suggesting that NO may be a final common pathway of cardioprotection.  
1.3.2.6 Sildenafil as a Novel Substrate for Endogenous NO Production 
1.3.2.6.1 Overview of Sildenafil 
The discovery of sildenafil two decades ago was a result of a large-scale project in search 
of suitable compounds for the treatment of angina pectoris (Raja, 2006; Moreland et al., 
1998). Although this quest did not yield promising anti-anginal drugs, sildenafil was 
serendipitously found to be effective in treating erectile dysfunction (Elrod et al., 2006).   
Sildenafil is a potent and specific inhibitor of the enzyme, phosphodiesterase 5 (PDE-5), 
found mostly in vascular beds such as the corpus cavernosum and also in cardiomyocytes 
(Das et al., 2005; Senzaki et al., 2001). PDE-5 catalyzes the breakdown of nitric oxide 
(NO)-driven cyclic guanosine 5’-phosphate (cGMP) to guanosine 5’-monophosphate (5’-
GMP). PDE-5 inhibitors such as sildenafil thus compete with cGMP for binding at the 
catalytic site of the enzyme, preventing the breakdown of cGMP (Elrod et al., 2006; 
Kukreja et al., 2005). Accordingly, sildenafil enhances cGMP accumulation, potentiating 






1.3.2.6.2 Sildenafil as a Cardioprotective Agent 
Recent years have seen several studies refocusing on the potential of sildenafil as a 
cardioprotective agent, particularly in models of ischemia/reperfusion (I/R) injury 
(Salloum et al., 2008; Rossoni et al., 2007; Kukreja, 2007; Salloum et al., 2007b; 
Rosanio et al., 2006; du Toit et al., 2005; Bremer et al., 2005; Reffelmann et al., 2003; 
Salloum et al., 2003b; Ockaili et al., 2002). In a study led by Das, rats were pre-treated 
with sildenafil at 0.05 and 0.1mg/kg and the hearts were isolated and subsequently 
subjected to ischemia. Sildenafil provided significant cardioprotection as evidenced by 
improved ventricular recovery, a reduced incidence of ventricular fibrillation and 
decreased MI. This protection was verified to be through a cGMP-signaling pathway 
(Das et al., 2002).  
Ockaili and colleagues demonstrated that sildenafil exhibited a preconditioning-mimetic 
effect. It reduced infarct size in an I/R rabbit model, possibly through a mitochondrial 
ATP-sensitive potassium (mitoKATP) channel-related pathway. This group suggested that 
sildenafil may open mitoKATP channels either directly, or through a range of signaling 
pathways such as activation of protein kinase C (PKC) or mitogen-activated protein 
kinases (MAP-K) (Ockaili et al., 2002). Ockaili’s results were further substantiated by 
Salloum and co-workers in a later study, who showed that sildenafil reduced infarct size 
in a global I/R mouse model in the Langendorff mode. In this study, sildenafil induced 
eNOS and iNOS expressions, and this induction is fundamental to sildenafil-induced 
delayed preconditioning, accounting for the improvement in cardiac functions (Salloum 
et al., 2003b). Thus, the authors hypothesized that sildenafil potentiates NO release 





produced through NO-mediated GC activation. The authors also suggested that cGMP 
accumulation will stimulate PKG activation, leading to the opening of mitoKATP channels, 
which will then result in vasodilation, thus linking this to their earlier study (Raja, 2006; 
Salloum et al., 2003b; Ockaili et al., 2002). Moreover, PKG may also initiate a protein 
phosphorylation cascade, along with a decrease in intracellular calcium levels, leading to 
vasodilation and consequently cardioprotection (Kukreja et al., 2005).  
Adding on to the cardioprotective mechanisms which have been unraveled so far, this 
same group further demonstrated that sildenafil pretreatment before hypoxia reduced cell 
necrosis and apoptosis in an isolated adult mouse cardiomyocyte model. They reported 
that with sildenafil treatment, there was an increase in prosurvival BCl-2/Bax ratio which 
was blocked by L-NAME treatment. eNOS and iNOS protein and mRNA expressions 
were also elevated with sildenafil treatment. To further support these results, they showed 
that sildenafil-induced cardioprotection was abolished in iNOS knockout mice (Das et al., 
2005). This study thus provides definitive evidence that sildenafil mediates 
cardioprotection though the NO signaling pathway independent of hemodynamic 
alterations to bring about reduced necrosis and apoptosis. 
In a recent paper by Das, the author extended his group’s findings in 2005 which 
illustrated sildenafil’s protective effect against MI/R injury through cGMP-dependent 
protein kinase (PKG) activation. Das and his team showed that in isolated hearts, prior 
sildenafil treatment resulted in PKG activating survival kinase ERK to bring about 
cardioprotection with a reduction in infarct size. This effect is brought about by an 





blocked using its inhibitor PD98059, the enhanced expressions of iNOS, eNOS and BCl-
2 were diminished, with a consequent loss in cardioprotection (Das et al., 2009). 
More recently, this group provided additional evidence (i.e improvement in cardiac 
functions) to support the involvement of a NO-dependent pathway in sildenafil-mediated 
cardioprotection. Using animal models, they reported that ‘sildenafil attenuates ischemic 
cardiomyopathy in mice by limiting necrosis and apoptosis and by preserving left 
ventricular function through a NO-dependent pathway’.  Improvements in left ventricular 
functions, specifically left ventricular end diastolic diameter and fractional shortening, as 
well as the reduction in mortality and infarct size were correlated to an increase in eNOS 
and iNOS protein expressions (Salloum et al., 2008). This in vivo study further confirms 
the results obtained from the earlier in vitro study led by Das (Das et al., 2005). 
In summary, sildenafil is demonstrated in several instances to bring about beneficial 
effects in the CV system by stimulating NO production via a NO/NOS-related pathway 
which resulted in cGMP production. Following, PKG is activated, which will lead to the 
opening of downstream mitoKATP channels to bring about cardiac cellular hyper-
polarization and subsequent vasodilation. Furthermore, the involvement of pro-survival 
molecules such as ERK and BCl-2 is also implicated in this mode of cardioprotection. 
1.3.3 Crosstalk between H2S and NO 
Recent years have seen several research groups demonstrating the individual protective 
effects of H2S and NO in the cardiovascular system (Zhu et al., 2007; Li et al., 2006; 





is plausible that these two molecules work together in the biological system to bring 
about synergistic and/or modulatory effects.  
1.3.3.1 H2S and NO: Common Functions 
Both NO and H2S share several similar functions in the biological system. Firstly, both 
gases exhibit vasodilatory properties as evidenced in several papers (Li et al., 2007a; 
Bhatia, 2005; Wang, 2002). Next, both are involved in the regulation of cardiac 
contractility (Geng et al., 2004b). These gases also individually promote hippocampal 
long-term potentiation involved in memory formation (Whiteman et al., 2004; Kimura, 
2002). Furthermore, levels of both gasotransmitters are elevated during septic shock and 
inflammation (O'Sullivan S, 2006; Bhatia et al., 2005); and lowered during spontaneous 
and L-NAME-induced hypertension (Bhatia et al., 2005). In the past five years, several 
groups have demonstrated possible interactions between H2S and NO using in vivo, in 
vitro as well as biochemical studies (Pong et al., 2009; Geng et al., 2007; Wang et al., 
2007; Whiteman et al., 2006b; Ali et al., 2006; Whiteman et al., 2006a; Yanfei et al., 
2006; Whiteman et al., 2004; Hosoki et al., 1997).  
1.3.3.2 H2S and NO: Evidence for Crosstalk 
Although several studies have been conducted to investigate the relationship between 
H2S and NO, the mechanism(s) governing their crosstalk is multi-faceted and has yet to 
be clearly elucidated. Several groups have demonstrated that both gases act in synergy to 
enhance each other’s production/effects. Conversely, equal amounts of evidence are also 
present to support a modulatory relationship between them; meaning that the increase in 





is also true; such that the decrease in one’s production will stimulate the synthesis of the 
other gasotransmitter. 
In a study performed by Zhao and colleagues, it was demonstrated that NO is an 
endogenous regulator for the production of H2S in vascular tissues. Firstly, when tissue 
homogenates of vascular tissues were incubated with various concentrations of NO donor 
sodium nitroprusside (SNP), H2S production was increased. It is putatively suggested that 
NO increased PKG activity, which then stimulates CSE, hence accounting for the 
elevated H2S production. In addition, when VSMCs were incubated with NO donor 
SNAP (S-ntirosoacetylpenicillamine), CSE protein expression was also upregulated 
(Zhao et al., 2001). 
Several experiments were carried out to investigate the interaction between NO and H2S 
in vascular tissues using an organ bath setup. In a study by Hosoki and co-workers, they 
noticed that addition of exogenous H2S (30µM NaHS) greatly enhanced the smooth 
muscle relaxation induced by NO donor SNP in phenylepinephrine (PE)-precontracted 
thoracic aorta. This thus supports a synergistic relationship between the two gases 
(Hosoki et al., 1997). On the other hand, a similar study by Zhao and Wang showed the 
exact opposite. This group reported that when 60µM NaHS was used, it inhibited SNP-
induced vasorelaxation in the thoracic aorta. Discrepancies in the observations of both 
studies may be partially explained by slight differences in tissue preparation (helical 
aortic strips vs. aortic rings, respectively) and different agents (norepinephrine vs. 





On the other hand, studies are also present to support a modulatory relationship between 
NO and H2S. Firstly, H2S was found to inhibit eNOS activity in a dose-dependent manner, 
thus further contracting PE-precontracted rat aortic rings when applied (Kubo et al., 
2007a). In addition, the same group also published data evidencing that NaHS could 
inhibit the activities of all three NOS isoforms (Kubo et al., 2007b). In a separate study, it 
was demonstrated that H2S downregulated aortic L-arginine/NO pathway in rats. Treating 
isolated aortic cells with exogenous H2S and NaHS (1-1000µM) reduced NO formation, 
eNOS activity and mRNA levels, and also decreased L-arginine transport. In vivo 
experiments performed by treating rats with 14µM NaHS/kg gave similar results— 
vascular L-arginine/ eNOS/NO pathway was downregulated (Geng et al., 2007). 
Moreover, it was reported by Zhou and colleagues that in a rat model of LPS- induced 
acute lung injury (ALI), administration of PAG served to increase plasma NO levels, 
lung iNOS activity and iNOS expression. Conversely, when rats were treated with NaHS, 
NO and iNOS system were downregulated (Zhou et al., 2009). Pong also observed that 
when retinal cells were treated with 200µM NaHS, there was a significant decrease in 
NO-induced cGMP (Pong et al., 2009). Thus, these studies on the other hand are in 
support of a modulatory relationship between NO and H2S.  
1.3.3.3 H2S and NO: Nitrosothiol Formation 
Other than affecting each other’s outcomes in the vascular system, a group has 
demonstrated that incubation of H2S gas, or its donor, sodium hydrosulphide (NaHS) 
with a series of NO donors in a test-tube system resulted in the formation of a nitrosothiol 





tested the physiological significance of this chemical reaction between H2S and NO in the 
control of vascular tone. When both NO and H2S donors were applied, the vasorelaxant 
effect of NO was inhibited in PE-precontracted aorta. It is hypothesized that H2S reacts 
with NO to produce RSNO which exhibits little or no vascular activity, thus quenching 
NO vasorelaxant effect. The addition of CuSO4 which converts nitrosothiols back to 
nitrate/nitrite compounds, to the mixture of NO and H2S donors restored the relaxation 
effect. Thus, it is proposed that H2S and NO interacted directly to bring about a 
modulatory relationship, with H2S regulating NO bioavailability (Ali et al., 2006). All in 
all, from these studies, it is evident that there is cross-talk between NO and H2S signaling 
pathways. However, the discrepancy in the relationship observed suggests that the 
interaction between these two gases is complex and is probably context-dependent. 
1.4 HYPOXIA-INDUCIBLE FACTOR (HIF-1α) 
1.4.1 Hypoxia 
Hypoxia refers to a state of reduced oxygen pressure below a critical threshold which 
limits the proper functioning of organs, tissues or cells. It is essential to maintain an 
adequate supply of oxygen to tissue for normal cell function and physiology. Normal 
oxygen partial pressure (pO2) ranges from 150 mmHg in the upper airway to 5 mmHg in 
the retina. In arterial blood, a pO2 of less than 40 mmHg constitutes hypoxia (Koh et al., 
2008). Hypoxia can arise from a reduction in oxygen supply, such as at high altitudes or 
by localized ischemia caused by the disruption of blood flow. Additionally, hypoxia is 





ischemic disorders, atherosclerosis, diabetes, inflammatory diseases as well as cancer 
(Brahimi-Horn et al., 2007).   
Having said this, hypoxia is not altogether bad. It also has an important and beneficial 
role in mammalian physiology such as during embryogenesis (Koh et al., 2008). To 
illustrate, hypoxic conditions is necessary to bring about the differentiation and 
maturation of cardiomyocytes from embryonic stem cells. In view that oxygen is the 
primary source of metabolic energy for eukaryotes, it is reasonable that over the course of 
evolution, we develop the capacity to respond to hypoxic insult with the transcriptional 
upregulation of certain genes (Cummins et al., 2005). 
1.4.2 Discovery of HIF 
HIF-1 was first identified when it was found to bind to the 50-bp hypoxia-response 
element (HRE) containing a core 5’-RCGTG-3’ sequence in the 3’ flanking region of the 
gene for erythropoietin (EPO), a hormone responsible for stimulating erythrocyte 
proliferation in response to hypoxia (Goldberg et al., 1988). Being the master regulator of 
hypoxic response, HIF-1 induces the transcription of a wide array of genes that facilitate 
adaptation and cell survival to hypoxia (Semenza et al., 1992). As such, its participation 
in the pathophysiology of several ischemic diseases, and its potential as a target for 
therapeutic agents has generated considerable interest in this field (Koh et al., 2008). 
HIF-1 is a heterodimer consisting of an oxygen-sensitive HIF-1α subunit and a 
constitutively expressed HIF-1β subunit. Both are members of the basic helix-loop-helix 
PER/ARNT/SIM (bHLH-PAS) family of transcription factors (Giaccia et al., 2003). So 





is expressed ubiquitously, whereas HIF-2α has a tissue-specific expression. HIF-3α has 
multiple splice variants, including the inhibitory PAS domain protein, which is 
essentially a truncated protein that functions as a dominant-negative inhibitor of HIF-1 
(Makino et al., 2002).  
1.4.3 Regulation of HIF 
HIF-1 protein abundance and its transcriptional activity are primarily determined by the 
subunit HIF-1α. In addition to being an oxygen-labile protein that is stably expressed 
during hypoxia, HIF-1α can also be stabilized in response to iron chelators and divalent 
cations. In contrast, HIF-1β is constitutively expressed and its mRNA and protein are 
maintained at regular levels regardless of pO2.  
The stability and activity of HIF-1α is regulated by post-translational modifications such 
as hydroxylation, ubiquitination, acetylation and phosphorylation. Under physiological 
normoxic conditions, de novo synthesized HIF-1α subunit is continuously degraded 
within 5 minutes of its synthesis (Salceda et al., 1997). Prolyl hydroxylase (PHD) 
hydroxylates two proline residues (Pro-402 and Pro-564) at the oxygen-dependent 
degradation domain (ODDD) of HIF-1α (Figure 1.7).  PHD activity is dependent on the 
presence of oxygen, 2-oxoglutarate (2-OG), ascorbate and iron. The hydroxylated proline 
residues facilitate recognition by von Hippel-Lindau (vHL) protein which functions as 
the E3 ubiquitin ligase (Loor et al., 2008). ODDD plays an important role in modulating 
HIF-1α protein stability. In addition, factor inhibiting HIF (FIH) hydroxylates an 
asparagine residue (Asn-803) at the C-terminal transactivation domain (c-TAD) of HIF-





involved in modulating transcriptional activation of HIF-1α under hypoxic conditions 
(Giaccia et al., 2003). The association of pVHL-E3 ubiquitin ligase to HIF-1α results in 
the eventual ubiquitination and degradation of HIF-1α via the ubiquitin-proteasome 
pathway (Ke et al., 2006).  
 
 
During hypoxia, the lack of oxygen hampers ubiquitin-mediated degradation. HIF-1α is 
in turn stably expressed and interacts with its co-activator cAMP response element-
binding protein (CBP)/p300 at the C-TAD. HIF-1α then translocates from the cytoplasm 
to the nucleus where it dimerizes with HIF-1β to form a functional HIF-1 complex 
(Kallio et al., 1997). Transcriptionally active HIF-1 subsequently binds to a conserved 
HIF-binding sequence within the HRE in the regulatory regions of target genes, thereby 
eliciting their transactivation with a corresponding induction in gene expression (Koh et 
al., 2008). The process of HIF regulation is complex and the mechanisms involved are 
illustrated in Figure 1.8. 
 
 
Figure 1.7 Domain structure of human HIF-1α. HIF-1α is a member of the bHLH and PAS 
protein family. HIF-1α contains an ODDD that mediate oxygen-regulated stability through the 
hydroxylation of two proline residues (Pro-402 and Pro-564). HIF-α also has two trans-
activation domains (c-TAD and N-TAD). Hydroxylation of an asparagine residue (Asn-803) at 
C-TAD inhibits the binding of co-activator CBP/p300 to HIF-1α. The total number of amino 







Figure 1.8 Oxygen-dependent regulation of HIF-1 stabilization and transactivation.  
Left panel depicts situation during normoxia. Two proline residues of HIF-1 (P402 and P564) 
and asparagine (N803) are hydroxylated by PHDs and FIH-1, respectively, in an O2, 2-OG, 
and Fe2+-dependent manner. Hydroxylated HIF-1α proteins bind to E3 ubiquitin ligase pVHL 
complex, leading to its ubiquitination and subsequent degradation. Acetylation of lysine 
(K532) by ARD1 favors the interaction of HIF-1α with VHL. Hydroxylated N803 blocks the 
recruitment of transcriptional coactivator CBP/p300. 
During hypoxia (right panel), PHDs and FIH-1 activities are inhibited due to lack of O2, 
resulting in no proline and asparagine hydroxylation. Hence, there is no pVHL binding and 
HIF-1α is stabilized. HIF-1α then translocates to the nucleus and binds to HIF-1β. Non-
hydroxylated N803 of HIF-1α recruits CBP/p300 to the target genes, resulting in gene 






1.4.4 HIF-1 and the Cardiovascular System 
Limitation of regional blood flow in the cardiovascular system results in ischemia as a 
consequence of decreased cellular oxygen tension. At the same time, cells are also 
deprived of metabolic nutrients such as glucose. Prolonged ischemia will ultimately lead 
to cell death, either by necrosis or apoptosis.  
Several mechanisms have evolved to bring about adaptive responses during hypoxic 
conditions. First of all, hypoxia exerts profound effects on endothelial function (Ramirez-
Bergeron et al., 2001). To illustrate, hypoxia activates endothelial cells in vivo to bring 
about a cascade of reactions involving neutrophils, platelets and smooth muscle cells. 
This in turn directly regulates the expression of several mediators that engage and 
promote neutrophil adhesion. Consequently, disturbance of endothelial cell activation 
such as vascular leakage can lead to profound pathological situations such as ischemia 
(Michiels et al., 2000).  
In the cardiovascular context, HIF-1 activation plays an essential role in triggering 
cellular protection and metabolic alterations arising from oxygen deprivation, conferring 
protection against ischemic damage (Loor et al., 2008). In patients with pathological 
evidence of infarction or acute ischemia undergoing coronary bypass surgery, increased 
HIF-1α and VEGF mRNA transcripts and protein levels were quantified in ventricular 
biopsy specimens (Lee et al., 2000). During MI, HIF-1 is stabilized prior to induction of 
VEGF expression in the human heart (Bergeron et al., 2000; Lee et al., 2000). Jurgensen 





systemic hypoxia, whereas in a coronary occlusion model, localized expression of HIF-
1α occurred mainly at the border zone of the infarcted tissue (Jurgensen et al., 2004). 
Shyu and colleagues demonstrated that when naked DNA encoding HIF-1α was injected 
to the myocardium of rats that subsequently underwent AMI, there was an improvement 
in infarct development as well as enhanced angiogenesis. Additionally, regional blood 
flow was elevated and plasma VEGF levels were also higher (Shyu et al., 2002). When 
transgenic rat models with constitutive HIF-1α overexpression in the myocardium were 
employed, infarcts were attenuated with an improvement in cardiac function in rats 
subjected to coronary artery occlusion. In the same study, immunohistochemical analyses 
revealed that that there was increased expressions of HIF-1α and its downstream targets 
VEGF and iNOS in the peri-infarct regions (Kido et al., 2005). In a recent study by 
Zhang and colleagues, it was demonstrated that an increase in HIF-1α expression with a 
subsequent upregulation of VEGF could confer cardioprotection against hypoxia-induced 
cardiomyocte necrosis and apoptosis (Zhang et al., 2009). 
1.4.5 Downstream Targets of HIF in the Heart 
In the heart, presence of the HIF system may induce expression of cardioprotective genes 
during ischemia (Dendorfer et al., 2005). Genes such as iNOS and cycloocygenase-2 
(COX-2) increase cell survival and have been associated with enhanced resistance to 
ischemia in mice (Bolli et al., 2002; Guo et al., 1999). In addition, iNOS is also involved 
in the regulation of vascular tone (Melillo et al., 1995). Next, HIF-1 also promotes the 
uptake and metabolism of glucose through anaerobic glycolysis by upregulating the 





phosphofructo-2-kinase and frustocse-2,6-biphosphatase (Koh et al., 2008). Further 
adaptations that occur at the tissue level to increase oxygen delivery include the induction 
of angiogenesis and erythropoiesis. HIF activates the expression of pro-angiogenic VEGF 
which is important for collateral vessel development, thus restoring local oxygen and 
nutrient supply. Upregulation of erythropoietin promotes cell survival by stimulating red 
blood cell proliferation which will then enhance the delivery of oxygen to tissues. 
1.4.5.1 iNOS as a Downstream Target of HIF-1 
As mentioned above, iNOS is an established downstream target of HIF-1, and has been 
shown to be cardioprotective in acute and chronic heart diseases (Jones et al., 2006; Tang 
et al., 2006; Cuong et al., 2006). The first direct relationship between iNOS and HIF was 
provided by Jung and colleagues (Jung et al., 2000). They demonstrated that HIF-1 
mediates hypoxia-induced iNOS gene regulation in cardiac myocytes. Mutation or 
deletion of the HIF-1 binding site abolished hypoxic induction of iNOS promoter activity. 
RNA interference is a coordinated, sequence-specific mechanism to bring about post-
transcriptional gene silencing. In a study by Natarajan, it was shown that in murine 
microvessel endothelial cells, siRNA silencing of PHD expression produced a time- and 
concentration-dependent increase in HIF-1α protein stabilization. This was also 
accompanied by a corresponding increase in iNOS mRNA and protein levels. When PHD 
siRNA construct was injected into the murine hearts, it was noted that infarct 
development and cardiac dysfunction was reduced post-ischemia. Moreover, the 





work, HIF-1 activation resulted in significant iNOS-dependent cardioprotection 
(Natarajan et al., 2006). 
In a similar study by Xi and colleagues employing a Langendorff perfusion model, DNA 
binding activity of HIF-1α was enhanced within 1h in CoCl2-treated hearts. This was 
accompanied by a corresponding reduction in infarct size. In iNOS knockout mice, the 
infarct-limiting effect of CoCl2 was abolished, thus illustrating the importance of iNOS in 
HIF-regulated cardioprotective pathway (Xi et al., 2004). 
1.5 PI3K/AKT SIGNALING PATHWAY 
Phosphoinositide-3-kinase (PI3K) belongs to a conserved family of lipid kinases that 
mediate diverse cellular effects including cell proliferation, cell survival, cytoskeletal 
rearrangements, and endocytosis (Martin, 1998). PI3K phosphorylates inositol lipids to 
produce phophatidylinositol-3,4-bisphosphate (PIP2) and phosphatidylinositol-3,4,5-
triphosphate (PIP3). An ever-increasing array of kinases, enzymes and transcription 
factors are activated in response to the simple act of PI3K 3'-phosphorylation on the 
inositol heads of membrane phospholipids. 
 The principal downstream target of PI3K is protein kinase B (PKB, also known as Akt), 
which is a serine-threonine kinase activated by phosphatidylinositol-dependent kinase 1 
(PDK1). PI3K/Akt signaling activates a repertoire of signaling cascades with diverse 
outcomes, including both cell survival and death (Toker et al., 2000). Numerous studies 
have reported that hypoxia induced HIF-1α expression via the PI3K/Akt pathway 
(Phillips et al., 2005; Treins et al., 2002). On the other hand, some groups have also 





et al., 2004). This discrepancy may be due to the differing disease states being studied 
and is likely to be highly context dependent. 
Several studies have implicated the involvement of PI3K signaling pathway in the 
regulation of HIF-1. Multiple signaling molecules were reported to stabilize HIF-1 
transcriptional complex through the Akt pathway. For instance, stretch-activated channels 
in the myocardium were shown to induce HIF-1α and VEGF expressions through a 
PI3K/Akt-mediated pathway. This is important in helping the ischemic myocardium cope 
with mechanical stress. When PI3K inhibitors were employed, the upregulation of both 
proteins (HIF-1α and VEGF) were abolished (Kim et al., 2002). 
In human cancer cell lines, insulin and epidermal growth factor were shown to increase 
HIF-1α expression. PI3K signaling is required for this upregulation of HIF-1α, as 
treatment with PI3K inhibitors wortmannin and LY294002 inhibited HIF-1α expression 
in a dose-dependent manner. Additionally, the activity of HIF-1 downstream target 
VEGF was also suppressed when PI3K inhibitor was employed (Jiang et al., 2000). This 
study thus provided evidence that PI3K signaling lies upstream of HIF activation as its 
inhibition abolished HIF-1α expression as well as its downstream target effects, such as 
angiogenesis in this instance. 
Exposure of primary microglial culture to hypoxia ensues in microglia activation, and 
this activation is positively correlated to neuronal injury. It is established that the 
activation of microglia is accompanied by an upregulation of iNOS expression and NO 
production. In a study on microglia activation led by Lu, they reported that HIF-1α was 





expression and transcriptional activity, providing evidence for PI3K-mediated HIF-1α 
activation. Additionally, it was also shown that iNOS expression was increased under this 
circumstance and it was regulated by PI3K/Akt signaling pathway, hence providing 
evidence for the PI3K/HIF-1α/iNOS pathway  (Lu et al., 2006).  
In summary, the activation of HIF-1α during hypoxia induced the expression of 
downstream target gene iNOS in several pathophysiological conditions. Furthermore, the 
involvement of pro-survival PI3K/Akt pathway is also implicated in several of these 
processes as discussed above. However, information is lacking about the participation of 
HIF-1α/iNOS and its likely regulation by PI3K/Akt in the heart and awaits further 
investigation. 
1.6 RESEARCH INTEREST AND OBJECTIVES 
The identification of gasotransmitters in the body has led to a new era of research in the 
field of cellular signaling. Intercellular communication is no longer limited by the 
presence of receptors or the distance between the cells. These gasotransmitters readily 
diffuse from one location to another, and can easily permeate across membranes to bring 
about their biological effects without needing to bind to specific membrane receptors to 
transduce their signals. To add on, both NO and H2S appear to share similar functions, 
bringing about the same responses. As such, it is conceivable that these gases interact in 
the physiological system to bring about a coordinated, well-regulated outcome.  
It was shown in a previous study that the conventional exogenous H2S donor, NaHS 
could confer cardioprotection in MI in both in vivo and in vitro models. In the rat model 





increased plasma H2S concentration.  Similarly, in vitro studies demonstrated that NaHS 
protected VSMCs, a major cell type in the heart, from hypoxic insult. NaHS attenuated 
hypoxia-induced cell death and also upregulated CSE expression and H2S production in 
these cells (Zhu et al., 2007).  
S-allylscysteine, a main organosulfur-containing compound in garlic is reported to be 
cardioprotective in several studies. As the substrate for endogenous H2S production is L-
cysteine, it is hypothesized that SAC, being a cysteine analogue may confer 
cardioprotection by providing additional substrate for H2S production. This will lead to a 
reduction in ischemic damage through the concomitant involvement of the H2S/CSE 
pathway, which was shown in earlier studies to be beneficial in AMI.  As such, the first 
objective of this thesis is to verify if: 
Experiment 1: SAC exerts cardioprotection in AMI rat models via a H2S-related 
pathway. In addition, the effects of SAC on NO production will be investigated. 
 
The usage of nitrates in the clinical setting for the treatment of AMI is well-established. 
Furthermore to its vasodilatory properties, NO alleviates ischemic damage in several 
other ways, such as the prevention of platelet aggregation and leukocyte adhesion, as well 
as minimizing inflammation in the injured region. 
In recent years, several groups have looked into the cardioprotective potential of 
sildenafil in the treatment of myocardial ischemia. Sildenafil, an inhibitor of the enzyme 
PDE-5, thwarts the breakdown of NO-driven cGMP. Thus, the increased bioavailability 





KATP channels to result in cellular hyperpolarization, and subsequently, cardioprotection. 
Moreover, it was reported that sildenafil could also lead to an increase in NO production 
via a positive feedback pathway. Thus, the next objective of the thesis would be to 
identify if: 
Experiment 2:  Sildenafil exerts its cardioprotective effect through a NO/NOS-
related pathway in AMI rats. In addition, the effect of sildenafil on the H2S/CSE 
pathway will be studied. 
 
The interaction between NO and H2S in the body has been documented in several studies.  
However, the outcomes of this apparent crosstalk between the two gasotransmitters are 
contradictory in several instances and still far from clear. It is likely that the two gases 
interact differently under varying pathological conditions and the crosstalk is highly 
context dependent. As such, a third study is carried out to investigate the effect of this 
interaction using both exogenous and endogenous sources of H2S and NO. Conventional 
and established H2S and NO donors, NaHS and molsidomine respectively, were used to 
introduce exogenous sources of gasotransmitters. Endogenous sources of H2S and NO 
were blocked using inhibitors of H2S and NO production. PAG is an irreversible inhibitor 
of CSE, and it inhibits endogenous H2S production in the cardiovascular system. L-
NAME is a non-specific NOS inhibitor, thus inhibiting NO production from all three 
isoforms of NOS.  The aim of this third study is to: 
Experiment 3: Examine the roles and interaction between endogenous/exogenous 





HIF-1 is a transcriptional factor that plays a vital role in regulating the expressions of 
genes and proteins during hypoxia. One of the downstream targets of HIF-1 is iNOS, 
which promotes cell survival during MI. Results from experiment 3 showed that that 
NaHS upregulated HIF-1 gene and protein expressions during MI. Thus, we hypothesize 
that H2S may enhance the activation of HIF-1 to confer cardioprotection by activating 
iNOS under ischemic conditions. Additionally, we also hypothesize the participation of 
the cell survival PI3K/Akt pathway in this mode of protection. To ensure a more 
consistent experimental condition, we opted to use two in vitro models instead for this 
part of the study. H9c2, which is a cardiac myoblast cell line and primary neonatal rat 
cardiomyocytes were utilized. This part of the thesis aims to: 
Experiment 4: Determine if exogenous H2S exerts cardioprotection by enhancing 
HIF-1α activation and iNOS expression in hypoxic conditions. In addition, possible 
involvement of the PI3K/Akt pathway will be investigated. 











CHAPTER 2  
MATERIALS AND METHODS 





 2.1.1 Drugs 
Sodium hydrosulfide (NaHS), propargylglycine (PAG) and Nω-Nitro-L-arginine methyl 
ester hydrochloride (L-NAME) were purchased from Sigma-Aldrich (St Louis, MO, 
USA). S-allylcysteine (SAC) was obtained from TCI Kyoto Kasei Kogyo (Tokyo, Japan) 
whereas sildenafil (Viagra®) was bought from Pfizer Limited (Kent, UK). In addition, 
molsidomine was purchased from Titanchem (Shanghai, China).  
Sildenafil tablets were crushed into fine powder before dissolving in saline and 
administered to the animals via the intraperitoneal route. All drugs with the exception of 
molsidomine were dissolved in saline before injecting intraperitoneally to the rats. 
Molsidomine, being an orally active drug, was dissolved in MilliQ water before feeding 
to the animals using an oral gavage.  
As for the cell culture component of this study, NaHS was dissolved in MilliQ water and 
subsequently added to the cell medium. Phosphatidylinositol-3-kinase inhibitors 
wortmannin and LY 294002 were dissolved in dimethylsulfoxide (DMSO) and protected 
from light. Wortmannin and LY 294002 were purchased from Sigma-Aldrich (St Louis, 
MO, USA) and Calbiochem (San Diego, CA, USA) respectively. The volume of all 
chemicals added to the culture medium was limited to less than 0.5% of the total volume 
of the medium present. 
 
 





All chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA) unless 
otherwise specified. Nuclear and cytoplasmic extraction, Lightshift® Chemiluninescent 
EMSA and Biotin 3’End DNA Labeling Kits were purchased from Pierce Biotechnology 
(Rockford, IL, USA).  Nitrate/nitrite colorimetric assay kit was obtained from Cayman 
Chemicals (Ann Arbor, MI, USA). 






Male adult Wistar rats weighing between 220g-260g were obtained from Laboratory 
Animal Centre, National University of Singapore (NUS). Animals were housed under 
diurnal 12h light/dark cycles and fed standard rat chow and water ad libitum according to 
regulations of animal care by NUS. All experimental procedures were undertaken in 
accordance with established International Guiding Principles for Animal Research. 
Additionally, the project conforms to the ‘Principles of Laboratory Animal Care’ (NIH 
publication no. 85-23, revised 1985) and was approved by the animal ethics committee 
(IACUC) of NUS (protocol no. 888/05; 888a/05 and 071/07). 
2.2.1.1 Animal Model of Acute Myocardial Infarction (AMI) 
Myocardial infarction (MI) was induced by a permanent ligation of the left anterior 
descending coronary artery (Chuah et al., 2007; Zhu et al., 2006; Stauss et al., 1994). The 
rats were anesthetized with an intra-peritoneal injection of ketamine + xylazine (75mg 
+10mg/kg b.w) cocktail. Subsequently, the rats were intubated, connected to a respirator 
through a tracheotomy and artificially ventilated. The third and fourth ribs were cut to 
expose the heart and a chest retractor was subsequently inserted. The ribs were gently 
spread apart to reveal the beating heart. The left coronary artery was ligated 
approximately 2-3mm from its origin between the pulmonary artery conus and the left 
atrium using a sterile 6-0 atraumatic silk suture. Proper ligation was verified visually by a 
change in colour of the heart apex to a paler shade as reported previously (Chuah et al., 
2007; Zhu et al., 2006; Ji et al., 2003). This indicates that blood flow to the ventricle was 




successfully occluded. The thorax was then closed using a sterile 4-0 atraumatic silk 
suture to stitch up the skin and muscle layers individually. The whole surgical procedure 
took approximately 10 minutes. Artificial ventilation was maintained for a period of 20 
minutes after the surgery to allow the animals to recover. 
2.2.2 Cell Culture  
2.2.2.1 H9C2 
Rat h9c2 cardiac myoblast cell line was cultured in Dulbecco’s Modified Eagle’s 
Medium (Gibco, Grand Island, NY, USA) containing high glucose (4.5mg/L) and sodium 
pyruvate (110mg/L), and supplemented with 10% fetal bovine serum (FBS) (Hyclone, 
Logan, UT, USA), 100U/ml penicillin and 100µg/ml streptomycin (Gibco, Grand Island, 
NY, USA). The cells were maintained in a humidified incubator with 5% CO2 and 95% 
air. Cells were passaged by trypsinization upon reaching 80% confluency to prevent them 
from losing their myoblastic properties. 
2.2.2.2 Neonatal Rat Primary Cardiomyocytes 
Rat primary cardiomyocytes were isolated from 1-2 day old Wistar rat pups. The isolated 
myocytes were cultured in 35mm Petri-dishes in Dulbecco’s Modified Eagle’s 
Medium/F12 (DMEM/F12; Gibco, Grand Island, NY, USA), supplemented with 10% 
FBS, 10% horse serum (Hyclone, Logan, UT, USA) and 100U/ml penicillin and 
100mg/ml streptomycin (Gibco, Grand Island, NY, USA). Myocytes were maintained in 
a separate humidified incubator with 5% CO2 and 95% air. 
 




2.2.2.3 Isolation of Primary Cardiomyocytes  
Following decapitation, hearts from 1-2 day old rat pups were rapidly excised and 
immediately transferred to ice-cold phosphate buffered saline (PBS) placed on ice. 
Thereafter, the associated tissue and atria were carefully removed using curved-end 
forceps, and the hearts were washed in 4 changes of ice-cold PBS to remove blood and 
tissue debris. Each heart was then cut into half along the lateral plane and immersed in 
fresh ice-cold PBS for approximately 3-5 minutes with gentle agitation to further clear 
the tissue of blood. The tissue suspended in PBS was subsequently centrifuged at 300G 
for 3min at room temperature and PBS was discarded at the end of the spin.  A 
preconditioning step was introduced prior to trypinization (Fu et al., 2005). Briefly, the 
cut tissue was transferred to a conical flask containing 10ml of 0.08% trypsin (Gibco, 
Grand Island, NY, USA). The flask was placed on ice for 15 minutes and gently shaken 
every few minutes to facilitate mixing. This allows typsin to better penetrate the tissue so 
as to improve digestion efficiency later on. 
Subsequently, tissue fragments were enzymatically digested for 8-10 minutes per cycle 
using 0.08% trypsin until all the material has been digested. Typically, 6-8 rounds of 
digestion were performed during each isolation. The digestion was carried out at 37°C 
with constant stirring (150rpm). At the end of each round, enzymatic digestion was 
stopped with FBS. The cell-containing solution was then centrifuged at 1000rpm for 
3min at room temperature and the pellet collected was resuspended in fresh medium. 
Thereafter, the cell-containing medium was plated onto a 35mm Petri dish which was 
placed in the incubator for 90 minutes to remove co-existing fibroblasts and endothelial 




cells. These cells attach to plastic surfaces more readily than cardiomyocytes. At the end 
of the 90 minutes, the supernatant which is now myocyte-enriched, is then collected and 
re-plated in new 35mm Petri dishes at a density of 2x105 cells/dish. 5-bromodeoxyuridine 
(BrdU; 0.1mM) was added to the medium during the first 48h to inhibit proliferation of 
non-myocytes. Typically, more than 95% of the cells collected are myocytes. These cells 
were left undisturbed during the first 48hr.  It was observed that myocytes had contractile 
activity and formed spontaneous beating clusters within 2-3 days. The myocytes were 
allowed to grow in culture for at least 72h before being deployed for use in various 
experiments. 
2.2.2.4 Hypoxia Model 
Physical and chemical hypoxia models were tested on h9c2 in a preliminary study to 
determine the most appropriate model to use. Physical hypoxia was induced by placing 
cells in a Modular Incubator Chamber (MIC-101™) (Billups-Rothenberg, Del Mac, CA, 
US) and flushing the chamber with a gas mixture containing 95% nitrogen, 4.5% carbon 
dioxide and 0.5% oxygen as previously described (Namiki et al., 1995).  Various hypoxia 
time points (4h, 6h, 12h, 18h, 24h, and 48h) were probed. 
Chemical hypoxia was simulated using hypoxia-mimetic agents cobalt chloride (CoCl2) 
and desferrioxamine (DFX) (Chen et al., 2009b; Shu et al., 2008; Montopoli et al., 2007; 
Chun et al., 2003). Different concentrations of CoCl2 (100µM-1000µM) and DFX 
(130µM-1040µM) were tested by subjecting the cells to hypoxia for various time 
durations (6h, 12h, 18h, 24h, 48h). Cell viability was used as an indicator to determine 




the most appropriate hypoxia condition. This was performed using the MTT assay, and 
subsequently confirmed with the LDH assay. 
It was established that CoCl2 is most suited at inducing hypoxia in both h9c2 and 
cardiomyocytes. From the concentration-dependent study, 200µM CoCl2 was selected as 
the optimal concentration to induce hypoxia in both cell types. In addition, hypoxia 
duration for h9c2 and myocytes were determined to be 24h and 1h respectively. 
2.3 EXPERIMENTAL PROTOCOL  
Animal  
The coronary artery ligation method was selected for use as the AMI model in 
experiment protocols (Chuah et al., 2007; Zhu et al., 2000). Within each treatment group, 
rats were randomly subdivided to either the (i) MI operation or the (ii) sham operation 
group. The first group (n ≥24) was subjected to a permanent ligation of the left anterior 
descending coronary artery (‘MI rats’) while the second group (n=6) served as controls 










2.3.1 Experimental Protocol 1 — SAC exerts Cardioprotection in AMI via a H2S-
related pathway with Concomitant NO Production 
The experimental protocol is as illustrated in Figure 2.1 below. Rats were randomly 
assigned to four different treatment groups, namely 1) S-allylcysteine (SAC) (50mg/kg 
b.w./day); 2) SAC+ propagylglycine (PAG) (50mg +10mg kg/b.w./day);  3) PAG 
(10mg/kg b.w./day) and  4) vehicle (saline) control group. The dose of SAC was selected 
based on a preliminary dose-dependent study which identified this dosage (50mg/kg 
b.w./day)  as the optimal dose to improve infarct size and mortality in rats subjected to 
AMI. 
The animals were pre-treated (prior to MI induction) with their respective treatment drugs 
for seven days via intra-peritoneal injection once daily. Blood pressure (BP), 
electrocardiogram (ECG) and heart rate (HR) were measured on three occasions 
throughout the animal model study. Firstly, BP, ECG and HR readings were recorded 
prior to the start of treatment (day 1). Subsequently, readings were taken on day seven 
after one week of drug pretreatment. The last set of readings was measured 48 hrs post-
MI prior to the sacrifice of the animal on day 10.  
MI was induced on day eight as described above (2.2.1.1). Following the surgery, 
treatment with their respective drugs continued for a further two days until the animals 
were sacrificed 48 hours post-surgery. Upon sacrifice, blood samples (5ml) were 
withdrawn from the apex of the right ventricle using a heparinized syringe for 
measurements of plasma H2S concentrations (as described below). Blood collected was 
immediately placed on ice and centrifuged at 4000G for 10min at 4°C. The plasma was 




aspirated and stored at -80°C. In addition, the heart was excised and subjected to at least 
three washes in ice-cold saline, then immersed in liquid nitrogen before storing at -80°C 
for subsequent experimental assays, including Western blot, H2S production assay, Griess 
assay and PCR.  Also, freshly isolated hearts were used for the measurement of infarct 
size, hypertrophy index and for morphological examination as described in the section 




Figure 2.1 Schematic representation of experimental protocol 1. Animals were treated with 
their respective drugs for a period of 1 week before inducing MI on day 8 and sacrificed 48hr 
post-MI. Blood and heart samples were collected for various assays. For details, please refer to 
the text.  




2.3.2 Experimental Protocol 2 — NO-mediated Cardioprotection by Sildenafil 
involves a CSE/H2S-related pathway during Myocardial Ischemia 
The experimental protocol for this part of the study is as portrayed in Figure 2.2 below. 
Rats were randomly assigned to three different treatment groups, namely 1) sildenafil 
(0.7 mg/kg b.w./day); 2) L-NAME (30mg kg/b.w./day);  and  3) vehicle (saline) control 
group. The dose of sildenafil employed is equivalent to a clinical dose of 50mg given to a 
70kg patient with erectile dysfunction. 
The animals were pre-treated with their respective treatment drugs for seven days via the 
intra-peritoneal route. BP, ECG and HR were measured on three occasions throughout 
the study. Firstly, BP, ECG and HR readings were recorded prior to the start of treatment. 
Subsequently, readings were taken on day seven after one week of drug pretreatment. 
The last set of readings was measured 48 hrs post-MI before the animal was sacrificed. 
MI was induced on day eight as described above. Following the surgery, treatment with 
the respective drugs continued for a further two days. Upon sacrifice, blood samples (5ml) 
were withdrawn from the apex of the right ventricle using a heparinized syringe for 
measurements of plasma H2S concentrations and nitrate/nitrite concentrations. Nitrate 
and nitrite are the end-products of NO metabolism, and hence, used as a surrogate marker 
of NO production. Blood collected was immediately placed on ice and centrifuged at 
4000G for 10min at 4°C. The plasma was aspirated and stored at -80°C. In addition, the 
heart was excised and subjected to at least three washes in ice-cold saline, then immersed 
in liquid nitrogen before storing at -80°C for subsequent experimental assays, including 
Western blot, Griess assay and H2S production assay.  Also, freshly isolated hearts were 




used for the measurement of infarct size and hypertrophy index as described in the 












Figure 2.2 Schematic representation of experimental protocol 2. Animals were treated 
with their respective drugs for a period of 1 week before inducing MI and sacrificed 48hr 
post-MI. Blood and heart samples were collected for various assays. For details, please refer 
to the text.  
 




2.3.3 Experimental Protocol 3 — Relationship between H2S and NO in a Rat Model 
of AMI 
The experimental protocol is as described in Figure 2.3 below. Rats were randomly 
assigned to five different groups, namely 1) NaHS (14µM/kg b.w./day); 2) molsidomine 
(5mg kg/b.w./day);  3) PAG (10mg/kg b.w./day); 4) L-NAME (30mg/kg b.w./day) and 5) 
vehicle (saline) control groups. The dose of molsidomine employed (5mg/kg b.w./day) is 
based on a preliminary dose-dependent study (5mg, 10mg and 20mg/kg b.w./day) which 
utilized infarct size and mortality as a basis to select the best dose. 
The animals were pre-treated for seven days with their respective drugs via intra-
peritoneal injection once daily. BP, ECG and HR were measured on three occasions 
throughout the study. Firstly, BP, ECG and HR readings were recorded prior to the start 
of treatment. Subsequently, readings were taken after one week of drug pretreatment and 
the last set of readings was measured 48 hrs post-MI. 
MI was induced on day eight as described above. Following surgery, treatment with the 
respective drugs continued for a further two days until the animals were sacrificed 48 
hours post-surgery. Upon sacrifice, blood samples (5ml) were withdrawn from the apex 
of the right ventricle for measurements of plasma nitrate/nitrite concentrations as well as 
plasma H2S concentrations. Blood collected was immediately placed on ice and 
centrifuged at 4000G for 10min at 4°C. The plasma was aspirated and stored at -80°C. In 
addition, the heart was excised and subjected to at least three washes in ice-cold saline, 
then immersed in liquid nitrogen before storing at -80°C for subsequent experimental 
assays, including Western blot, Griess assay, H2S production assay and PCR.  Freshly 




isolated hearts were also used for the measurement of infarct size and hypertrophy index 
as described below.  
 
 Fig 2.3 Schematic representation of experimental protocol 3. Animals were treated with 
their respective drugs for a period of 1 week before inducing MI and sacrificed 48hr post-
MI. Blood and heart samples were collected for various assays. For details, please refer to 
the text.  
 




2.3.4 Experimental Protocol 4 — H2S exerts Cardioprotection by enhancing HIF-1α 
activation and iNOS expression through the PI3K/Akt-dependent pathway 
H9c2 
Six treatment groups were employed; namely (i) normoxic controls; (ii) hypoxic controls; 
(iii) normoxic 300µM NaHS, (iv) hypoxic 300µM NaHS; (v) hypoxic 100nM 
wortmannin + 300µM NaHS and (vi) hypoxic 200nM wortmannin + 300µM NaHS.  
Hypoxia was induced by incubating cells with 200µM CoCl2, a hypoxia mimetic, for 24h. 
The treatment groups are more clearly illustrated in Table 2.1 below. 
For experiments, h9c2 were quantified and seeded either at a density of 2x105 cells/T-75 
flask or at a density of 5000 cells/well into 96 well-plates. Cells were allowed to grow 
overnight to reach 80% confluence. The medium was then removed with a single wash of 
PBS and replaced with serum-free medium. The cells were then allowed to adapt 
overnight. Subsequently, the cells were treated with 300µM NaHS for 1h prior to 
addition of 200µM CoCl2 to induce hypoxia. In treatment groups where PI3K inhibitor 
wortmannin was employed, the cells were treated with the chemical 1h prior to the 




Fig 2.4 Schematic representation of experimental protocol 4 (h9c2). H9c2 were 
equilibrated in serum-free medium overnight before treatment with their respective 
drugs as illustrated.  For details, please refer to the text. 
 




GROUPS TREATMENT PROTOCOL 
 wortmannin 300µM NaHS 200µM CoCl2 
Normoxic control    
Hypoxic control    
Normoxic + 300µM NaHS    
Hypoxic + 300µM NaHS    
Hypoxic + 100nM wortmannin + 300µM NaHS    
Hypoxic + 200nM wortmannin + 300µM NaHS    
 
Cardiomyocytes 
Six treatment groups were employed; namely (i) normoxic controls; (ii) hypoxic controls; 
(iii) normoxic 100µM NaHS, (iv) hypoxic 100µM NaHS; (v) hypoxic 100nM 
wortmannin + 100µM NaHS and (vi) hypoxic 25µM LY 294002 + 100µM NaHS.  
Hypoxia was induced by incubating cells with 200µM CoCl2, a hypoxia mimetic, for 1h. 
Table 2.2 shows the various treatment groups for myocytes. 
Cardiomyocytes were allowed to grow in culture for 72h before using for experiments. 
On the day of treatment, the medium was removed with 2 washes of PBS and replaced 
with fresh medium. The myocytes were allowed to adapt to the fresh medium for 1h 
before initiating the treatment protocol. Cells were treated with 100µM NaHS for an hour 
before adding 200µM CoCl2 to induce hypoxia. In treatment groups where PI3K 
inhibitors wortmannin or LY 294002 were employed, the cells were treated with the 
chemicals 1h prior to the addition of 100µM NaHS. The experiment protocol is as 
illustrated in Figure 2.5 below. 
Table 2.1 Treatment groups for h9c2. 







GROUPS TREATMENT PROTOCOL 
 PI3K inhibitor 100µM NaHS 200µM CoCl2 
Normoxic control    
Hypoxic control    
Normoxic + 100µM NaHS    
Hypoxic + 100µM NaHS    
Hypoxic + 100nM wortmannin + 100µM NaHS    
Hypoxic + 25µM LY 294002 + 100µM NaHS    
 
Fig 2.5 Schematic representation of experimental protocol 4 (myocytes). 
Myocytes were equilibrated in fresh medium for an hour before initiating the various 
treatment protocols. For details, please refer to the text. 
 
Table 2.2 Treatment groups for cardiomyocytes. 




2.4 EXPERIMENTAL METHODS 
ANIMAL 
2.4.1 Measurement of Infarct Size  
Three rats from each treatment group that underwent the MI procedure were randomly 
chosen for the measurement of infarct size. Upon sacrificing the animal, the isolated heart 
was washed in saline to clear the ventricles of any residual blood. The heart was then 
immersed in 1% triphenyl tetrazolium chloride (TTC) solution for approximately 30 
minutes. This technique relies on the ability of dehydrogenase enzymes and cofactors in 
the non-infarcted tissue to react with terazolium salts to form a formazan pigment. 
Infarcted myocardium lacks dehydrogenase activity and fails to stain (Fishbein et al., 
1981). Ischemic myocardium remained pale where as the non-ischemic zone was stained 
deep purple. At the end of the 30 minutes, TTC solution was drained, and the left 
ventricle (LV) was separated from the rest of the heart and placed between two 
microscope slides which were secured with clips. The stained LV was then scanned and 
the image was stored digitally. Total left ventricular area and the infarct area were 
determined by computerized planimetry (Scion Image, CA, USA). Infarct size was 
expressed as a percentage of the infarct area to the LV area (Zhu et al., 2006). 
2.4.2 Measurement of Hypertrophy Index 
The animal was weighed prior to their sacrifice and their weight recorded in grams (g). 
Isolated rat heart was also weighed upon sacrificing and the wet weight of the heart was 
recorded in milligram (mg). Hypertrophy index, an indicator of ventricular hypertrophy, 




was determined by the ratio of the whole heart weight in milligrams over body weight in 
grams.  
2.4.3 Hemodynamic Measurements 
2.4.3.1 Blood Pressure 
BP was measured by the tail-cuff method using the NIBP (Non-invasive Blood Pressure) 
System (ML125/R, ADInstruments Powerlab System, Castle Hill, New South Wales, 
Australia) which uses a specialised tail cuff and pulse transducer to measure BP at 
intervals based on the periodic occlusion of tail blood flow. The rat was placed in a heat-
box for approximately 10 min and heat was applied to its tail using a tungsten lamp to 
facilitate the detection of arterial pulse by the NIBP. Triplicate readings of BP were 
obtained on each occasion.  
2.4.3.2 Electrocardiogram (ECG) and Heart Rate 
ECG was recorded in the anaesthetized animal for a period of one minute using the 
Animal BioAmp amplifier (ML 136, ADInstruments Powerlab System) as described 
(Cher et al., 2005; Zhu et al., 2000). The amplifier amplifies and filters the small 
bioelectrical signals associated with nerve and muscle activity. In addition, heart rate of 
the anaesthesized rat was also monitored for at least one full minute.  




2.4.4 Morphological Examination— Hematoxylin & Eosin staining 
After sacrificing the animal, hearts obtained from all treatment groups were isolated and 
washed immediately in 3 changes of ice-cold saline. Transverse sections of the hearts 
from three rats of each treatment group were obtained and stored individually in 
histology cassettes which were subsequently immersed in 10% buffered neutral formalin 
solution. Following fixation, the heart tissue was processed and embedded in paraffin.  
The myocardial tissue was then sectioned at 5µm and mounted onto a microscropic slide.  
Briefly, the paraffin sections were deparaffinised by soaking slides in xylene for 
approximately 10 min. This was followed by a series of rehydration steps by immersing 
slides in 100% ethanol, 95% ethanol, 80% ethanol and deionised water in the stated order. 
Next, the slides were stained in hematoxylin, followed by rinsing in distilled water to 
clear the excess stain. Eosin counterstaining was followed by immersing the slides in 
eosin for 30 seconds to two minutes, depending on the age of eosin.  The slides were 
dehydrated in graded concentrations of ethanol, starting from 70%, followed by 80% and 
absolute ethanol until excess eosin was removed. Slides were then soaked in xylene for 
10 min. to clear the ethanol. Last but not least, a drop of Permount (mounting medium) 
was used to mount the coverslip and it was ensured that no air bubbles were trapped and 
that the mounting medium covered the entire tissue. The slides were left to dry overnight 









2.4.5 Cell Count 
Cells were counted before seeding into either a T-75 flask or a 96-well plate to ensure 
that the number of cells used for each assay is uniform. This will prevent inconsistencies 
in cell numbers from confounding the experimental data. Cell counting was done using a 
haemocytometer. The number of cells in each 1mm2 area should be kept between 15-50 
cells for an accurate determination. Triplicate readings were made from each cell 
suspension sample.  
2.4.6 MTT Assay 
Cell viability was determined using the colorimetric MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) (Roche, Mannheim, Germany) assay. This assay is 
based on cleavage of yellow tetrazolium salt MTT to purple formazan crystals by 
metabolically active cells. The formazan crystals are solubilized, and the colour change 
can then be measured spectrophotometrically. 
Briefly, cells were grown in 96-well plates at a density of 5000 cells/well as described 
earlier. After being subjected to their respective treatment protocols, 10µl of 5mg/ml 
yellow MTT were added to each well and incubated at 37°C under 5% CO2 for 4h. At the 
end of the incubation period, the medium in each well was removed by quickly flipping 
the plate over. Purple formazan salt crystals which are attached to the cells adhered to the 
base of the wells and can then be solubilized by the addition of 100µl DMSO. The plate 
was then incubated for a further 10min at 37°C for the formazan crystals to dissolve fully 
after which the optical density was measured at 550nm using the SUNRISE Absorbance 




microplate reader (Tecan Systems Inc., Switzerland). Data were expressed as a 
percentage of viable cells compared to the normoxic controls.  
2.4.7 LDH Assay 
Cell death was analyzed by using the LDH based in vitro toxicology assay kit (TOX-7, 
Sigma, St Louis, MO, USA). Cytotoxicity is typically determined by quantifying the 
extent of plasma membrane damage. Lactate dehydrogenase (LDH) is a stable 
cytoplasmic enzyme which is present in all cells. Thus, the LDH assay allows the 
measurement of membrane integrity as a function of cytoplasmic LDH released into the 
medium. The assay is based on the reduction of NAD to NADH by the action of LDH. 
The NADH formed is utilized in the conversion of a tetrazolium dye to a soluble, 
coloured formazan derivative.  
Briefly, cells were grown in 96-well plates at a density of 5000 cells/well as described 
earlier. After their respective treatments, 60µl of medium was removed from each well 
and transferred to a new 96-well plate. 30µl of the LDH assay mixture containing equal 
volumes of LDH assay substrate, LDH Cofactor and LDH dye solution were then added 
into each of the wells. The plate was immediately protected from light and incubated at 
room temperature for 30min. Following, 9µl of 1M hydrochloric acid was added to each 
well to quench the reaction and the plate was then read at an absorbance of 490nm with a 
background absorbance of 690nm. Data were presented as a percentage of cytotoxicity as 
determined by the amount of LDH released compared to normoxic controls. 
 
 




2.4.8 Trypan Blue Exclusion Assay 
Trypan Blue exclusion assay was used to further validate cell viability. It is based on the 
principle that viable cells have intact cell membranes, and hence, are able to exclude the 
uptake of this dye. On the contrary, the membranes of dying cells are ruptured and are 
thus able to take up the dye. Briefly, cells were grown in T-75 flasks and subjected to the 
various treatment protocols. The cell pellet was then collected after the trypsin 
neutralization step and resuspended in PBS. 100µl of the cell suspension was thoroughly 
mixed with 100µl of Trypan Blue by pipetting. Next, 9µl of the mixture was then loaded 
onto a haemocytometer for cell counting as described earlier. Viable cells remain 
unstained, while dead cells stained blue. Cell viability was expressed as a percentage of 
viable unstained cells over the total cells present. Data were presented as a percentage of 










2.4.9 Measurement of CSE Activity in the Left Ventricle 
H2S-synthesizing activity of myocardial tissue in the LV was assayed as described by 
Stipanuk and Beck, with slight modifications (Stipanuk et al., 1982). Briefly, 0.1g of left 
ventricular myocardial tissue was thawed on ice and homogenized in 2ml of 100mM ice-
cold potassium phosphate buffer (pH 7.4). The tissue homogenate was subsequently 
centrifuged at 24000G for 5min at 4°C and the supernatant obtained was used for the 
assay. The reaction mixture contained 20µl of 10mM L-cysteine, 20µl of 2mM 
pyridoxal-5-phosphate, 30μl of saline and 430µl tissue homogenate. The reaction mixture 
was prepared in 2ml microtubes and sealed with a double layer of Parafilm. The catalytic 
reaction was initiated by transferring the tubes from ice to a 37°C water bath where the 
tubes were incubated for 30 minutes. 250µl of 1% zinc acetate was then added to the 
tubes using a 25G needle to trap the evolved H2S. 250µl of 10% trichloroacetic acid 
(TCA) was next added to quench the enzymatic reaction. 133 µl of N,N-dimethyl-p-
phenylenediamine dihydrochloride (NNDPD) in 7.2M hydrochloric acid (HCl) and 133 
µl of iron chloride (FeCl3) in 1.2M HCl were next added in sequence. The absorbance of 
the final reaction mixture was measured at 670nm using a 96-well microplate reader 
(Tecan Systems Inc., Switzerland).  
For every sample, the background H2S concentration was determined. Enzymatic activity 
of cystathionine-γ-lyase (CSE) was arrested by the addition of 10% TCA prior to addition 
of L-cysteine and pyridoxal phosphate. This served as the basal H2S level in the tissue 
homogenate. Similarly, all samples were assayed in duplicates and the H2S concentration 




for each sample was calculated against a calibration curve for NaHS (3.125µM – 250µM). 
Results are expressed as µmol/g protein/hr. Protein quantitation was determined using the 
Bradford assay (Bio-Rad, CA, USA). 
2.4.10 Measurement of H2S Concentration in the Plasma 
Plasma H2S concentration was determined as described (Mok et al., 2004). Briefly, 75µl 
of plasma was added into a 1.5ml microtube containing 0.25ml of 1% zinc acetate and 
0.425ml of distilled water. H2S is chemiadsorbed by zinc acetate and transformed into 
stable zinc sulfide. The sulfide is then recovered by extraction with water. Next, 20mM 
of NNDPD in 7.2M HCl and 30mM FeCl3 in 1.2M HCl were added into each microtube. 
The solution was then incubated at room temperature for ten minutes. In contact with 
FeCl3 in a strongly acid solution, the extracted sulphide reacts with N,N-dimethyl-p-
phenylendiammonium ion to yield methylene blue. Following, 0.25ml of 10% TCA was 
added to remove the proteins present. The microtubes were briefly shaken after each 
addition. This final solution was then centrifuged at 24000G for 5min at 4°C. The optical 
absorbance of the resulting supernatant was measured at 670nm using a 96-well 
microplate reader (Tecan Systems Inc., Switzerland).  
Each plasma sample was assayed in duplicates and H2S concentration was calculated 
against a standard calibration curve of NaHS (3.125µM to 250µM) which was performed 
on the same day the samples were measured. 
 
 




2.4.11 Measurement of Nitrate/Nitrite (NOx) Concentration in Left Ventricle and 
Plasma  
NO is rapidly oxidised into its stable end products, nitrate and nitrite in the body. As such, 
the amount of nitrate/nitrite (NOx) is used as an indicator of endogenous NO synthesis 
(Li et al., 2009). NOx levels in the LV and plasma were determined according to the 
method of Green (Green et al., 1982) with slight modifications.  
For the preparation of tissue samples, left ventricular tissues (10% w/v) were 
homogenized in ice-cold PBS. Tissue homogenates were then centrifuged at 24000G for 
30min at 4°C. A portion of the supernatant was set aside for the quantification of total 
cellular protein using the Bradford method. The remaining supernatant was then filtered 
through 10K Molecular Weight Cut-Off (MWCO) Vivapsin tubes (Sartorius; Goettingen, 
Germany).  
80µl of each tissue/plasma sample was incubated together with 20µl of the 
enzyme/cofactor Mastermix in a 96-well plate for 30 minutes at 37°C and this was 
protected from light by covering the plate with aluminium foil. The enzyme/cofactor 
Mastermix is made up of 250µl of 0.1mM flavin adenine dinucleotide (FAD), 250µl of 
2mM β-NADPH and 500µl of 2U/ml nitrate reductase. The reaction was initiated by the 
reduction of nitrate to nitrite by nitrate reductase. At the end of the incubation, 100µl of 
Griess reagent, (1:1 ratio of 0.2% w/v N-1 napthylethylenediamine in 5% H3PO4: 2% w/v 
sulphanilamide in 5% H3PO4) which detects the presence of organic nitrite was added to 
each well to terminate the reaction. Addition of Griess reagent resulted in the formation 
of a purple-pink azo dye. Nitrite levels were then determined spectrophotometrically at 




λ=540nm. Each sample was assayed in duplicates and nitrite concentration was 
calculated against a standard calibration curve of sodium nitrite (0µM to 100µM) 
performed on the same day when the assay was conducted. NOx levels in the tissue are 
expressed as umol/g protein and that in plasma expressed as NOx concentration (µM). 
2.4.12 Measurement of Nitrate/Nitrite Concentration in Cell Medium 
NOx levels were quantified in the cell medium using a Nitrate/Nitrite Colorimetric Assay 
kit purchased from Cayman (MI, USA). Briefly, 1ml of cell medium was collected from 
each treatment group and immediately placed on ice after the termination of their 
treatment protocols.  The assay was performed on the same day as medium collection. 
80µl of each sample was added to wells on a 96-well plate. Next, 10µl of Enzyme 
Cofactor mixture was added, followed by 10µl of Nitrate Reductase mixture. The plate 
was then covered with a plate cover to minimize evaporation and incubated at room 
temperature for 2h in the dark. Following incubation, 50µl of Griess reagent 1 was added 
to each well, and this was immediately followed by the addition of 50µl Griess reagent 2. 
The color was allowed to develop for 10min and the absorbance was quantified using a 
96-well microplate reader (Tecan Systems Inc., Switzerland). A nitrate standard curve 
(0µM to 35µM) was performed each time the samples were assayed. NOx levels in the 
medium were expressed as µmol/ml medium/106cells. 
2.4.13 Total RNA Isolation from Animal Tissue 
Total RNA was isolated from the LVs of rats from each treatment group according to a 
modified method of Chomczynski and Sacchi as previously reported (Zhu et al., 2000). 
Briefly, 100mg of tissue sample was homogenized in 1ml of ice-cold Trizol reagent 




(Invitrogen, CA, USA) using a homogenizer (Diax 900, Heidolph, Germany). 
Subsequently, the homogenate was centrifuged at 12000G for 10min at 4°C to remove 
insoluble materials. The supernatant containing the RNA was then transferred to a fresh 
tube and incubated at room temperature for 5 minutes to allow complete dissociation of 
nucleoprotein complexes. Next, 0.2ml of chloroform was added and the tubes were 
shaken vigorously for 15 seconds and centrifuged again at 12000G for 15min at 4°C. 
RNA remained exclusively in the colourless aqueous phase. Following, RNA was 
precipitated by the addition of 0.5ml isopropanol and incubated at room temperature for 
10 min. The sample was once again centrifuged at 12000G for 10min at 4°C. RNA pellet 
was then formed at the side and bottom of the tube. After which, the pellet was washed 
with 75% ethanol and centrifuged at 7500G for 5min at 4°C. The RNA pellet was air-
dried to remove traces of ethanol, re-dissolved in 40µl diethyl pyrocarbonate (DEPC) 
water and incubated at 55°C-60°C for 10 min on a heat block. The RNA sample was then 
immediately placed on ice to prevent RNA degradation. 
2.4.14 Total RNA Isolation from Cell Sample 
Total RNA was isolated from h9c2 and cardiomyocyte samples using RNeasy Mini Kit 
(Qiagen, Hilden, Germany). After collection of cell pellet following trypsin neutralization, 
350µl of Buffer RLT was added and each tube was vortexed briefly. The samples were 
then homogenized by passing the cell lysate at least 10 times through a blunt 20-gauge 
needle fitted to an RNase-free syringe.  An equal volume of 70% ethanol was then added 
to each tube and mixed well by pipetting. The samples were next transferred to an 
RNeasy spin column placed in a 2ml collection tube, which was then centrifuged at 
8000G for 15s at 24°C. The flow-through was discarded, and 700µl of Buffer RW1 was 




added to the spin column, and centrifuged at 8000G for 15s at 24°C for a second time. 
Once again, the flow-through was discarded, and 500µl Buffer RPE was added to the 
spin column to wash the RNA adhering to the spin column membrane by centrifuging at 
8000G for 15s at 24°C. This was repeated another time. Finally, to elute the RNA, 30µl 
of RNase-free water was added directly to the spin column membrane and centrifuged at 
8000G for 1min at 24°C. The eluate collected is then immediately placed on ice prior to 
RNA quantitation to prevent RNA degradation. 
2.4.15 RNA Quantitation 
The RNA isolated was quantified and degree of purity verified using a 
spectrophotometer (Nanodrop 1000, Thermo Fisher Scientific, MA, USA). RNA 
quantitation was performed by measuring the absorbance at 260nm and the ratio of 
A260/A280 was used to determine its purity. RNA was subsequently stored at -80°C for 
reverse transcriptase-polymerase chain reaction (RT-PCR). 
2.4.16 Reverse transcription-Polymerase Chain Reaction (RT-PCR) 
RT-PCR was performed using a two-step RT-PCR kit obtained from Takara (Shiga, 
Japan). The first part involves reverse transcription of mRNA to cDNA. Briefly, 1 µg of 
RNA was placed in a 0.2ml microtube together with 1µl of 50µM oligo(dT)12-18 primer 
and topped up to 6µl with RNase-free distilled water. The mixture was briefly mixed and 
subsequently heated at 70°C for 10min. Next, the tubes were rapidly cooled on ice for 
5min and briefly centrifuged to concentrate the reagents to the bottom of the tube. After 
which, 2µl of 5x M-MLV Buffer, 0.5µl of 10mM dNTP mixture, 0.25µl RNase inhibitor 
(40U/µl), 0.5µl reverse-transcriptase M-MLV and 0.75µl of RNase-free distilled water 




were added to each tube. The tubes were briefly vortexed and incubated at 42°C for 1h, 
followed by 70°C for 15min and rapidly placed on ice thereafter. The cDNA synthesized 
was then either used for PCR amplification, or stored at -20°C for later use.  
In the second part, PCR amplification was carried out in a total volume of 50µl, 
containing 5µl template cDNA, 33.75µl RNase-free water, 0.25µl of 5U/µl Takara Ex 
Taq, 5µl 10x ExTaq buffer, 4µl 2.5mM dNTP mixture, 1µl 20µM reverse primer and 1µl 
20µM forward primer. It is crucial that the preparation work was performed on ice. PCR 
amplification was carried out in a thermocycler (GeneAmp PCR System 2700). Three-
step PCR of denaturation, annealing and extension were executed at 94°C for 30 seconds 
for the denaturation step, and 72°C for 30 seconds for the elongation step. Depending on 
the PCR product size and melting temperature of the different primers, the annealing step 
duration and temperature were adjusted accordingly. It was ensured that the PCR 
amplification cycle number for each gene of interest was in the linear range and the 
plateau phase was not reached. GAPDH was employed as the housekeeping control. 
Primer sequences are given in Table 2.3 and conditions for the target genes with their 
corresponding product sizes are as listed in Table 2.4. 
Upon completion of PCR, the products were run and separated by agarose gel 
electrophoresis. A 1.5% agarose gel was prepared by dissolving agarose in Tris-acetate-
EDTA (TAE) buffer and microwaved. The agarose solution was allowed to cool briefly 
and 0.05% GelRed®(Biotium, CA, USA) was added to stain DNA. Following, 10µl of 
sample product was loaded into each well and electrophoresis was conducted at 120mV. 
 










Genes Sequence GenBank Access No. 
eNOS (s) 5’-CTG GCA AGACCG ATT ACA CGA C-3’ NM_021838 
(as) 5-CGC AAT GTG AGT CCG AAA ATG-3’ 
iNOS (s)5’-CTA CCT ACC TGG GGA ACA CCT GGG-3’ NM_012611 
(as)5’-GGA GGA GCT GAT GGA GTA GTA GCC G-3’ 
nNOS (s)5’-AAT GGA GAC CCC CCT GAG AAC-3’ NM_052799 
(as)5’-TCC AGG AGG GTG TCC ACC GC-3’ 
CSE (s)5’-CAT GGA TGA AGT GTA TGG AGG C-3’ AY032875 
(as)5’-CGG CAG CAG AGG TAA CAA TCG-3’ 
HIF (s)5’- GAA GTT AGA GTC AAG CCC AGA G 3’ NM_023459.1 
(as)5’- GTG GCA GTG ACA GTG ATG GTA G -3’ 
GAPDH (s) 5’-CAT GGT CTA CAT GTT CCA GT-3’ XM_221353 
(as) 5’-GGC TAA GCA GTT GGT GGT GC-3’ 





eNOS 28 55 45 423 
iNOS 38 60 45 442 
nNOS 42 60 30 383 
CSE 34 55 45 444 
HIF 28 54 30 414 
GAPDH 25 55 30 349 
Table 2.3 Primer sequences for each gene of interest, including eNOS, iNOS, nNOS, 
CSE, HIF and GAPDH. 
Table 2.4 Conditions (cycle number, annealing temperature and duration) used for PCR 
amplification for eNOS, iNOS, nNOS, CSE, HIF and GAPDH. The cDNA product sizes of 
each gene are also shown. 




2.4.17 Collection of Nuclear and Cytoplasmic Extracts 
NE-PER® Nuclear and Cytoplasmic Extraction Reagents were obtained from Pierce 
Biotechnology (Rockford, IL, USA). Briefly, after obtaining the cell pellet following the 
trypsin neutralization step at the end of treatment, 100µl of ice-cold Cytoplasmic 
Extraction Reagent I (CER-I) which was pre-loaded with protease inhibitor cocktail and 
phosphatase inhibitor cocktails was added  The tube was then vortexed vigorously for 15s 
to fully resuspend the cell pellet. Thereafter, the sample was placed on ice for 10min. 
Next, 5.5µl of CER-2 was added and the mixture was vortexed and incubated on ice for 
1min. The tube was vortexed for a second time, and centrifuged at 16000G for 5min at 
4°C. The supernatant containing the cytoplasmic fraction was immediately transferred to 
a clean pre-chilled tube which was placed on ice or stored at -80°C until use. 
Subsequently, the pellet fraction was resuspended in 30µl of ice-cold Nuclear Extraction 
Reagent (NER). This was then vortexed for 15s and returned to ice, and continued 
vortexing for 15s every 10 minutes, for a total of 40 minutes. Finally, the tube was 
centrifuged at 16000G for 10min at 4°C. The supernatant containing the nuclear extract 
was then transferred to a clean chilled tube and placed on ice. Samples were then stored 
at -80°C until use. 
2.4.18 Electrophoretic Mobility Shift Assay (EMSA) 
Nuclear extracts were obtained from cell samples as described above. EMSA was 
performed on the same day as nuclear protein extraction. This assay is used to identify 
protein: nuclei acid interactions based on the principle that protein: DNA complexes 




migrate more slowly through a native polyacrylamide gel than unbound DNA. It allows 
for the detection of transcription factors binding to DNA. 
The gel-shift oligonucleotide probes for wild-type HIF-1α [(s) 5’-
TCTGTACGTGACCACACTCACCTC-3’ and (as) 5’-GAGGTGAGTGTGGTCACGTACAGA-
3'] and mutated HIF-1α [(s) 5'-TCTGTAAAAGACCACACTCACCTC-3' and (as) 5'-
GAGGTGAGTGTGGTCTTT
The specific DNA: protein complex was separated on a 6% native polycarylamide gel. 
The gel was pre-electrophoresed using ice-cold 0.5x Tris-Borate EDTA (TBE) buffer for 
1h at 100V to remove ammonium persulfate from the gel and to ensure a constant gel 
temperature. 5µl of 5x loading buffer was added to each 20µl binding reaction and mixed 
TACAGA-3'] were labeled with biotin at the 3’end using the 
Biotin 3’end DNA Labeling Kit obtained from Pierce (Rockford, IL, USA). Briefly, the 
binding reaction mixture consisted of 5 µg of nuclear protein, 1µg of poly(dI-dC), 2µl 
10x binding buffer, 1µl 50% glycerol, 1µl 100mM MgCl2, 1µl 1M KCl, 1µl 1% NP-40, 
0.25µl 50µg/µl BSA, 0.1µl 100mM dithiotreitol (DTT) and 1µl 200mM EDTA. 0.3125µl 
of 50fmol biotin-labeled wild-type probe was then added to each tube, and the reaction 
mixture was topped up to 20µl with double distilled water. The mixture was then 
incubated at room temperature for 20min to allow binding to take place. In control 
experiments, mutated probe was used in place of the wild-type probe to ensure the 
specificity of the labeled probe. In addition, 0.1µl of HIF-1α antibody was also added to 
the reaction tube containing wild-type labeled probes. This super-shift control experiment 
will further retard the migration of the complex due to the presence of the antibody 
binding to the transcription factor. Furthermore, negative controls were also performed 
by omitting the addition of labeled probes and substituting it with an unlabelled version. 




gently by pipetting. The samples were then loaded into the wells and gel electrophoresis 
was conducted using fresh ice-cold 0.5x TBE buffer at 100V for 75 minutes. 
Subsequently, transfer was carried out using Biodyne B Nylon membrane (Pierce, 
Rockford, IL, USA) at 380mA, 60min with fresh ice-cold 0.5x TBE buffer with constant 
stirring. Following, the membrane was then cross-linked at 120mJ/cm2 for 60s using a 
commercial UV light cross-linker instrument (XLE-1000, Spectroline, NY, USA). 
This was followed by blocking the membrane with gentle shaking with the Blocking 
Buffer for 15min and further incubated with conjugate/blocking buffer for another 15 min 
with gentle agitation. Next, the membrane was washed briefly with the Wash Buffer for 4 
cycles of 5 minutes each on a rocker platform. The membrane was then transferred to a 
container with Substrate Equilibration Buffer and incubated for 5 minutes with gentle 
shaking. Subsequently, the membrane was blotted on a paper towel to remove the excess 
buffer, and incubated with the Substrate Working Solution for 5 minutes without shaking. 
Finally, biotin-labeled DNA on the membranes was detected by chemiluminescence. 
Band shifts were visualized by exposure to X-ray film. 
2.4.19 Protein Extraction from Animal Tissue 
Briefly, 0.1g left ventricular tissue from each rat was homogenized in 1ml of ice-cold 
CelLytic (Sigma, MO, USA) mammalian tissue extract lysis buffer using a Heidolph 
DIAX900 homogenizer (Heidolph Instruments, Germany). 10µl of protease inhibitor 
cocktail was also added to each sample to prevent the degradation of protein in the tissue 
extract. The ventricular homogenate was then centrifuged at 24000G for 10min at 4°C. 
The supernatant fraction containing the cellular protein was collected and stored at -80°C 




until use. Protein concentration was determined by measuring the absorbance at 280nm 
using a spectrophotometer (Nanodrop 1000, Thermo Fisher Scientific, MA, USA). 
2.4.20 Protein Extraction from Cells 
Growth medium was removed, and the cells were rinsed once with PBS. Cells were then 
trypsinized and centrifuged at 700rpm for 3min at room temperature. The supernatant 
was subsequently discarded, and 40µl (myocyte in 35mm Petri-dish) or 120µl (h9c2 in T-
75 flask) of CelLytic (Sigma, MO, USA) mammalian cell extract lysis buffer was then 
added to resuspend the cell pellet. Protease inhibitor and phosphatase inhibitor cocktails 
were added. The cell suspensions were placed on ice and incubated for 20min on a shaker 
to allow cell lysis to take place.  
Following, lysed cells were centrifuged at 16000G for 15min at 4°C to pellet the cellular 
debris. The supernatant fraction containing the cellular protein was collected and stored 
at -80°C until use. Protein concentration was determined by measuring the absorbance at 
280nm using a spectrophotometer (Nanodrop 1000, Thermo Fisher Scientific, MA, USA). 
2.4.21 Western Blot 
50µg of protein samples (total cell lysate, nuclear extract or cytoplasmic extract) were 
boiled at 95°C for 5min prior to loading for 10% SDS-polyacrylamide gel electrophoresis 
(PAGE). Electrophoresis was performed at 120V for 75 minutes and the proteins were 
subsequently transferred from the gels to PVDF membranes. Protein transfer was carried 
out at 100V for 60 minutes at 4°C with constant stirring. Subsequently, the membranes 
were blocked with 5% BSA in 1x Tris-buffered saline containing 0.1% Tween-20 (TBS-




T) at room temperature for 60 minutes. After blocking, the membranes were incubated 
with their respective primary antibodies as listed in Table 2.5 below.  
β-tubulin (1:1000, Sigma, USA) was used as the loading control for both animal tissue 
and h9c2 cell-line. α-tubulin (1:1000, Santa Cruz, USA) was used as the loading control 
for cardiomyocyte samples. Additionally, histone was employed as the loading control 
for nuclear extracts. The incubation was performed at 4°C overnight on a rocking 
platform. The membranes were then washed in TBS-T and incubated with their 
respective horseradish peroxidase-conjugated secondary antibodies for 60 minutes (refer 
to Table 2.5 below). Protein bands were visualized by chemiluminescence using an ECL 
detection system (Pierce Biotechnology, Rockford, IL, USA). Protein quantification was 
done by measuring band intensities using the BioRad QuantityOne software. Protein 
amounts are expressed by normalizing the band intensities from the various treatment 
groups to their corresponding loading controls. Results are reflected as the fold difference 
in protein expression of different treatment groups to that of the saline control (animal 












2.5 STATISTICAL ANALYSIS 
Results shown are mean ± S.E.M. Statistical comparisons between groups were analyzed 
using One-way analysis of variance (One-way ANOVA) with post-hoc Tukey’s test 
using GraphPad Prism software (version 5, 2007). The statistical significance of 
difference between two groups was determined using Student’s t-test. Chi-square test was 
employed to evaluate the significance of mortality data. A probability value of p<0.05 













CSE self-synthesized 1:250 Rabbit 1:20000 44 
eNOS Cell Signaling 1:500 Rabbit 1:4000 140 
iNOS BD Transduction 1:500 Mouse 1:10000 130 
nNOS Santa Cruz 1:2000 Mouse 1:10000 155 
HIF-1α Novus 
Biologicals 
1:500 Mouse 1:10000 120 
p-eNOS Cell Signaling 1:500 Rabbit 1:4000 140 
Akt Cell Signaling 1:2000 Rabbit 1:8000 60 
p-Akt Cell Signaling 1:500 Mouse 1:2000 60 
α-tubulin Santa Cruz 1:1000 Mouse 1:5000 55 
β-tubulin Sigma 1:1000 Mouse 1:5000 50 
histone Sigma 1:400 Goat 1:10000 32 
Table 2.5 Antibody (primary and secondary) information and conditions used for Western 
blot for CSE, eNOS, iNOS, nNOS, HIF-1α, p-eNOS, Akt and p-Akt. α-tubulin was used as the 
loading control for myocytes, while β-tubulin was used as loading controls for both animal 
tissue and h9c2 samples. Histone was employed as the loading control for nuclear extracts. The 
protein sizes are also depicted. 
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S-ALLYLCYSTEINE MEDIATES CARDIOPROTECTION VIA A 
HYDROGEN SULPHIDE-RELATED PATHWAY WITH 
CONCOMITANT NITRIC OXIDE PRODUCTION  
 
3.1 RESULTS 
3.1.1 Preliminary Study 
A preliminary study was conducted to determine the optimal dose of SAC to treat the 
animals with. Three doses (50mg/kg b.w/day, 100mg/kg b.w/day and 200mg/kg b.w/day) 
were selected based on existing literature which employed SAC in their work 
(Padmanabhan et al., 2007; Padmanabhan et al., 2006; Mizuguchi et al., 2006; Perez-
Severiano et al., 2004; Nagae et al., 1994). All rats in the 50mg group survived past 48h 
after MI at which the animals were sacrificed and their hearts harvested for the 
measurement of infarct size (Table 3.1).  In the 100mg group, 2 out of 4 rats died within 
48h after the surgery, thus yielding a mortality of 50%. Lastly, in the 200mg group, 2 out 
of 4 rats died during the 1 week of drug treatment, even before MI was induced. Hence, 
this dosage is deemed unsuitable and may have cumulative toxic effects when 
administered daily over a period of one week. However, it is noted that the number of 
animals used in this trial study is small (n=4) and is not substantial to draw a sound 
conclusion. 
Thereafter, the hearts collected were used for the measurement of infarct size. Infarct 
sizes for the 50mg, 100mg and 200mg groups were 44.0%, 32.2% and 48.3% 
respectively. Although the 100mg group had a smaller infarct size compared to the 50mg 
group, rats treated with this dose had 50% mortality. On the other hand, despite the 50mg 




group having a larger infarct size compared to the 100mg group, all rats survived the MI 
surgery. The 200mg group was not considered as it resulted in the death of two animals 
during the treatment window. As such, 50mg/kg b.w was deemed the most suitable dose 
to administer to the animals.     
 
 
3.1.2 Survival Rate after Myocardial Infarction (MI) 
Survival rate of the animals that lived past 48h after the induction of MI is depicted in 
Figure 3.1. Rats in the saline-treated control group had a survival rate of 66.7%. 
Treatment with SAC drastically improved survival to 87.5% (p<0.05 vs. saline). 
Comparing SAC-treated animals to that treated with SAC+PAG revealed a significant 
improvement in mortality (p<0.05), hence suggesting that SAC ameliorates MI-induced 
death via a H2S-related mechanism. In addition, the survival rates of SAC+PAG and 
PAG-treated groups are 65.2% and 52% respectively, comparable to untreated rats.   
3.1.3 Exclusion Criteria 
Animals that died before regaining full consciousness after the surgery were excluded 
from the study. These rats were assumed to have died due to surgical complications. 
 
Table 3.1 Preliminary dose-dependent study showing the mortality and infarct sizes of 
rats treated with 50mg, 100mg and 200mg/kg b.w./day of SAC. 






3.1.4 Infarct Size 
Infarct size is defined as a ratio of left ventricular infarct area to whole LV area. All rats 
subjected to the infarction procedure developed myocardial infarctions. The results 
obtained (n=3 per treatment group) are shown in Figure.3.2. The average infarct size of 
control group was 50.0±0.03%. Rats treated with SAC had a smaller infarct size of 43.9 ± 
0.03% compared to control. In addition, SAC+PAG and PAG-treated groups developed 
significantly larger infarcts compared to the saline-treated group (60.9± 0.01% and 62.0± 
0.03% respectively, p<0.05 vs. control). In addition, there was considerable reduction in 
the infarct size (p<0.005) when SAC-treated rats were compared to those treated with 
SAC+PAG. No statistically significant difference in infarct size was observed between 
SAC+PAG and PAG-treated groups. Once more, this result suggests that SAC offers 
cardioprotection via a CSE-related pathway as inhibition of CSE by PAG in the 
Figure 3.1 Survival rates of saline, SAC, SAC+PAG and PAG-treated groups after 
myocardial infarction (n ≥ 23).  * p<0.05 when compared to saline-treated group. ^ p<0.05 
when compared to SAC+PAG treated group. 
 




SAC+PAG group exacerbated the infarct development in SAC-treated group. 
Furthermore, the larger infarcts noted in groups given PAG points to the fact that H2S 
plays a vital role in preserving cardiac function after ischemic injury. 
3.1.5 Ventricular Hypertrophy 
The ventricular hypertrophy index is indicative of the extent of cardiac remodeling in the 
LV. Following MI induction, occlusion of blood vessels causes the heart to be enlarged 
as the remaining healthy cardiac muscles have to pump harder to supply the myocardium 
with sufficient oxygenated blood. Six hearts from each treatment group (n=3 from MI-
operated rats; n=3 from sham-operated rats) were randomly selected for the evaluation of 
ventricular hypertrophy. The results are shown in Figure 3.2. Despite being statistically 
not significant, SAC-treated group had a lower hypertrophy index (3.13±0.001) when 
compared to saline-treated group (3.23± 0.086). Moreover, SAC+PAG and PAG-treated 
groups also had slightly larger hypertrophy indices (3.51± 0.189 and 3.29±0.052 
respectively) than the control group. Hypertrophy indices for sham-operated rats in all 
four treatment groups were also quantified. The results were similar in all groups, with 
hypertrophy indices ranging between 2.71±0.026 –– 2.82± 0.050. When compared within 
each treatment group, the sham data were significantly smaller (p<0.01) compared to 
their MI counterparts.  







3.1.6 Hemodynamic Parameters 
3.1.6.1 Blood Pressure 
Six rats from each treatment group that underwent the MI procedure were randomly 
selected for the measurement of systolic blood pressure (BP) on day 1, 7 and 10 of 
treatment. The results obtained are illustrated in Figure 3.3. Comparisons were made 
within each treatment group. BP readings measured prior to the start of treatment (day 1) 
and that taken after one week of drug treatment were compared. Expectedly, treatment 
with saline did not affect BP as indicated by the results obtained (122.5±3.6 on day 7 vs. 
122.9±1.6 on day 1). Additionally, SAC did not affect BP after one week of drug 
treatment. On the other hand, both SAC+PAG and PAG-treated groups had significantly 
elevated BP after one week of treatment (130.4±1.9 on day 7 vs. 120.2±1.8 on day 1; 
Figure 3.2 Infarct sizes and hypertrophy indices of rats in saline, SAC, SAC+PAG and 
PAG-treated groups. Data shown are mean ± S.E.M. (n=3). *p<0.05 when compared to 
saline-treated group. 
 




120.7±2.3 on day 7 vs. 114.4±1.6 on day 1 respectively; p<0.05). These findings thus 
indicate that endogenous H2S plays a critical role in regulating BP as blocking its 
production by PAG significantly raised BP.  
 
 
3.1.6.2 Electrocardiograms (ECGs) 
ECG patterns were similar in all groups before treatment was initiated as well as one 
week after drug treatment. A typical representation of such a pattern is shown in 
Figure.3.4a. All showed a regular ECG pattern with defined P, QRS and T waves as 
indicated. In addition, typical ECG charts of rats from each treatment group that 
underwent the MI procedure recorded on day 10, 48hr after the induction of MI are 
Figure 3.3 Blood pressure (mmHg) of rats in saline, SAC, SAC+PAG and PAG-treated 
groups. Readings were made on day 1 (prior to start of treatment), day 7 (after one week of 
treatment) and day 10 (48hr post surgery). Comparisons were made within a group between 
readings obtained on day 1 and that on day 7. Data shown are mean ± S.E.M. (n≥6).  *p<0.05 
when compared to their respective treatment blood pressure readings on day 1. 
 




shown in Figure 3.4b-3.4e. All groups showed significant ST elevation, which is 
characteristic of MI. SAC+PAG (Figure 3.4d) and PAG-treated groups (Figure 3.4e) had 
similar durations and peaks of ST-segment as that of saline-treated group (Figure 3.4b). 
SAC-treated group had a less elevated ST-segment although the duration of this segment 
was comparable to the other treatment groups. In addition, pathological Q waves which 
may occur in the early stage of MI were observed in the ECG charts of all treatment 
groups. All treatment groups showed ‘noise’ in the ECG patterns which can be attributed 
to the uneven and disturbed blood flow coupled with the incomplete contraction of the 
damaged ventricles. 






Figure 3.4 ECG charts for saline, SAC, SAC+PAG and PAG treatment groups. 
Typical ECG prior to treatment— (a) pre-treatment, showing a normal, healthy ECG 
with regular P wave, QRS complex and T wave. ST segment elevation and pathological 
Q waves were observed in all post-treatment groups (indicated by arrows) (b) post-
treatment saline control group, (c) post-treatment SAC-treated group, ST elevation was 
improved (arrow), (d) post-treatment SAC+PAG-treated group and (e) post-treatment 
PAG-treated group. 




3.1.6.3 Heart Rate 
Heart rates were analyzed for all treatment groups and observed to be irregular and 
constantly fluctuating during the one-minute time span when ECG was recorded, 
indicative of ventricular arrhythmia. The average heart rate in all treatment groups is 
noted in Table 3.2.  The readings ranged from 405.4±12.7 bpm to 427.5±7.8 bpm with no 
significant difference between and within the treatment groups. 
 
   
 
   3.1.7 Morphological Examination 
The morphology of myocardial tissues subjected to both sham and MI operations were 
visualized by hemotoxylin and eosin (H&E) staining. Myocardium of rats in all treatment 
groups that underwent the sham operation had normal healthy cardiac fibre without any 
infarction, edema and inflammatory cells as shown by a representative diagram in 
Figure3.5a. In the saline-treated control group that underwent MI, edema was evident and 
inflammatory cells were observed in the infarct area as shown in Figure 3.5b. The 
myocardium of SAC-treated MI group showed mild edema with few inflammatory cells 
(Figure 3.5c). In addition, the morphology of the tissue was better preserved in this group 
when compared to other treatment groups. Edema was visible in the myocardium of 
Table 3.2 Heart rates for saline, SAC, SAC+PAG and PAG-treated rats. Data shown 
are mean ± S.E.M. (n≥6). 




SAC+PAG treated group that was subjected to MI operation. Inflammatory cells were 
seen throughout the infarct area as well as the area at risk (Figure 3.5d). PAG-treated MI 
group showed severe edema in the infarct zone with inflammatory cells distributed 
throughout. Signs of necrosis were also observed. 
 
 
3.1.8 CSE Activity in the Left Ventricle 
From each treatment group, left ventricular CSE activity was analyzed using tissue 
homogenates from 6 rats (n=3 from MI-operated rats; n=3 from sham-operated rats). In 
general, sham-operated rats had higher levels of CSE activity compared to their MI 
Figure 3.5 Representative morphology of heart tissue of sham, saline, SAC, SAC+PAG 
and PAG-treated animals. (a) Sham treatment groups showing normal healthy cardiac fibre 
without any infarction, edema and inflammatory cells (indicated by astericks), (b)Saline-treated 
control group showing oedema (), inflammatory cells seen in infarct area, (c) SAC-treated 
group displaying mild edema, (d)SAC+PAG -treated group showing edema (), inflammatory 
cells seen throughout infarct area and area at risk, (e)PAG-treated group showing severe edema 













counterparts (Figure 3.6). Among rats that were subjected to the infarction procedure, 
SAC-treated group had significantly higher CSE activity when compared to saline-treated 
control group (2.75±0.34 µmol/g protein/hr vs. 1.23±0.16 µmol/g protein/hr; p<0.01). 
PAG-treated group had the lowest CSE activity at 0.85 µmol/g protein/hr. In addition, 
SAC+PAG treated group had significantly lower CSE activity when compared to SAC-
treated group (1.22±0.27µmol/g protein/hr vs. 2.75±0.34umol/g protein/hr; p<0.05). 
From this finding, SAC is thus implicated to act as a novel CSE substrate, since the 
increase in its H2S-synthesizing activity is abolished when co-administered with PAG. 
Next, sham-operated rats in saline, SAC and SAC+PAG-treated groups had comparable 
CSE activity (3.27±0.52––3.42±0.27µmol/g protein/hr) while PAG-treated rats had a 
significant decrease in its activity when compared to the saline control (2.27±0.16 µmol/g 










3.1.9 Plasma H2S Concentration 
Plasma H2S concentration was evaluated in 12 rats (n=6 from MI-operated rats; n=6 from 
sham-operated rats) from each treatment group.  MI-operated rats had a slightly higher 
plasma H2S concentration when compared to their sham counterparts. In rats that 
underwent the MI operation, SAC treatment ensued in higher plasma H2S concentration 
compared to saline controls. Moreover, PAG-treated group had significantly lower H2S 
concentration (26.3±1.4µM; p<0.05) as PAG inhibited the H2S-synthesizing activity of 
CSE. To add on, plasma H2S concentration of SAC+PAG-treated group was significantly 
lower than that of SAC-treated group (33.3±3.1µM vs. 43.4±3.6µM; p<0.01). Yet again, 
this result implies that SAC is involved in H2S production via a CSE-dependent pathway 
during MI.   
Figure 3.6 CSE activity in the left ventricles of MI and sham-operated rats in all 
treatment groups. Results are shown as µmol/g protein/hr. Data shown are mean ± S.E.M. 
(n=3). *p<0.05 when compared to saline-treated group. **p<0.01 when compared to saline-
treated group. ^p<0.05 when compared to SAC-treated group. 
 




On the other hand, in rats that underwent the sham operation, plasma H2S concentrations 
were similar in saline and SAC-treated groups. SAC+PAG and PAG-treated groups had 
significantly lower plasma H2S concentration (25.5±1.2µM and 22.9±1.2µM respectively, 
p<0.05) when compared to saline-treated group (27.1±0.6µM). The results are 
graphically depicted in Figure 3.7. 
 
 
3.1.10 CSE Protein Expression 
CSE protein expression was analyzed in the LVs of MI-and sham-operated rats. The data 
obtained is demonstrated in Figure 3.8 and Figure 3.9 respectively. In all treatment 
groups, MI-operated rats had significantly lesser CSE protein expression when compared 
to their sham-operated counterparts. This is indicated by the darker CSE band intensities 
of sham-operated rats. Between rats that underwent the MI procedure (Figure 3.8), SAC-
treated rats showed a slight but significant increase (1.1 fold of control; p<0.05) in CSE 
Figure 3.7 Plasma H2S concentration of MI and sham-operated rats in all treatment 
groups. Results are expressed in µM H2S. Data shown are mean ± S.E.M. (n=6).* p<0.05 
when compared to saline-treated group. **p<0.01 when compared to saline-treated group. 
***p<0.005 when compared to saline-treated group. ^^p<0.01 when compared to SAC-
treated group. 




protein expression. In addition, SAC+PAG and PAG-treated rats showed a significant 
downregulation of protein expression to 0.88 fold (p<0.005) of control in both groups.  
On the contrary, in sham-operated rats, CSE protein was similarly expressed in all 
treatment groups (Figure 3.9). Treatment with the various drugs seemingly did not affect 
CSE protein expression in the myocardium of healthy rats. 
    
  
             
Figure 3.8 CSE protein expressions in all treatment groups of MI-operated 
rats. Results are expressed as the fold difference of that of saline control group. 
Data shown are mean ± S.E.M. (n=3). *p<0.05 when compared to saline-treated 
group. 
 







3.1.11 Nitrate/Nitrite Levels in the Left Ventricle 
The major oxidative products of NO, nitrate and nitrite, collectively termed NOx, is used 
as a surrogate measure of NO production in the body. Twelve left ventricular tissue 
homogenates (n=6 from MI-operated rats; n= 6 from sham-operated rats) were randomly 
selected from each treatment group to assess their NOx content. The results in Figure 
3.10 showed that MI rats generally had a higher NOx levels than sham rats. Between MI-
operated rats, SAC treatment surprisingly resulted in a 2-fold increase in NOx levels 
(16.28±0.48 µmol/g tissue vs. 8.55±0.47 µmol/g tissue in controls, p<0.01). Furthermore, 
treatment with PAG also resulted in an upsurge of NOx levels by 1.6 fold (13.63 ±1.03 
µmol/g tissue vs. 8.55±0.47 µmol/g tissue in controls, p<0.01). In rats treated with 
SAC+PAG, the NOx level was 11.98±1.62 µmol/g tissue. Between sham-operated rats, 
Figure 3.9 CSE protein expressions in all treatment groups of sham-operated rats. Results 
are expressed as the fold difference of that of saline control group. Data shown are mean ± 
S.E.M. (n=3). 
 




there was so significant difference in NOx content. NOx amounts for saline, SAC, 
SAC+PAG and PAG-treated groups are 7.19±0.76 µmol/g, 7.42±0.32 µmol/g, 5.70±0.33 
µmol/g and 6.39±3.04 µmol/g protein respectively. 
 
 
3.1.12 Plasma NOx Concentration 
Plasma NOx levels were measured in twelve rats (n=6 from MI-operated rats; n=6 from 
sham-operated rats) from each treatment group. From Figure 3.11, it is noted that within 
the same treatment group, MI rats had higher plasma NOx concentration than those that 
underwent the sham protocol. Between MI-operated rats, SAC and PAG treatments 
significantly increased NOx concentration compared to controls (40.26±1.70µM and 
38.97±2.53µM respectively vs. 27.98±0.75µM, p<0.005), while SAC+PAG group also 
had appreciably higher NOx concentration (39.00±2.53 µM vs. 27.98±0.75µM; p<0.05).   
Figure 3.10 Left ventricular NOx levels in saline, SAC, SAC+PAG and PAG treatment 
groups of both MI and sham-operated animals. Results are expressed as µmol/g protein. 
Data shown are mean ± S.E.M. (n=3). ** p<0.01 compared to saline-treated controls.  




Treatment with different drugs did not affect the plasma NOx concentrations in healthy 
sham-operated rats. There was no difference in NOx levels for all groups, with the 
animals having a NOx concentration spanning between 19.44±1.39µM — 20.04±1.30µM. 





Figure 3.11 Plasma NOx levels in saline, SAC, SAC+PAG and PAG treatment 
groups of both MI and sham-operated animals. Results are expressed in µM. Data 
shown are mean ± S.E.M. (n=6).* p<0.05 compared to saline-treated controls. *** p<0.005 
compared to saline-treated controls. 
 






3.2.1 H2S as a Cardioprotective Agent 
The recent discovery of H2S as a novel gasotransmitter has sparked interest in several 
fields within the research community. H2S is reported to be involved in several models of 
inflammation such as septic and hemorrhagic shock (Mok et al., 2004; Lyons et al., 
2001), caerulein-induced pancreatitis (Bhatia et al., 2005) as well as hypertension 
(Chunyu et al., 2003), diabetes mellitus (Kaneko et al., 2006) and Alzheimer’s disease 
(Eto et al., 2002). Recently, the involvement of hydrogen sulfide in erectile dysfunction 
has also been suggested (Shukla et al., 2009; Srilatha et al., 2006). In the cardiovascular 
context, H2S is implicated in diseases such as stroke (Qu et al., 2006), myocardial 
ischemic injury (Zhu et al., 2007) and isoproterenol-induced myocardial infarction (Geng 
et al., 2004a). When rats were given an intravenous bolus injection of NaHS, a dose-
dependent decrease in mean arterial pressure was observed (Zhao et al., 2001). 
Furthermore, this role of H2S as a vasodilator is also substantiated in a separate study 
conducted by Cheng and co-workers (Cheng et al., 2004). They showed that H2S induced 
the relaxation of rat resistance mesenteric arteries. In addition, our group has previously 
demonstrated that H2S plays a beneficial role in the ligature-induced MI rat model. We 
reported that NaHS improved mortality and infarct size whereas PAG, an inhibitor of 
CSE showed the reverse. In vitro studies also revealed that after exposure to hypoxic 
conditions, higher H2S levels in the culture medium of cells treated with NaHS showed 
an improvement in cell viability (Zhu et al., 2007). 
 




3.2.2 Garlic as a Cardioprotective Agent 
Recent studies demonstrated that garlic plays a beneficial role in the heart by reducing 
oxidative stress in isoproterenol-induced MI rat models. Banerjee and colleagues showed 
that rats fed with raw garlic homogenates had a significant preservation of myocardial 
superoxide dismutase activity and an improvement in myocardial morphology upon MI 
induction (Banerjee et al., 2003). In a separate study, Savaranan and Prakash further 
verified the antioxidant role of garlic in MI. It was reported that garlic oil preserved the 
activities of a range of antioxidant enzymes including superoxide dismutase and catalase. 
They also presented that garlic oil lowered lipid peroxide levels in the serum and heart 
(Saravanan et al., 2004).  
3.2.3 S-allylcysteine (SAC) as a Cardioprotective Agent 
More recently, similar studies investigating the cardioprotective potential of a specific 
active component of garlic—SAC have been launched. Padmanabhan and Prince showed 
that SAC exerted anti-oxidative effects in an isoproterenol-induced MI rat model by 
decreasing lipid peroxide products and improving the antioxidant status of the infarcted 
myocardium (Padmanabhan et al., 2006). In a follow-up study, the same group reported 
that SAC improved isoproterenol-induced cardiac damage by stabilizing cardiac and 
lysosomal enzymes to non-MI levels  (Padmanabhan et al., 2007). 
These studies investigating the cardioprotective potential of SAC in treating AMI have 
been carried out using isoproterenol, a catecholamine to induce myocardial damage. This 
model results in the development of necrotic lesions in the myocardium of experimental 
animals (Padmanabhan et al., 2008). However, the mechanism of action is based on an 




increase in oxygen consumption; and not due to a limitation in blood flow which is the 
case in MI. As such, the surgical ligation model is a more superior one as it models after 
the actual scenario in MI, with a restriction of blood flow to the myocardial tissue. 
Furthermore, functional data such as survival, infarct size and blood pressure in SAC-
treated rats have not been reported. Hence, our current study aims to fill the gap in 
knowledge in this aspect. 
The main purpose of this experiment is to determine if SAC (50mg/kg b.w.) pretreatment 
for a period of one week prior to the induction of MI is able to confer cardioprotection in 
rats. Functional studies such as mortality, infarct size and hypertrophy index were used as 
indicators. In addition, BP measurement, ECG recordings and morphological 
examination were performed. Biochemical assays such as expression anlyses of CSE, 
together with the amount of H2S produced in the heart and plasma H2S concentrations 
were quantified to verify if SAC brings about cardioprotection via a H2S-related pathway. 
Moreover, as evidence for a cross-talk between H2S and NO has been on the rise, the 
involvement of NO in this mode of cardioprotection was also determined. 
3.2.4 SAC Improved Survival and Infarct Size after AMI 
Firstly, we showed that SAC reduced mortality to 12.5% in a ligature-induced MI rat 
model when compared to controls (33.4%). This improvement in survival is in fact better 
(12.5% vs. 29.2%) than that when rats were treated with the conventional H2S donor, 
NaHS in an identical AMI model (Chapter 5). Moreover, rats in SAC+PAG and PAG-
treated groups had comparable mortalities (34.8% and 37.5%).  




Infarct size, a key indicator of the ischemia extent is important for the prognosis of MI. In 
agreement with our hypothesis, SAC-treated rats had smaller infarcts, signifying that 
SAC is beneficial to the heart. The infarct sizes were similar in both SAC+PAG and 
PAG-treated groups, and were significantly larger compared to controls. Thus, it can be 
deduced that PAG abrogated the protective effects of SAC in the SAC+PAG treated 
group, suggesting that SAC elicits cardioprotection through a CSE-related pathway. 
Furthermore, the worsening of infarct development with PAG administration also reveals 
the importance of endogenous H2S in preserving myocardial function. 
All rats subjected to MI developed hypertrophy of the LV. During an infarct, blood flow 
is reduced to the myocardium. As a consequence, the injured heart will then have to 
pump harder in an attempt to supply sufficient blood and oxygen to the rest of the body. 
This will in turn lead to an enlargement of the LV. SAC-treated MI rats had smaller 
hypertrophy indices when compared to the other groups. Although the result is not 
statistically significant, it suggests that rats in this group experienced an improvement in 
LV remodeling, which resulted in lesser hypertrophy development. To add on, additional 
cardiac markers such as levels of troponin I and creatine kinase may be employed in 
future studies to evaluate cardiac functions in the infarcted myocardium. 
3.2.5 Effect of SAC on BP, ECG and Heart Rate 
Next, our results demonstrated that SAC did not affect blood pressure after one week of 
treatment. However, both SAC+PAG and PAG-treated groups had a slight but significant 
increase in BP after one week. This indicates that when PAG is given, the blockade of 
endogenous H2S production resulted in an elevation in BP, providing evidence to support 




the role of H2S as a vasodilator. On the other hand, when an exogenous source of H2S—
SAC is given, BP was not affected. This implies that endogenous H2S plays a greater role 
than exogenous H2S in BP regulation.  
Electrocardiograms recorded forty-eight hours after the induction of MI showed obvious 
ST segment elevations and pathological Q waves in all rats. The ST-segment indicates 
the initiation of ventricular repolarization, and the elevation in this segment during an 
infarct development may arise from (i) left bundle branck block, (ii) ventricular rhythms, 
(iii) left ventricular hypertrophy, (iv) pericarditis, or (v) early repolarization.  SAC-
treated rats had lower elevation of the ST segment, while SAC+PAG and PAG-treated 
rats had more pronounced elevation in the same segment, further substantiating that SAC 
is effective in improving MI. The ECG patterns observed were similar to that reported by 
Padmanabhan and Prince, who also noted an improvement in ST segment elevation in 
their study (Padmanabhan et al., 2007).  
3.2.6 SAC Improved Morphology of Ischemic LV 
Examination of the infarcted LV showed a significant improvement in the morphology of 
SAC-treated rats. Ventricular tissue of this group displayed only mild edema and was 
similar to the morphology of sham-operated rats which had healthy cardiac fibre. 
Morphological assessment of the saline, SAC+PAG and PAG-treated groups revealed 
edema in the infarct zone as well as fraying of the cardiac fibre. In addition, infiltration of 
inflammatory cells was also seen in the infarct area. Sections from the sham-operated rats 
in all treatments showed normal myocardial tissues, indicating that the various treatments 
did not pose adverse effects under normal circumstances. 




3.2.7 Participation of H2S/CSE Pathway in SAC-Mediated Cardioprotection 
To investigate if the cardioprotective potential of SAC is mediated through a H2S-related 
pathway, left ventricular CSE enzyme activity and plasma H2S concentration were 
measured. Our results revealed that on the whole, MI-operated rats had lower H2S 
production in the LV when compared to their sham-operated counterparts. This may be 
partially explained by a reduction in CSE enzyme activity in the injured myocardium. 
Between rats that underwent the MI procedure, SAC-treated group demonstrated the 
highest level of CSE activity that was 2.2 fold of saline controls. SAC is suggested to 
increase CSE activity in the infarcted myocardium either by increasing the enzyme 
efficiency through an increase in substrate bioavailability or via an upregulation of 
enzyme expression. Conversely, SAC+PAG-treated rats had significantly lowered levels 
of CSE activity compared to the SAC-treated group. This is attributed to the additional 
treatment of this group with PAG, which is an irreversible inhibitor of CSE, thus 
lowering the amount of H2S produced. Also, PAG-treated rats conceivably had 
significantly lower CSE activity than controls but the inhibition of CSE is not complete 
as low quantities of H2S were still produced in the tissue.   
Surprisingly, in sham-operated rats, CSE activities were similar in saline, SAC and 
SAC+PAG-treated groups. This led us to conclude that SAC is only capable of 
stimulating CSE activity in the injured myocardium when the basal CSE activities are 
lower. Only sham-operated rats treated with PAG showed a notable reduction in CSE 
activity when compared to the saline control.  




Plasma H2S levels were also measured as it will give a better indication of the overall 
H2S amount in the whole body. The findings were unexpected as plasma H2S 
concentrations were higher in rats subjected to the MI procedure compared to sham-
operated rats. This trend was in stark contrast to that observed with the LV CSE activity. 
It is suggested that the lowered enzyme activities in the injured myocardium stimulated 
healthy tissues elsewhere to compensate for the reduced H2S production in the injured 
LV so as to keep the overall H2S concentration in the body in check. This over-
compensation in H2S production may account for the higher plasma H2S concentration 
observed in MI rats.  
More specifically, between MI-operated rats, SAC-treated group showed the highest 
plasma H2S concentration. Next, it was noted that the elevated plasma H2S level in SAC-
treated group was significantly higher when compared to SAC+PAG-treated group. This 
increase in H2S amount is blocked by PAG in rats treated with SAC+PAG. Thirdly, 
PAG-treated rats had significantly lower plasma H2S levels than controls. All three trends 
noted for plasma H2S concentrations were similar to that observed about the LV CSE 
activity. For rats that underwent the sham operation, SAC treatment only increased 
plasma H2S levels marginally. On the other hand, SAC+PAG and PAG treatments 
significantly lowered plasma H2S levels in sham-operated rats due to the blockade in H2S 
production. Thus, it may be suggested that the body can fine-tune the amount of H2S 
present. As such, exogenous sources of CSE substrates such as SAC can only increase 
H2S levels when their concentration is below optimal levels in situations such as MI.  
CSE protein expression was next evaluated to determine whether the higher levels of H2S 
produced in SAC-treated rats was due to an upregulation of CSE expression and/or an 




increased in efficiency of CSE since SAC increased the availability of CSE substrates. 
Our findings showed that SAC indeed upregulated CSE protein in MI rats albeit slightly. 
However, this phenomenon was not observed in non-MI rats. As such, SAC may only 
induce an increase in CSE expression when there is a drop in basal H2S levels in the 
injured myocardium such as during MI.  
3.2.8 Participation of NO in SAC-Mediated Cardioprotection 
As one of the objectives of this thesis is to examine the crosstalk between NO and H2S 
during MI, we next examined if SAC treatment altered NO production in the myocardium 
and plasma. It was noted that SAC indeed upregulated NO levels in the LV of MI rats.  
This observation is in agreement with that reported by Kim and colleagues, who showed 
that SAC increased NO production in endothelial cells (Kim et al., 2001), which is one of 
the three major cell types in the heart . Also, earlier studies by Maslin have also shown 
that garlic is able to exert its therapeutic effect by increasing NO production (Maslin et 
al., 1997). Similar observations were made for plasma NOx concentrations, with SAC 
increasing this level noticeably.  
In contrast, PAG-treated rats which endogenous H2S production was inhibited also 
reported a significant increase in LV and plasma NO levels. This is possibly due to a 
compensatory NO production to make up for the decrease in H2S production since both 
H2S and NO share similar roles in the body. The redundancy may thus ensure that normal 
physiological functions can still be maintained in situations whereby the production of 
one gasotransmitter is compromised. Once again, this trend is only observed for MI rats 
which are more vulnerable due to the ischemic injury and not in healthy sham rats. 




3.2.9 Summary of Findings for Experimental Protocol 1  
This is the first piece of work to offer an alternative mechanism to how garlic, more 
specifically, SAC, offers cardioprotection during myocardial ischemia. In addition to its 
well-established antioxidative properties, we now report that SAC also exerts its 
beneficial effects via the H2S pathway. The ‘seminal observation’ made in this study was 
rigorously discussed in the Editorial Focus section when the work was published (Das, 
2007; Chuah et al., 2007).  
In summary, this study demonstrated that SAC lowered mortality as well as reduced 
infarct size and ventricular hypertrophy to bring about cardioprotection. Further to the 
anti-oxidative role of SAC as reported by other groups, we propose that the 
cardioprotection observed is also mediated through a H2S-related pathway. This is 
because when rats were treated with (i) SAC+PAG or (ii) PAG, their infarcts were 
significantly exacerbated, indicating the important role endogenous H2S plays in 
mediating cardioprotection. Moreover, SAC upregulated both the protein expression and 
activity of CSE in the infarcted myocardium, and this was accompanied by a significant 
increase in plasma H2S concentration. These increases were abrogated when rats were 
treated concurrently with PAG. Last but not least, this study also revealed that SAC 
upregulated NO production in both LV and plasma of MI rats. This novel finding hence 
provides evidence to substantiate the interaction between H2S and NO. All in all, the 
beneficial effects of SAC in the ischemic myocardium hold great potential for its 
development into a cutting-edge drug for the treatment of MI. 
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NO-MEDIATED CARDIOPROTECTION BY SILDENAFIL IN MYOCARDIAL 
ISCHEMIA INVOLVES A H2S/CSE PATHWAY  
4.1 RESULTS 
4.1.1 Survival Rate after Acute Myocardial Infarction 
Mortality of rats in the three treatment groups was observed for a period of 48h after MI 
induction. Most death cases occurred within the first 24h post-MI. The results are 
presented in Table 4.1. Saline-treated controls had a survival rate of 64.3%. In 
comparison, there was a slight improvement in sildenafil-treated rats with a survival rate 
of 75.0%. In addition, L-NAME treated group had a survival rate of 59.3%, which is 
comparable to the control group. However, these results lack statistical significance due 
to the small sample size employed. All sham operated rats survived.  
 
 
4.1.2 Exclusion Criteria  
Rats (n= 5) which did not regain consciousness after the surgical procedure or those that 
bled excessively during the operation were excluded from the study.  
 
Table 4.1 Survival rate of the animals in saline, sildenafil and L-NAME-treated groups 
following MI. The rats were monitored for a period of 48h after the surgery. The number of 
animals employed in each treatment group is stated. Significance testing was carried out using 
the chi-square test. 




4.1.3 Infarct Size  
Infarct size is quantified by evaluating the ratio of LV infarct area to total LV area. All 
rats subjected to the infarction protocol developed MI. The results obtained are illustrated 
in Figure 4.1. When rats were treated with sildenafil for a period of seven days before 
performing the MI induction surgery, infarct size was reduced to 44.7±1.6% compared to 
controls (50.2±3.2%). On the other hand, rats in the L-NAME-treated group had a 
significantly larger infarct size of 64.1± 1.9% (p <0.05). 
4.1.4 Ventricular Hypertrophy 
Hypertrophy index is used to determine the degree of ventricular remodeling in the LV 
(Salloum et al., 2008; Chuah et al., 2007). Six hearts from each treatment group (n=3 
from MI-operated rats; n=3 from sham-operated rats) were selected at random for the 
evaluation of ventricular hypertrophy. Among rats that were subjected to the MI 
operation, control rats had a hypertrophy index of 3.23±.09, while sildenafil-treated rats 
had a slightly lower index of 3.09± 0.08. In the meanwhile, L-NAME treated rats had the 
highest hypertrophy index of 3.31±0.05. As expected, hypertrophy indices of sham-
operated rats were significantly lower (between 2.69-2.79) than their MI counterparts and 
were comparable with each other as they had healthy hearts which were not subjected to 
ischemic stress. The results are graphically depicted in Figure 4.1.  






4.1.5 Hemodynamic Parameters 
4.1.5.1 Blood Pressure 
Systolic BP was measured on day 1, day 7 and day 10 of treatment. The data collected is 
illustrated in Figure 4.2. Intra-group comparisons of readings measured prior to the start 
of treatment and that measured after one week of drug treatment were made. Saline-
treated control rats had no change in BP readings throughout the treatment window 
(122.5±3.6mmHg on day 7 vs. 122.9±1.6mmHg on day 1; p>0.05). Similarly, sildenafil 
treatment did not significantly alter BP as indicated by the results obtained (113.8±4.0 
mmHg on day 7 vs. 121.2±4.0 mmHg on day 1). In contrast, L-NAME treatment resulted 
in a slight elevation in BP, from 114.3±2.2mmHg on day 1 to 126.8±4.9 mmHg (p <0.05) 
on day 7.  BP was slightly lowered in all groups on day 10. 
Figure 4.1 Infarct size and hypertrophy indices of rats in saline, sildenafil and L-
NAME-treated groups. Data are expressed as mean ± S.E.M. (n=3). *p < 0.05 when 
compared to saline-treated controls. 






4.1.5.2 Electrocardiograms  
ECG patterns were similar in all groups before and after one week of treatment. This 
indicates that the various treatments did not alter ECG patterns. All groups demonstrated 
a regular ECG with defined P, QRS and T waves. A typical representation of such a 
pattern is shown in Figure 4.3a. Two days after induction of MI, ECG was once again 
recorded and the representative charts of rats with injured myocardium are shown in 
Figure 4.3b-4.3d.  
All groups had significant ST elevation, which is characteristic of MI. Sildenafil-treated 
group exhibited a shorter duration of ST-segment elevation when compared to saline-
treated rats, which is indicative of a better preserved myocardial function. The duration of 
Fig 4.2 Blood pressure (mmHg) of rats in saline, sildenafil and L-NAME treated groups. 
Readings were measured on day 1 (prior to start of treatment), day 7 (after one week of 
treatment) and day 10 (48hr post surgery). Comparisons were made within a group between 
readings obtained on day 1 and that on day 7. Data shown are mean ± S.E.M. (n≥6).  *p<0.05 
when compared to their respective blood pressure readings on day 1. 
 




ST-segment elevation of L-NAME treated group is comparable to that of the saline 
control. In addition, pathological Q waves which occur in the early stage of MI were 
observed in the ECG charts of all groups. All three groups showed ‘noise’ in the ECG 
patterns which can be attributed to the uneven and disturbed blood flow coupled with the 
incomplete contraction of the damaged ventricles. 









Figure   4.3  ECG charts for saline, sildenafil and L-NAME treatment groups. 
Typical ECG prior to treatment— (a) pre-treatment, showing a normal, healthy ECG 
with regular P wave, QRS complex and T wave. ST segment elevation and 
pathological Q waves were observed in all MI-operated post-treatment groups 
(indicated by arrows) (b) post-treatment saline control group, (c) post-treatment 
sildenafil-treated group, and (d) post-treatment L-NAME treated group. 
 




4.1.5.3 Heart Rate 
Heart rates were recorded concurrently when ECG was being monitored. From Table 4.2, 
there was no significant difference in heart rate between and within treatment groups 
when readings were taken on different days. The readings were in the range between 
397.2±16.2 bpm to 430.6±17.4 bpm. 
 
 
4.1.6 NOx Content in the Left Ventricle  
From each treatment group, six LV tissue homogenates (n=3 from MI-operated rats; n= 3 
from sham-operated rats) were randomly chosen for the assessment of NOx content. The 
results obtained are shown in Figure 4.4. Between MI-operated rats, sildenafil resulted in 
a major increase in NOx levels in the LV (18.10±1.71 µmol/g tissue vs. 8.55±0.47 
µmol/g tissue in controls, p<0.005). In contrast, L-NAME treatment noticeably lowered 
NOx levels in the tissue (6.48±0.64 µmol/g tissue vs. 8.55±0.47 µmol/g tissue in controls, 
p<0.05).  
As for sham-operated rats, sildenafil did not increase NOx levels. This group had 
comparable NOx levels as the untreated control group (7.23±2.35 µmol/ g tissue vs. 
7.19±0.76 µmol/ g tissue respectively, p>0.05). On the contrary, L-NAME-treated sham-
Table 4.2 Heart rates for saline, sildenafil and L-NAME treated rats. Data shown are 
mean ± S.E.M. (n≥6). 
 




operated rats were observed to have lower NOx levels in the LV (4.81±0.21 µmol/ g 
tissue vs. 7.19±0.76 µmol/ g tissue in saline controls, p<0.05).  
 
 
4.1.7 Plasma NOx Concentration 
The concentration of plasma NOx was measured in twelve rats (n=6 from MI-operated 
rats; n=6 from sham-operated rats) from each treatment group. Figure 4.5 showed that 
between the three MI-operated groups, sildenafil exceptionally increased NOx 
concentration (46.26±2.09µM vs. 27.98±0.75µM in control, p<0.005), while L-NAME, 
which inhibits NOS activities, expectedly lowered NOx concentration (19.02±0.63 µM vs. 
27.98µM±0.72µM; p<0.005).  As for sham-operated rats, sildenafil was also observed to 
dramatically increase NOx concentration by 1.7 fold (33.37±5.46 µM vs. 20.03±1.53µM, 
p<0.05) while L-NAME reduced NOx levels (8.23±1.67µM vs. 20.03±1.53µM, p<0.005). 
Figure 4.4 NOx levels in the left ventricles of MI and sham-operated rats in saline, 
sildenafil and L-NAME treated groups. Results are expressed as µmol/g protein. Data 
shown are mean ± S.E.M. (n=3). * p<0.05 when compared to saline-treated group. *** 
p<0.005 when compared to saline-treated group.  
 
 




Generally, for both tissue and plasma NOx levels, it is noted that levels are higher among 
MI-operated rats compared to their sham controls.  
 
 
4.1.8 Protein Expressions of eNOS and nNOS 
eNOS and nNOS protein expressions were examined by Western blot analysis in the LV 
of MI-operated rats. From Figure 4.6, sildenafil induced a slight but significant increase 
in eNOS expression (1.19±0.04; p<0.05). However, treatment with L-NAME did not alter 
eNOS expression in the LVs of MI-operated rats. 
 In addition, sildenafil resulted in a greater elevation of nNOS expression, with an 
increase of 1.8 fold of control (p<0.01) (Figure 4.7). Once again, nNOS expression was 
unaffected by L-NAME as expression levels was similar to that of saline control. With 
rats that underwent the sham operation, there was no difference in eNOS and nNOS 
Figure 4.5 NOx concentration in plasma samples of MI and sham-operated rats in saline, 
sildenafil and L-NAME treated groups. Results are expressed in µM. Data shown are mean 
± S.E.M. (n=6). *** indicates that p<0.005 when compared to saline-treated group.  
 










Figure 4.7 nNOS protein expression in MI-operated rats in saline, 
sildenafil and L-NAME treated groups. Data shown are mean ± S.E.M. 
(n=3). ** indicates that p <0.01when compared to saline group. 
 
Figure 4.6 eNOS protein expression in MI-operated rats in saline, 
sildenafil and L-NAME treated groups. Data shown are mean ± S.E.M. 
(n=3). * indicates that p <0.05 when compared to saline group. 




4.1.9 iNOS Gene Expression 
As iNOS is only induced during pathological conditions, its mRNA levels were first 
checked to determine if there was expression 48h after MI. As shown in Figure 4.8, iNOS 
transcripts were present in all three treatment groups after MI. Sildenafil-treated rats had 
the highest iNOS gene expression, which was 4.9 fold that of saline-treated controls 
(2.05±0.07 vs. 0.42±0.04, p<0.001). Both L-NAME and saline-treated controls had 
similar amounts of iNOS expressed (0.42±0.07 vs.0.42±0.04 respectively), indicating that 
L-NAME did not inhibit the induction pattern of iNOS following MI. iNOS gene 





Figure 4.8 Gene expressions of iNOS in saline, sildenafil and L-NAME 
treated groups. Results are expressed as a ratio of intensity of iNOS bands 
to GAPDH. Data shown are mean ± S.E.M. (n=3). ****p<0.001 when 
compared to saline-treated group. 
 




4.1.10 iNOS Protein Expression 
Since iNOS gene transcripts can be detected at this time point, it is conceivable to 
investigate if iNOS protein has been expressed at this stage. Sildenafil greatly elevated 
protein expression levels to 1.8 fold of control which was statistically significant, as 
depicted in Figure 4.9. iNOS protein levels were not altered by L-NAME treatment, and 
is comparable to that of the saline-treated rats.  
 
 
4.1.11 Effect of Sildenafil on H2S Production in the Left Ventricle 
Left ventricular CSE activity was analyzed in 6 rats from each treatment group (n=3 from 
MI-operated rats; n=3 from sham-operated rats) to determine the rate of H2S production. 
Sham-operated rats generally had higher levels of H2S production than their MI 
counterparts (Figure 4.10). Intriguingly, among rats that were subjected to the infarction 
Figure 4.9 Protein expression of iNOS in MI-operated rats of saline, sildenafil 
and L-NAME treated groups. Data shown are mean ± S.E.M. (n=3). *p <0.05 
when compared to saline group. 
 




procedure, sildenafil-treated group had considerably higher rates of H2S production 
compared to controls (3.56±0.45 µmol/g protein/hr vs. 1.43±0.18 µmol/g protein/hr; 
p<0.05). In contrast, L-NAME treatment did not affect H2S production in this case. There 




4.1.12 Effect of Sildenafil on Plasma H2S Concentration 
Plasma H2S concentration was also analyzed for all groups and the results are shown in 
Figure 4.11. Surprisingly, for all treatment groups, MI-operated rats had significantly 
higher plasma H2S compared to their sham counterparts. This is as opposed to the trend 
observed for H2S production rates in the LV, where sham-operated rats were found to 
have higher rates of H2S production. Interestingly, animals that were treated with 
Figure 4.10 Effects of sildenafil on H2S production in all treatment groups. Rate of H2S 
production in the left ventricles are displayed as µmol/g protein/hr. Data are expressed as mean 
± S.E.M. (n=3). * p<0.05 when compared to saline-treated group. 
 
 




sildenafil were once again found to have significantly higher plasma H2S concentration 
than controls (50.48±1.98µM vs. 40.45±2.23µM, p<0.05). L-NAME treated rats had 
comparable plasma H2S concentration (38.78± 2.2µM) to the saline-treated controls. 
Additionally, plasma H2S concentration did not differ between sham rats treated with 
varying drugs and the H2S levels are 27.11±0.62, 30.81±1.32 and 28.55±1.39 µM in 
saline, sildenafil and L-NAME treated rats respectively. 
 
 
4.1.13 Effect of Sildenafil on CSE Protein Expression 
It was next determined if the increase in sildenafil-mediated H2S production was due 
solely to an increase in CSE activity, or it also involves an upregulation of CSE protein. 
As such, CSE protein expression was detected in the LV of both MI and sham-operated 
Figure 4.11 Plasma H2S concentration in both MI and sham-operated rats treated with 
saline, sildenafil and L-NAME. Results are expressed in µM. Data are expressed as mean ± 
S.E.M. (n=6). * p<0.05 when compared to saline-treated group.  
 
 




animals (Figure 4.12). Between MI-operated rats, it was noted that L-NAME treatment 
resulted in a significant upregulation in CSE protein expression (1.2 fold of control, 
p<0.01). Sildenafil did not alter CSE expression, implying that the increase in H2S 
observed in both LV and plasma is largely due to an increase in CSE activity. Between 
sham operated rats, there was no difference in the protein expression patterns between the 
different treatments (data not shown). 
 
 
Figure 4.12 CSE protein expression of MI-operated rats in saline, sildenafil and 
L-NAME treated groups. Data shown are mean ± S.E.M. (n=3). ** p <0.01 when 
compared to saline group. 
 





4.2.1 Sildenafil as a Cardioprotective Agent  
Recent years have seen renewed interest in the cardioprotective potential of sildenafil, 
with the focus mainly on evaluating the beneficial effects of this drug in 
ischemia/reperfusion (I/R) models. These studies have reported a favorable role of 
sildenafil in attenuating cardiac damage. Some of the outcomes observed include the 
reduction in infarct size (Salloum et al., 2007a; Rosanio et al., 2006; Elrod et al., 2006; 
Salloum et al., 2003a), upregulation of eNOS and iNOS mRNA (Salloum et al., 2003a) 
and protein expressions (Salloum et al., 2008), involvement of protein kinase C (PKC) 
(Das et al., 2004), cAMP and cGMP pathways (du Toit et al., 2005; Hassan et al., 2005) 
as well as the opening of mitoKATP channels (Salloum et al., 2007b; Ockaili et al., 2002).  
The involvement of a multitude of molecules and signaling pathways suggests that the 
protection conferred is likely to be multi-faceted. Furthermore, several studies have 
implicated the involvement of a NO-related pathway in this observed cardioprotection 
(Salloum et al., 2008; Kukreja, 2006; Das et al., 2005; Salloum et al., 2003b). As a result, 
the promising potential of sildenafil in ischemia-reperfusion models has prompted us to 
evaluate if sildenafil will also elicit a similar protection in a non-reperfused model of 
myocardial infarction.  
Our findings demonstrated that sildenafil indeed exerts cardioprotection in the permanent 
ligation model of MI by decreasing infarct size. Moreover, we have shown the 
involvement of a NO-related pathway, as well as a newly-discovered H2S-associated 
pathway in this mode of protection. Physiological parameters such as survival rate, 
infarct size, hypertrophy index, blood pressure and heart rate were evaluated. 




Electrocardiograms were also monitored. Additionally, we carried out biochemical assays 
to verify the involvement of NO and H2S-associated pathways in sildenafil-mediated 
cardioprotection. 
4.2.2 Sildenafil Improved Survival and Limits Infarct Development in AMI 
There was an improvement in the survival of sildenafil-treated rats after MI compared to 
saline controls despite not being statistically significant due to the small sample size. It 
appears to be promising that sildenafil, at a clinically relevant dosage of 0.7mg/kg will 
reduce mortality of patients with AMI. 
Several studies using the I/R model have demonstrated that sildenafil is able to limit 
infarct size when administered before the ischemia insult. In our study, it was shown that 
sildenafil-treated rats had notably smaller infarct sizes compared to controls. This is in 
agreement with that reported by several other groups which showed that sildenafil can 
minimize infarct size in I/R models of the rabbit heart (Das et al., 2004) and mouse heart 
(Salloum et al., 2008; Elrod et al., 2006).  Du Toit and colleagues noted that sildenafil 
attenuated infarct development from 35.2% in control rats to 12.4% in sildenafil-treated 
rats. Thus, this evidence strongly supports that sildenafil is effective in minimizing infarct 
development in MI. Additionally, L-NAME (a non-specific NOS inhibitor) treated rats 
had significantly larger infarct sizes when compared to control, indicating the blockade of 
endogenous NO production exacerbated infarct development during MI.  
A trend similar to that of the infarct size was observed for the hypertrophy indices of MI 
rats. As the rats were sacrificed 48 hours after MI induction, the injured hearts would not 
have sufficient time to undergo complete ventricular remodeling. However, from the 




results, it can be noted that sildenafil-treated rats underwent a lesser extent of ventricular 
hypertrophy compared to controls. L-NAME treated rats had the most severe hypertrophy. 
These results substantiate the work done by Salloum and colleagues who also showed 
that sildenafil-treated mice had reduced cardiac hypertrophy (Salloum et al., 2008). Thus, 
this serves to provide additional evidence for the cardioprotective effects of sildenafil in 
MI. This beneficial effect is brought about possibly via a NO-related pathway, as the 
additional NO in sildenafil-treated group improved ventricular remodeling; and the lack 
thereof in L-NAME treated group worsened it.  
PDE-5 inhibitors are suggested to confer beneficial effects during MI by releasing 
endogenous mediators of cardioprotection, such as adenosine or bradykinin which will 
then trigger a signaling cascade to result in the phosphorylation of eNOS. NO synthesized 
will then activate guanyl cyclase (GC) to result in enhanced cGMP formation, hence 
activating PKG. Subsequently, the activation of PKG will lead to the opening of 
mitoKATP channels, ensuing in cardioprotection against myocardial ischemia (Kukreja et 
al., 2005; Kukreja et al., 2004). 
4.2.3 Effect of Sildenafil on Hemodynamic Parameters 
From our data, sildenafil did not alter BP after one week of treatment. Although it was 
reported in Ockaili’s study that sildenafil lowered BP in rabbits within 2 minutes of 
intravenous drug administration, it was also mentioned that BP was restored near baseline 
values at the end of 5 minutes (Ockaili et al., 2002). In our study, there was a slight dip in 
BP but was of no statistical significance. It is suggested that we overlooked the decrease 
in BP as readings were only taken one hour after drug treatment. Moreover, we 




administered the drugs via the intra-peritoneal route which was different from theirs 
which was through an i.v route. These differences may therefore partially account for the 
lack of observation of a sildenafil-mediated decrease in BP. In contrast, L-NAME treated 
rats had a 9.5mmHg significant increase in mean arterial pressure after one week of drug 
treatment. This observation concurred with that of Rossoni and colleagues who showed 
that L-NAME appreciably increased systolic BP (Rossoni et al., 2007).  
Thus, from our findings, it is hypothesized that sildenafil treatment which led to cGMP 
accumulation induced mild vasorelaxation, leading to a slight drop in BP. In addition, we 
further hypothesize that sildenafil may enhance the expression and/or activities of NOS 
isoforms to result in greater NO generation. This will hence accelerate the GC-mediated 
reaction of cGMP formation to subsequently lead to cardioprotection. On the contrary, L-
NAME inhibits NOS activities, thus preventing NO generation. Consequently, the lack of 
NO reduces the drive of NO-mediated GC to synthesize cGMP. Lesser cGMP availability 
will thus result in a corresponding increase in BP.  
ECG recordings made 48hr after MI induction revealed obvious ST-segment elevations 
and pathological Q waves in all rats, which is characteristic of MI development. 
Sildenafil-treated rats had a better preserved ECG pattern when compared to both saline 
controls and L-NAME treated groups. This, coupled with the more regular heartbeats 
observed in sildenafil-treated animals, serves as yet another evidence of the 
cardioprotective potential of this drug. Overall, the heart rates were comparable between 
treatment groups and this finding is similar to that published by Salloum (Salloum et al., 
2007a). 




4.2.4 Effect of Sildenafil on Nitrate/Nitrite Concentrations in the Body 
To examine if the protective mechanism of sildenafil is mediated through a NO-related 
pathway, we first analyzed if NO levels (using nitrate and nitrite as surrogate markers) 
were altered in the LV and plasma. Plasma NOx levels were examined as it will better 
reflect the overall NOx amount in the body. From our findings, it was demonstrated that 
sildenafil increased NOx levels in both the LV and plasma of MI-operated rats. Sildenafil 
appeared to have triggered a surge in NO production in the ischemic myocardium, 
perhaps in a bid to stimulate vasodilation in the injured heart with partially occluded 
vessels. This led to a corresponding surge in plasma NO levels.  
In healthy sham-operated rats, sildenafil did not seem to trigger further NO production. 
This was an interesting observation as it hinted that the body has a mechanism to regulate 
endogenous NO concentrations, maintaining it at optimal levels during physiological 
conditions. This may prove to be useful as sildenafil only regulates NO levels in the 
damaged myocardium and not upset the delicate NO balance in the healthy heart. 
Maintaining NO levels is essential as it is a key regulator of vascular homeostasis, 
regulating blood flow and BP in the endothelium of blood vessels (Radomski et al., 1993). 
Thus, by triggering further NO production during ischemic conditions, sildenafil may 
relieve the stress on the ischemic heart, conferring cardioprotective benefits. 
On the other hand, L-NAME treatment significantly lowered NOx levels in the tissue of 
both MI and sham rats. The significant reduction in NOx levels in both groups can be 
largely accounted for by the inhibition of NOS activities by the non-specific NOS 
inhibitor (L-NAME), which blocks endogenous NO production. 




4.2.5 Effect of Sildenafil on the Expressions of NOS Isoforms 
Next, we wanted to further understand if the increase in NO production observed was due 
to an increase in NOS expressions. As such, we went on to analyze the protein 
expressions of the three NOS isoforms. The increase in eNOS protein expression seen in 
sildenafil-treated group was in agreement with the results published by Salloum and 
colleagues (Salloum et al., 2008; Salloum et al., 2003b) who also demonstrated that 
sildenafil upregulated eNOS marginally after ischemia. It is suggested that this increase 
in eNOS may participate as a trigger to initiate downstream cardioprotective pathways.  
More importantly, we are the first to report that sildenafil upregulated nNOS protein 
expression after MI. However, this is in contrast to that reported by Rosanio who noted 
no difference in nNOS expression following sildenafil treatment (Rosanio et al., 2006). 
The disparity may arise from the different experimental protocols used. In his study, 
Rosanio worked with the I/R model, and treated the animals only once with sildenafil 18h 
prior to the I/R surgery.  Moreover, the rats were sacrificed immediately after a 4h 
reperfusion window.  In contrast, the rats in our study underwent a permanent ligation of 
the coronary artery, were treated with sildenafil once daily for a period of 1 week before 
MI was induced, and were only sacrificed 48h after the surgery. nNOS-derived NO in 
vagal nerve fibres may play a role in reducing and moderating heart rate after sustaining 
myocardial injury (Myers et al., 1974). In addition, vagal stimulation may also prevent 
ventricular arrhythmia and reduce oxygen consumption, thus conferring beneficial effects 
to the heart (Takimoto et al., 2000).  




As iNOS is an inducible protein, we first detected for the presence of iNOS mRNA 
transcripts in the LV of MI models. Indeed, the results obtained showed that at this 
selected timepoint of 48h post-MI, sildenafil dramatically induced iNOS expression. 
Upon the successful detection of iNOS gene expression, we next went to detect its 
protein expression.  The results correlated to that obtained for the gene expression: 
sildenafil upregulated iNOS protein levels. This result is once again in agreement with 
several published reports which showed that sildenafil induced an increase in iNOS 
expression after ischemia (Salloum et al., 2008; Rosanio et al., 2006; Das et al., 2005). 
iNOS-catalyzed NO production may thus activate GC, leading to enhanced cGMP 
synthesis and subsequently PKG activation (Salloum et al., 2003b). This will then lead to 
opening of mitoKATP channels, an end effector of myocardial protection (Han et al., 2002; 
Wang et al., 2001). As such, from our protein and gene expression data, we can soundly 
conclude that sildenafil upregulated the expressions of all three isoforms of NOS during 
MI, and this resulted in an accompanying increase in NO levels in both the LV and 
plasma as noted earlier on. 
4.2.6 H2S Involvement in Sildenafil-mediated Cardioprotection 
Recent studies have reported a relationship between NO and a second gaseous  mediator, 
H2S in the cardiovascular system (Whiteman et al., 2006a; Ali et al., 2006; Yanfei et al., 
2006; Whiteman et al., 2006b; Zhao et al., 2003; Hosoki et al., 1997). However, the 
mechanism governing their interaction has yet to be elucidated. Similar to NO, H2S also 
has a cardioprotective role and this is largely recognized to be mediated by its opening of 
mitoKATP channels to induce vasorelaxation (Zhao et al., 2001).   As we have identified 
that one of the mechanisms which sildenafil brings about cardioprotection is by 




stimulating NO production through the upregulation of NOS isoforms, we were interested 
to investigate if this may also involve the H2S/CSE pathway. 
Interestingly, we noted that sildenafil could stimulate H2S production in the LV without 
affecting CSE protein expression. This implies that sildenafil increased the activity of the 
H2S producing enzyme, CSE. As sildenafil was implicated to be involved in the opening 
of mitoKATP channels, the increased production of H2S in the injured myocardium of 
sildenafil-treated rats may hence account for the opening of these channels to bring about 
protection. Opening of mitoKATP channels may then partially compensate the membrane 
potential to allow additional protons to be transferred out to the inter-mitochondrial space. 
The accumulation of protons will then facilitate the generation of a proton gradient for 
both ATP synthesis and calcium transport (Szewczyk, 1996). These actions will then 
contribute towards preserving myocardial functions, bringing about cardioprotection in 
the ischemic heart. However, further investigation is warranted before a conclusion can 
be drawn.  
4.2.7 Summary of Findings for Experimental Protocol 2 
These preliminary findings have demonstrated that sildenafil is promising as a 
cardioprotective agent in the permanent ligation model of myocardial infarction. 
Functional studies have shown that sildenafil improved survival rate, reduced infarct size 
and hypertrophy after MI. In addition, ECG charts also revealed an improvement in 
cardiac functions. We propose that this cardioprotection is conferred by both NO and 
H2S-related pathways as sildenafil was shown to significantly increase left ventricular 
and plasma NO and H2S levels. Additionally, we have also reported that sildenafil 




mediated the increase in NO levels by upregulation of eNOS, nNOS and iNOS protein 
abundance in the MI setting. Furthermore, we reported that sildenafil increased H2S 
production in the LV by increasing CSE activity. We hypothesized that both NO and H2S 
may have interacted either directly, or indirectly to bring about the opening of mitoKATP 
channels in the heart to confer cardioprotection. Sildenafil-induced NO may have acted 
upstream of the H2S-synthesizing pathway to result in an increase in H2S production. H2S 
would then open mitoKATP channels to bring about cardioprotective benefits. However, 
further investigations are in order to validate the involvement of mitoKATP channels in 
this mode of cardioprotection.  This may be achieved by utilizing a pharmacological 
approach by employing blockers of mitoKATP channels such as glibenclamide and 5-
hydroxydecanoate in the study. Further studies are necessary to clarify how sildenafil 
mediates its cardioprotective effects, as well as to verify the involvement of NO and H2S 
in this mode of cardioprotection. This will then contribute to the possible utilization of 
this drug as a treatment for MI patients. 












RESULTS & DISCUSSION 
EXPERIMENTAL PROTOCOL 3 
H2S and NO in myocardial ischemia 




ROLES AND RELATIONSHIP OF HYDROGEN SULFIDE AND NITRIC OXIDE 
IN A RAT MODEL OF ACUTE MYOCARDIAL INFARCTION 
5.1 RESULTS 
5.1.1 Survival Rate after Acute Myocardial Infarction 
The results of the survival rate 48h after myocardial infarction is reported in Table 5.1. 
Survival rates for H2S donor NaHS and NO donor molsidomine-treated groups are 70.8% 
and 79.2% respectively, which are both higher than saline-treated controls (64.3%). 
Although the improvement is not statistically significant, NaHS and molsidomine 
seemingly contributed to a reduction in mortality. In addition, molsidomine appears to be 
more effective than NaHS in improving survival. On the contrary, PAG and L-NAME-
treated rats had lower survival rates than the control group (52.0% and 59.3% 
respectively, vs. 64.3%).  
 
  
5.1.2 Exclusion Criteria 
Rats that bled profusely during the surgery, or died before regaining consciousness after 
the surgery were excluded from the study. These rats were assumed to have died due to 
excessive loss of blood and/or surgical complications. 
Table 5.1 Survival rates of rats 48h after induction of myocardial infarction in saline, 
NaHS, molsidomine, PAG and L-NAME treated groups. The number of rats employed 
in each group is shown. Statistical significance testing was conducted using chi-square test. 




5.1.3 Infarct Size  
It is observed that there is a corresponding diminution in infarct size in groups with better 
survival rates. To further substantiate this correlation, the infarct sizes were also larger in 
groups which had higher mortality. This data is represented in Figure 5.1 below. Three 
hearts from each treatment group were used for this assessment. The infarct size of rats 
pre-treated with molsidomine was calculated to be 29.6±3.4% which is significantly 
lower than that of control with an infarct size of 48.3±2.9% (p<0.01). On the contrary, 
when NO production was blocked, L-NAME treated rats had an infarct size of 64.1±1.9% 
which is significantly higher than saline-treated rats (p<0.05). The infarct sizes of NaHS 
and PAG-treated rats were 40.7±4.0% and 61.9±3.2% respectively. 
5.1.4 Ventricular Hypertrophy 
Results of the hypertrophy index are graphically depicted in Figure 5.1. Expectedly, MI-
operated rats had higher hypertrophy indices compared to sham animals as the injured 
LV would have undergone ventricular remodeling to supply the remaining viable 
myocardium with adequate blood. The hypertrophy index of rats in the MI-operated 
untreated group is 3.23±0.09. When H2S and NO donors were administered, the value 
dipped slightly to 2.99±0.12 and 2.96±0.05 respectively. On the other hand, blocking 
endogenous H2S and NO production with PAG and L-NAME correspondingly resulted in 
more severe ventricular remodeling. The hypertrophy values were 3.29±0.05 and 
3.31±0.05 respectively. Though statistically insignificant, it is noted that the hypertrophy 
index correlated with the infarct sizes. In treatment groups with smaller infarcts such as 




NaHS and molsidomine, the hypertrophy indices were also lower, and the converse is 
true. There was no difference in hypertrophy indices of rats subjected to the sham surgery. 
 
 
5.1.5 Hemodynamic Parameters 
5.1.5.1 Blood Pressure 
Figure 5.2 shows the systolic BP measured from rat tails on day 1, day 7 and day 10 of 
drug treatment. Six rats were randomly selected for the measurement of BP on each 
occasion.  Comparisons were made between readings obtained on day 1 before treatment 
was initiated, and that on day 7 after one week of drug treatment. 
NaHS treatment significantly lowered BP from 124.1±1.06 mmHg to 112.5±1.76 mmHg 
(p<0.05). Next, treatment with molsidomine did not alter BP which remained relatively 
Figure 5.1 Infarct sizes and hypertrophy indices of rats in saline, NaHS, molsidomine, 
PAG and L-NAME-treated groups. Data are expressed as mean ± S.E.M. (n=3). *p<0.05 
when compared to saline-treated group. **p<0.01 when compared to saline-treated group. 
 




constant at 120.4±1.34 mmHg on day 1 and 121.9±0.60 on day 7. Conversely, BPs of rats 
administered with PAG and L-NAME significantly increased after one week of 
administration. In the PAG group, systolic BP raised from 114.4±1.6 mmHg to 120.7±2.3 
mmHg (p<0.05). Furthermore, L-NAME treatment resulted in a more pronounced 
increase, from 114.3±2.16 mmHg on day 1 to 123.2±4.8 mmHg on day 7 (p<0.05). BP 




Before MI surgery was performed, all groups showed a regular, healthy ECG pattern with 
defined P, QRS and T waves. A typical representation of such a pattern is depicted in 
Figure 5.3a. On day 10, ECGs of rats in the various treatment groups were once again 
Fig 5.2 Blood pressure (mmHg) of rats in saline, NaHS, molsidomine, PAG and L-
NAME treated groups. Readings were measured on day 1 (prior to start of treatment), day 7 
(after one week of treatment) and day 10 (48hr post surgery). Comparisons were made within 
a group between readings obtained on day 1 and that on day 7. Data shown are mean ± 
S.E.M. (n≥6).  *p<0.05 when compared to their respective blood pressure readings on day 1. 
 




recorded. This is shown in Figure 5.3b-5.3f. All groups exhibited significant ST elevation, 
which is characteristic of MI. In addition, pathological Q waves which occur in the early 
stage of MI were also observed in charts of all treatment groups. To add on, there was 
‘noise’ observed in the ECGs of all groups. This can be accounted for by the uneven and 
disturbed blood flow coupled with the incomplete contraction of the damaged ventricles 
following MI. 
 







Figure 5.3 ECGs of saline, NaHS, molsidomine, PAG and L-NAME-treated rats. 
(a) Typical ECG prior to MI induction. ST segment elevation and pathological Q 
waves (indicated by arrows) were observed in all post-treatment MI-operated 
groups (b) saline, (c) NaHS, (d) molsidomine (e) PAG and (f) L-NAME-treated 
groups. 




5.1.5.3 Heart Rate 
Heart rates were monitored throughout the study on day 1, day 7 and day 10 of drug 
treatment for at least one continuous minute. The readings often fluctuate during this 1-
minute time window as a result of irregular heartbeat, a sign of ventricular arrhythmia. 
There was no difference in the heart rates before or after the different treatments as 




5.1.6 CSE Gene Expression 
CSE gene expression was quantified in the LVs of both MI and sham-operated rats by 
RT-PCR. The results are as illustrated in Figure 5.4. It is noted that saline-treated sham-
operated rats had lower CSE levels (0.5 fold) compared to those subjected to the same 
treatment but underwent the MI procedure. Between rats that were assigned to the MI 
procedure, despite being statistically insignificant, it was observed that NaHS and 
Table 5.2 Heart rates for saline, NaHS, molsidomine, PAG and L-NAME-treated rats. 
Data were measured on day 1 prior to the start of treatment, on day 7, after one week of 
treatment, and on day 10, before the animals were sacrificed. Data shown are mean ± S.E.M. 
(n≥6). 
 




molsidomine-treated groups had higher level of CSE gene expressions (1.3 and 1.2 fold 
respectively) compared to saline-treated controls.  
Conversely, CSE expression in L-NAME treated rats was slightly reduced to 0.82 fold of 
control (p>0.05). PAG-treated rats had similar levels of CSE expression as the control 
group. CSE gene expressions in the LV of sham-operated rats were also analysed. There 
was no difference in their abundance and the result is not shown. The levels of CSE 
mRNA expressions in each treatment group were normalized to that of housekeeping 
gene, GAPDH and subsequently expressed as a fold difference of saline-treated MI-
operated rats. 
 




Figure 5.4 CSE gene expression in sham (saline-treated sham-operated), MI-operated 
saline, NaHS, molsidomine, PAG and L-NAME treated groups.CSE expression was 
normalized to that of housekeeping control GAPDH and expressed as a fold difference over 
saline-treated MI-operated group. Data are given as mean ± S.E.M. (n=6). * p<0.05 when 
compared to saline-treated MI-operated group. 




5.1.7 CSE Protein Expression 
The amount of CSE protein in the healthy (sham-operated) and ischemic LVs of rats 
treated with the different drugs were determined by Western Blot. The results in Figure 
5.5 showed that CSE protein levels in sham-operated rats were 1.86±0.21 fold higher 
than their MI counterparts. This result is surprising because in the gene expression study, 
the CSE levels in sham-operated rats were only 0.4 fold of MI rats. This thus suggests 
that despite the low abundance of mRNA transcripts in healthy rats, CSE protein 
translation is likely to have taken place very rapidly in the myocardium to account for the 
high abundance of CSE protein observed in sham controls. This result requires further 
confirmation.  
As for the MI group administered with NaHS, CSE protein expression was visibly 
upregulated to 2 fold of control (p<0.05). Additionally, treatment with L-NAME also 
upregulated CSE protein in MI rats by 1.5 fold (p<0.05). The CSE expression levels for 
molsidomine and PAG-treated rats were 0.96±0.15 and 1.19±0.19 folds which were akin 
to that observed in the saline group. Between sham-operated groups, CSE protein 
expressions were similar despite undergoing different drug treatments (data not shown). 






5.1.8 H2S Production in the Left Ventricle 
Left ventricular H2S production (CSE catalyzing activity) was evaluated in the tissue 
homogenates of rats treated with the various drugs. Both sham and MI samples (n=3 each) 
were assayed. Generally, rats subjected to the sham surgery had higher levels of CSE 
catalyzing activity in comparison to those which MI was performed on. This is shown in 
Figure 5.6. This trend is similar to that observed in the previous two experiments. 
For rats subjected to the MI procedure, NaHS and molsidomine treatments increased H2S 
production levels to 4.04±0.98 and 3.39±0.36 µmol/g protein/h respectively, which were 
significantly higher compared to saline-treated rats (1.43±0.19µmol/g protein/h; p<0.05). 
Additionally, in L-NAME-treated rats, the rate of H2S production was 2.88±0.95 µmol/ g 
Figure 5.5 Protein expression of CSE in sham-operated saline-treated group (grey) 
and MI-operated (black) saline, NaHS, molsidomine, PAG and L-NAME treated 
groups.  CSE expression was normalized to that of loading control β-tubulin for each 
treatment group. Data are expressed as mean ± S.E.M. (n=6). *p<0.05 when compared to 
saline-treated MI-operated group. 




protein/h. Quite the opposite, treatment with PAG which inhibits CSE activity was 
demonstrated to significantly reduce H2S production to 0.73±0.08µmol/ g protein/h 
(p<0.05). Among sham-operated rats, PAG-treated rats had the lowest rate of H2S 
production which was significantly lower compared to control rats (2.64±0.19 µmol/ g 
protein/h vs. 4.68±0.45 µmol/ g protein/h in control, p<0.05). 
 
 
5.1.9 Plasma H2S Concentration 
The concentration of H2S in the plasma was measured to determine the overall H2S levels 
in the body. From Figure 5.7, it is noted that plasma H2S concentrations were higher in 
rats subjected to MI when judged against those that underwent the sham surgical 
procedure. This is in contrast to the trend observed for H2S production rates in the heart. 
Figure 5.6 Rate of H2S production in both MI and sham-operated rats in the various 
treatment groups. The results are expressed in µmol/g protein/hr. Values shown are mean ± 
S.E.M. (n=6). *p<0.05 when compared to saline-treated controls that underwent the same surgical 
procedure. 




A possible explanation for this discrepancy is that other healthy tissues capable of H2S 
production over-compensated for the reduction of H2S levels in the injured myocardium, 
resulting in the higher plasma H2S levels.  Among MI-operated groups, plasma H2S 
concentration in saline-treated controls is 40.45±2.23 µM. NaHS significantly increased 
this concentration to 50.48±1.98 µM (p<0.01). In contrast, in rats pretreated with PAG, 
the H2S concentration was greatly reduced to 23.40±0.71 µM (p<0.005 when compared 
to saline-treated rats). As for sham-operated animals, plasma H2S concentration of PAG-
treated rats was noticeably reduced to 22.94±1.16 µM, p<0.05. The levels of H2S in rats 
treated with NaHS and L-NAME were 32.87±3.47µM and 28.55±1.39µM respectively. 
 
 
5.1.10 Gene Expressions of NOS Isoforms 
mRNA levels of NOS isoforms— eNOS, nNOS and iNOS were measured in the 
ischemic and healthy hearts of rats subjected to the various treatments. From Figure 5.8, 
Figure 5.7 Plasma H2S concentrations in both MI and sham-operated rats in the various 
treatment groups. The results are expressed in µM. Values shown are mean ± S.E.M. (n=6-
10). *p<0.05 compared to the saline-treated group. **p<0.01 compared to saline-treated group. 
***p<0.005 when compared to saline-treated group. 
 




it is observed that in untreated (saline) rats, eNOS expression levels were comparable 
between sham and MI-operated animals. Also, in both NaHS and PAG treated groups, 
eNOS expressions were elevated to 1.60 and 1.57 folds of MI-operated saline control 
respectively (p<0.05). eNOS levels of molsidomine and L-NAME rats were comparable 
to controls. Besides, eNOS levels in sham-operated rats were similar between the 
different treatments (data not shown). 
Next, nNOS expressions in all groups were also analyzed. Figure 5.9 showed that nNOS 
was upregulated in sham rats by 1.8 fold compared to those that underwent MI (p<0.005). 
Between MI-operated rats, nNOS expression levels were analogous between the various 
treatments, with NaHS treated group displaying the highest nNOS level of 1.35 fold of 
control (p>0.05). 
Lastly, iNOS gene expression was also determined. Rats subjected to the sham surgery 
had very low levels of iNOS (0.4 fold of MI-operated untreated rats). This was consistent 
between the different groups of sham-operated rats treated with the various drugs. In MI-
operated rats that were pre-treated with 1 week of NaHS, iNOS expression was 
tremendously upregulated to 2.3 fold of control group (p<0.005). Similarly, iNOS mRNA 
abundance was also increased to 1.9 fold in PAG-treated rats (p<0.05). Molsidomine and 
L-NAME treatments did not significantly affect the iNOS expressions in the animals. The 
data obtained is illustrated in Figure 5.10. 








Figure 5.9 nNOS gene expressions in sham (grey) and MI (black)-operated rats 
subjected to different drug treatments. nNOS expression was normalized to that of 
GAPDH in each group. Data shown are expressed as the fold difference of MI-operated saline 
group. Results are mean ± S.E.M. (n=4-6). ***p<0.005 when compared against saline group. 
Figure 5.8 eNOS gene expressions in sham (grey) and MI (black)-operated rats 
subjected to different drug treatments. eNOS expression was normalized to that of 
GAPDH in each group. Data shown are expressed as the fold difference of MI-operated 
saline group. Results are mean ± S.E.M. (n=6) *p<0.05 when compared against saline group. 






5.1.11 Protein Expressions of NOS Isoforms  
The protein expressions of eNOS, nNOS and iNOS are shown in Figure 5.11-5.13. Firstly, 
from Figure 5.11, it is observed that the trend of eNOS protein expression corresponded 
largely to that of its mRNA expression. Sham-operated saline-treated rats had similar 
expression levels as their MI counterparts. Animals treated with NaHS were found to 
upregulate eNOS protein expression by 1.5 fold (p<0.05). The remaining treatment 
groups, namely molsidomine, PAG and L-NAME had comparable intensities to that in 
the saline group. As for animals that underwent the sham operation, eNOS expression 
levels were comparable between treatment groups (data not shown). 
Secondly, nNOS expression levels were also evaluated. There was no difference in 
protein amount between treatment groups in both MI and sham-operated rats as 
Figure 5.10 iNOS gene expressions in sham (grey) and MI (black)-operated rats 
subjected to different drug treatments. iNOS expression was normalized to that of GAPDH 
in each group. Data shown are expressed as the fold difference of MI-operated saline group. 
Results are mean ± S.E.M. (n=4-6). *p<0.05 when compared against saline group. 
***p<0.005 when compared against saline group. 




illustrated in Figure 5.12. In addition, protein abundance was similar between sham and 
MI-operated rats, suggesting that MI did not affect nNOS levels in these treatment groups. 
Following, iNOS protein was also quantified as shown in Figure 5.13. Being a protein 
that is induced during inflammatory conditions, the amount of iNOS expressed in sham-
operated healthy animals was very low, at about 0.5 fold of control (p<0.05). Among 
those that underwent the MI procedure, it was noted that NaHS treatment upregulated 
iNOS levels by 1.6 fold (p<0.05). Molsidomine, PAG and L-NAME had similar iNOS 
abundance as the saline group.  
 
 
Figure 5.11 eNOS protein expressions in sham (grey) and MI (black)-operated rats 
subjected to different drug treatments. eNOS expression was normalized to that of β-
tubulin in each group. Data shown are expressed as the fold difference of MI-operated 
saline group. Results are mean ± S.E.M. (n=6). *p<0.05 when compared to saline group.  
 








Figure 5.13 iNOS protein expressions in sham (grey) and MI (black)-operated rats 
subjected to different drug treatments. iNOS expression was normalized to that of β-
tubulin in each group. Data shown are expressed as the fold difference of MI-operated saline 
group. Results are mean ± S.E.M. (n=6). *p<0.05 when compared to saline group.  
 
Figure 5.12 nNOS protein expressions in sham (grey) and MI (black)-operated rats 
subjected to different drug treatments. nNOS expression was normalized to that of β-
tubulin in each group. Data shown are expressed as the fold difference of MI-operated saline 
group. Results are mean ± S.E.M. (n=6).  
 




5.1.12 Nitrate/ Nitrite (NOx) Content in the Left Ventricle 
Figure 5.14 shows the NOx levels in the LVs of both MI and sham-operated rats. A 
similar pattern between the MI and sham-operated groups was observed for the various 
treatments. It was also noted that the tissue NOx levels were higher in MI-operated rats. 
Based on the fact that both eNOS and nNOS protein expressions were similar between 
MI and sham-operated rats, the higher NOx levels observed is largely accounted for by 
the higher iNOS abundance seen in MI rats. 
Firstly, in rats that underwent the MI surgery, NOx levels in saline-treated control group 
was  8.55±0.47 µmol/g protein and this was increased to 11.33±0.34 µmol/g protein in 
NaHS-treated rats (p<0.05). Also, NOx levels were drastically increased to 22.69±0.99 
µmol/g protein in rats treated with molsidomine, a NO donor (p<0.005). When H2S 
synthesis was inhibited by PAG, NOx levels in the myocardium was elevated to 
13.63±1.04 µmol/ g tissue (p<0.01). On the other hand, when treated with a non-specific 
inhibitor of NOS, L-NAME, there was a significant reduction in NOx content in the heart 
to 7.02±0.16 µmol/ g protein (p<0.05). 
Next, among rats that underwent the sham surgery, molsidomine treatment served to 
increase NOx levels significantly (11.81±0.69 µmol/g protein vs. 7.19±0.76 µmol/ g 
protein in control, p<0.05). Similar to the trend in MI rats, L-NAME treatment also 
reduced the NOx amount in the ventricles to 4.81±0.21 µmol/ g protein (p<0.05). 






5.1.13 Plasma Nitrate/Nitrite Concentration 
The trend observed for plasma NOx concentration largely follows that of the tissue NOx 
levels. Firstly, NOx concentration was higher in the MI-operated rats when compared to 
their sham partners as demonstrated in Figure 5.15. Also, molsidomine greatly elevated 
the plasma NOx concentration and L-NAME reduced the NOx concentration in both MI 
and sham rats. 
The concentration of plasma NOx for saline-treated rats subjected to the MI insult was 
27.98±0.75 µM. Treatment with NaHS and PAG yielded a slight but significant increase 
in NOx levels (35.18±1.15 µM and 38.97±2.53 µM respectively, p<0.05). As mentioned, 
molsidomine treatment resulted in a marked increase in plasma NOx concentration to 
52.79±5.53 µM (p<0.005). Plasma NOx concentration in L-NAME treated rats was 
reduced to 19.02±0.63 (p<0.01) due to the inhibition of NOS. 
Figure 5.14 NOx levels in the left ventricles of MI and sham-operated rats in saline, 
NaHS, molsidomine, PAG and L-NAME treated groups. Results are expressed as µmol/g 
protein. Data shown are mean ± S.E.M. (n=4-6). * p<0.05 when compared to saline-treated 








In sham-operated rats treated with NaHS and PAG, the NOx concentrations were similar 
to that in saline controls (20.03±1.53 µM). Molsidomine expectedly increased plasma 




5.1.14 HIF-1α Protein Expression 
The protein abundance of HIF-1α in MI and sham-operated rats is as displayed in Figure 
5.16. HIF-α is activated under conditions of hypoxia. As such, HIF-1α expression levels 
in untreated sham-operated rats are significantly lower (0.37 fold, p<0.05) compared to 
MI-operated controls. 
Figure 5.15 Plasma NOx concentrations of MI and sham-operated rats in saline, NaHS, 
molsidomine, PAG and L-NAME treated groups. Results are expressed in µM. Data shown 
are mean ± S.E.M. (n=6-10). * p<0.05 when compared to saline-treated group. ** p<0.01 








Between rats that were subjected to the ischemic insult, NaHS treatment significantly 
upregulated HIF-1α levels by 1.57 fold (p<0.05). Rats in the remaining treatment groups 
had comparable HIF-1α levels to saline controls. 
 
 
5.1.15 HIF-1α Gene Expression 
To determine if HIF-1α is regulated at the transcriptional or translational level, the gene 
expression of HIF-1α was verified. From Figure 5.17, it can be seen that HIF-1α mRNA 
levels in sham rats is much lower (0.32 fold, p<0.05) compared to MI controls. This trend 
is similar to that observed for HIF-1α protein. However, there was no difference in HIF-
1α mRNA levels in MI rats subjected to the different drug treatments. All expressed HIF-
1α at a level similar to saline controls. 
Figure 5.16 HIF-1α protein expression in sham (grey) and MI (black)-operated rats 
subjected to different drug treatments. HIF-1α expression was normalized to that of β-
tubulin in each group. Data shown are expressed as the fold difference of MI-operated saline 
group. Results are mean ± S.E.M. (n=5). *p<0.05 when compared to saline group.  
 






Figure 5.17 HIF-1α gene expression in sham (grey) and MI (black)-operated rats 
subjected to different drug treatments. HIF-1α expression was normalized to that of 
GAPDH in each group. Data shown are expressed as the fold difference of MI-operated saline 
group. Results are mean ± S.E.M. (n=4). *p<0.05 when compared to saline group.  
 





5.2.1 Interplay between H2S and NO 
In the two earlier studies, there appears to be evidence for an interaction between 
gasotransmitters H2S and NO in the context of AMI using in vivo rat models. In the first 
experiment, SAC, which we propose to be a novel CSE substrate for H2S synthesis is 
capable of elevating NO levels in the heart and plasma. It was demonstrated in the second 
study that PDE-5 inhibitor sildenafil brought about its cardioprotective effects via a 
NO/NOS-related pathway. Additionally, sildenafil stimulated H2S production in the heart 
alongside an increase in plasma H2S concentration. We thus propose that it serves as a 
novel NO donor, and showed that it augmented the CSE/H2S pathway in this work. From 
both studies, it is noted that the exogenous source of one gaseous transmitter (i.e H2S) 
enhanced the endogenous production of the other gas (i.e NO), suggesting a possible 
synergistic relationship between the two. As a result, we are curious to explore this 
exciting notion of a possible crosstalk between the two gasotransmitters.  
To minimize confounding factors, well-established, conventional H2S and NO donors— 
NaHS and molsidomine respectively, were employed to understand how additional 
sources of these gases will influence the ischemic heart. NaHS is a commonly used H2S 
donor that dissociates rapidly to its ionic form (Na+ & HS-) in solution. HS- will then 
recombine with H+ present in the physiological system to form H2S. About 1/3 of the 
NaHS introduced will exist as H2S in equilibrium (i.e 300µM NaHS will yield 100µM 
H2S). Molsidomine is an orally active NO donor, which is enzymatically metabolized in 
the liver to the active NO-releasing metabolite SIN-1. Thus, NO is released in a gradual 




manner, with long-lasting effects. This slow-release produces peak NO plasma levels that 
are lower but last longer (Meinertz et al., 1985). 
Additionally, the functions of endogenously synthesized H2S and NO were also probed. 
This was conducted by treating the animals with inhibitors of H2S (D,L-propagylglycine) 
and NO (L-NAME) production to investigate how the infarcted heart would be affected 
when synthesis of these gases are blocked. 
However, it is recognized that when exogenous donors of H2S and NO were administered, 
the endogenous production of these two gasotransmitters was not inhibited. Hence, 
endogenous sources of H2S and NO may have confounded the beneficial effects noted for 
H2S and NO donors. The experimental design may have been better improved by 
including groups with (i) molsidomine + L-NAME and (ii) NaHS + PAG treatments. 
Furthermore, we also carried out preliminary studies to investigate the effects of blocking 
both H2S and NO pathways by co-treating rats with both PAG and L-NAME. However, 
the results obtained did not deviate significantly from those rats that were treated with 
either inhibitor, and hence, the data obtained will not be reported in this work. 
Findings from this study revealed that exogenous H2S and NO exert cardioprotection in 
MI as they improved survival and also attenuated infarct development. In addition, the 
crosstalk between H2S and NO is also evident. Firstly, NaHS increased eNOS and iNOS 
expressions, which was accompanied by an increase in NO production. In addition, 
blockade of H2S production by PAG also stimulated eNOS and iNOS gene expressions 
with a corresponding increased in NO levels. Last but not least, non-specific NOS 
inhibitor L-NAME upregulated CSE protein expression together with an elevation in LV 




H2S production. As such, it is apparent from this study that H2S and NO do indeed 
interact, and influence each other’s production during MI. 
5.2.2 Exogenous H2S and NO Ameliorates MI 
Majority of the studies have reported that H2S plays a beneficial role in the 
cardiovascular system. Firstly, H2S is verified to be a vasodilator by acting through the 
opening of mitoKATP channels in VSMCs (Zhao et al., 2001). This will facilitate blood 
flow in the ischemic myocardium, ensuring that the oxygen-deprived myocardium 
receives an adequate supply of oxygenated blood. To add on, H2S preconditioning also 
yields cardioprotective effects against ischemia in rat cardiomyocytes as reported by Hu. 
This group suggested that this cardioprotection is mediated through KATP/PKC/ERK1/2 
and PI3K/Akt pathways (Hu et al., 2008).  Moreover, the role of H2S as an anti-
inflammatory agent has also been documented (Hu et al., 2007; Li et al., 2007b).  
NO, generated from various isoforms of NOS is beneficial in the ischemic tissue. These 
actions include direct NO actions on metabolism to bring about a reduction in oxygen 
utilization, or indirect effects through cGMP signaling (Imagawa et al., 1999). cGMP 
stimulates PKG activation and brings about an enhancement of mitoKATP activity 
(Murphy et al., 1995). To add on, it was reported that NO attenuated calcium influx into 
myocytes; antagonized the effects of β-adrenergic stimulation and also decreased 
myocardial contractility. These coupled with the opening of mitoKATP channels may 
minimize calcium overload and depletion of high-energy phosphates associated with 
AMI (Takano et al., 1998). 




In this third study, rats treated with NaHS displayed an improvement in survival rate 
which was accompanied by a reduction in infarct size. This further confirms that NaHS is 
beneficial in AMI as a similar finding was published earlier on by our group (Zhu et al., 
2007).  Also, in a work performed by Johansen and co-workers, they reported that 
treatment of isolated rat hearts with NaHS prior to the onset of coronary occlusion 
brought about a concentration-dependent diminution of infarct size (Johansen et al., 
2006).   
As for animals treated with molsidomine, the improvement in MI was more pronounced. 
Firstly, the survival rate was higher when compared against those treated with NaHS. 
Moreover, the infarct developed was also smaller. This is in agreement with a study 
performed which showed that molsidomine given before left anterior descending artery 
ligation reduced infarct size (Nitz et al., 1985). In our study, it was also observed that the 
LV hypertrophy correlated with the infarct size— animals with smaller infarcts 
developed lesser hypertrophy due to a better preservation of ventricular functions. 
On the other hand, when endogenous H2S and NO production were blocked in PAG and 
L-NAME groups correspondingly, the survival and infarct size deteriorated considerably. 
Firstly, PAG treatment reduced survival from 64.3% in saline controls to 52%. This result 
once again endorsed that observed by Zhu who noted that PAG increased mortality in MI 
(Zhu et al., 2007). Similarly, the infarct sizes from these animals were also observed to 
be significantly greater than controls. This is once again in line with several reports 
which noted that inhibiting endogenous H2S production enhanced infarct development 
(Zhu et al., 2007; Sivarajah et al., 2006). Next, when endogenous NO synthesis was 
blocked by L-NAME, it similarly lowered survival with a corresponding exacerbation of 




infarct. In fact, these results are not unexpected, as Veeravalli and colleagues have 
showed previously that L-NAME abrogated NO-elicited reduction in infarct size 
(Veeravalli et al., 2004). Separately, it was likewise demonstrated that L-NAME 
significantly worsened the infarct in a rabbit myocardial ischemia model (Hoshida et al., 
1995).  
5.2.3 Effect of H2S and NO on BP, ECG and Heart Rate 
 Systolic BP was lowered following one week of NaHS treatment, indicating a 
hypotensive role of NaHS. This data agreed with that published by Zhao, who treated rats 
with an identical dose of NaHS and observed a decrease in BP by 12-30mmHg (Zhao et 
al., 2001). To further substantiate this finding, Geng showed that NaHS lowered mean 
arterial BP and induced a negative inotropic effect as characterized by a reduction in left 
ventricular pressure (Geng et al., 2004b). On the other hand, despite being a well-
established NO donor, molsidomine did not affect BP. This is also confirmed in reports 
by Nitz and Meinertz who stated that molsidomine did not affect BP (Nitz et al., 1985; 
Meinertz et al., 1985). This may be due to the slow NO-releasing property of 
molsidomine. 
 In groups where endogenous H2S and NO production were blocked, BP was greatly 
elevated. Both PAG and L-NAME-treated groups reported a significant increase in BP, 
thus validating the role of endogenous H2S and NO as vasodilators. In support, Zhao 
recorded a significant increase in systolic BP following PAG administration in rats (Zhao 
et al., 2003). Similar observations were made by Yan (Yan et al., 2004). NO has an 
influential role in the physiologic regulation of BP. Reduction in NO generation or 




bioavailability consequently results in vasoconstriction and may be involved in the 
pathogenesis of hypertension (Deniz et al., 2006; Balaszczuk et al., 2002). Several 
studies have documented that L-NAME resulted in an increase in BP (Zicha et al., 2003; 
Ribeiro et al., 1992).  
Following, ECG charts reflected that the wave pattern was better restored, and resembled 
the healthy, non-infarct rats more closely in NaHS and molsidomine-treated animals. 
Those administered with PAG and L-NAME in turn had more sustained ST-segment 
elevations, and more pronounced pathological Q waves. Once again, this observation is 
in accordance with the beneficial role NaHS and molsidomine play in MI. On a different 
note, heart rates remain unaltered in all groups, before and after MI. It was also noted that 
HR was more fluctuating and erratic in rats with bigger infarcts, suggestive of more 
serious ventricular arrhythmias in these rats. 
5.2.4 Effect of H2S and NO on CSE/H2S System 
Majority of the H2S in the body is synthesized by pyridoxal phosphate-dependent 
enzymes, CBS and CSE. The distribution of these enzymes is tissue-specific, with CBS 
primarily localized in the central nervous system and brain, and CSE mainly in the 
cardiovascular system and in organs such as pancreas and kidney. Genetic deletion of 
CSE in mice markedly reduced H2S synthesized in the heart, indicating that CSE is 
indeed the main enzyme responsible for H2S production (Yang et al., 2008). 
The next step in this study would be to examine how different origins (exogenous and 
endogenous) of H2S and NO affect H2S/CSE-related pathway. To begin, it is identified 
that CSE mRNA transcripts were significantly upregulated in the LV following MI. This 




observation is in agreement with that of Geng’s, who reported that CSE gene expression 
was enhanced in isoproterenol-induced myocardial infarction (Geng et al., 2004a). 
However, when CSE protein abundance was next analyzed, it was noted that MI rats had 
a significant downregulation of this protein compared to their sham counterparts. This 
finding correlated with the lower CSE activity observed in MI rats compared to their 
sham controls. This result is similar to that published by Geng, who showed that MI 
resulted in a decrease in tissue H2S levels (Geng et al., 2004a). Additionally, it was 
shown that H2S concentration in the medium of cardiac myocytes was attenuated after 
ischemia injury (Bian et al., 2006). This thus suggests that despite higher mRNA levels 
observed, H2S production is compromised in the ischemic heart owing to a reduction in 
CSE protein expression as well as diminished CSE activity.  
Between MI rats, it was noted that NaHS considerably upregulated CSE protein 
expression accompanied by an increase in H2S production in the LV. This result was 
hardly surprising as several others have demonstrated that exogenous H2S increased CSE 
expression and activity in other CV disease models (Yan et al., 2004; Chunyu et al., 
2003). On the other hand, abrogation of NO production in L-NAME treated rats also 
resulted in an upregulated CSE protein expression with a corresponding rise in H2S 
production. This is conceivable as a compensatory mechanism may exist to make up for 
the decrease in NO synthesis. Since both NO and H2S share similar roles in the body, the 
decrease in one gasotransmitter may stimulate the other’s production so that normal 
physiological functions (i.e modulation of vascular tone, anti-inflammatory roles) may be 
maintained. Thus, in this case, the inhibition of NO production by L-NAME stimulated 
an increase in CSE protein expression, which in turn led to the higher H2S production 




observed. This phenomenon thus provides evidence for a modulatory relationship 
between endogenous NO and H2S. 
Plasma H2S levels were also quantified and it was observed that MI rats had higher H2S 
concentrations compared to their sham counterparts. As H2S production was observed to 
be on the whole higher in LV of sham rats, this anomaly may arise from an over-
compensation by healthy tissues to make up for the reduced H2S synthesized in the 
injured myocardium. Between animals that underwent the MI protocol, NaHS-treated rats 
had the highest H2S concentration as NaHS was able to stimulate CSE activity as justified 
earlier on. On the other hand, PAG inhibited CSE activity and this resulted in a dramatic 
decrease in H2S levels.  
5.2.5 Effect of H2S and NO on the NOS/NO System 
The role of NO as a vasodilator is firmly established, and plays a pivotal role in 
governing the normal physiology in the cardiovascular system (Cengel et al., 2006). NO 
is synthesized in endothelial cells from L-arginine and molecular oxygen by a family of 
NOS isoforms, including eNOS, nNOS and iNOS. As all three members are present in 
the heart, the first task was to characterize their gene and protein expressions in the 
infarcted myocardium.  
Berges reported higher mRNA and protein levels of eNOS and iNOS in the infarcted LV 
of AMI rats (Berges et al., 2005). Our results did not fully agree with theirs as 
constitutively-expressed eNOS and nNOS expressions were comparable between sham 
and MI rats in our study. Moreover, our data for eNOS coincided with that by Takimoto 
and colleagues who examined mRNA expression of eNOS in the LV three days after MI 




(Takimoto et al., 2000). The disparity between Berges’ and our findings concerning 
eNOS may have arisen due to the different time-points in which the animals were 
sacrificed. In our study, the animals were killed 48h after the induction of MI, while 
Berges only sacrificed the animals one week after the surgery. 
In contrast, iNOS was dramatically upregulated upon ischemic insult in our study and 
was in agreement with Berges’ report.  As such, we can draw the conclusion that iNOS is 
induced early, at least within 48h post-MI, in the ventricular remodeling process. On the 
other hand, eNOS is only upregulated in the later part of the remodeling process as 
demonstrated by Berges’ study. Furthermore, the higher NO content observed in the LV 
and plasma of MI rats is largely iNOS-derived, since eNOS and nNOS levels were 
similar between MI and their sham counterparts. This burst of NO observed may serve to 
regulate morphological and architectural modifications, such as scar formation and 
myocardial hypertrophy in the ischemic myocardium (Wildhirt et al., 1995). 
Studies investigating the effects of H2S on the NO pathway have been conducted. Geng 
reported that both exogenous and endogenous H2S reduced eNOS transcript abundance 
and activity, as well as lowered NO formation in healthy rats (Geng et al., 2007).This is 
in stark contrast to our current findings, which reported that NaHS potentiated the 
NO/NOS pathway. This discrepancy may stem from the different physiological 
conditions of the rats (i.e healthy rats in Geng’s and MI rats in ours). It was observed that 
NaHS treatment markedly upregulated both eNOS and iNOS gene and protein 
expressions to result in a significant upsurge of NO levels in both the LV and plasma of 
MI rats. This seems to suggest that when exogenous H2S is applied, the relationship 




between H2S and NO is a synergistic one during MI, as the introduction of additional H2S 
further triggered NO production. 
Conversely, in rats with high pulmonary blood flow, treatment with PAG for a period of 
4 weeks could increase lung tissue NO production and eNOS expression to bring about 
protective effects (Li et al., 2007c).  In our study, both eNOS and iNOS expressions were 
also elevated following PAG treatment in MI, though to a lesser extent compared to 
NaHS. This increase was only observed at the level of gene expression and not detected 
at the protein level. This implies that the higher NO content observed in the LV and 
plasma is likely to arise from stimulation of the activity of NOS enzymes by PAG as 
protein abundance was unaltered. The increase in NOS activity may be due to a 
compensatory mechanism by the body to make up for the reduction in endogenous H2S 
production, since both gasotransmitters have largely similar roles. In contrary to the 
observations about NaHS made above, this finding seemed to lend strength to a 
modulatory relationship between the two gases instead. 
5.2.6 Effect of H2S and NO on the HIF System 
HIF-1 is a transcription factor and master regulator of several hypoxic-sensitive genes, 
and it brings about a change in the transcriptional repertoire of tissues during ischemia. 
An early increase in cardiac expression of HIF-1α has been observed in response to 
myocardial ischemia or infarction in humans (Lee et al., 2000). Among the wide array of 
genes regulated by HIF-1α, iNOS is one of them. As noted above, NaHS upregulated 
eNOS and iNOS gene and protein expressions, with an accompanying increase in NO 
levels in both plasma and LV. This consistent upregulation of the NO/NOS pathway is 




intriguing. It is suggested that HIF-1α may be the link between NaHS and the increase in 
iNOS observed during MI. 
To investigate if exogenous H2S enhanced HIF-1 activation during MI, HIF-1α gene and 
protein expressions were probed in the LV of the animals.  The abundance of HIF-1 
mRNA transcripts was significantly higher in rats that were subjected to the MI insult. 
The data obtained corroborated with that reported by Forkel, who showed that HIF-1α 
mRNA levels were elevated in the LVs of isolated rat hearts subjected to hypoxia 
stimulus (Forkel et al., 2004). This finding was further verified by several others (Li et al., 
2007d; Kim et al., 2002). Among the MI rats, there was no noticeable difference in gene 
expression levels between various treatment groups. To better understand the function or 
activity of HIF-1, the abundance of HIF protein was evaluated. When HIF-1 protein was 
quantified, it was noted that HIF levels were immensely upregulated in MI rats. This was 
similarly detected by several groups (Li et al., 2007d; Kim et al., 2002). Interestingly, 
NaHS treatment further enhanced this increase in HIF-1α, thus suggesting that our earlier 
hypothesis may hold some truth. However, more in-depth experiments need to be 
conducted before this conclusion can be made. 
5.2.7 Summary of Findings for Experimental Protocol 3 
As the roles of exogenous and endogenous H2S and NO have not been examined in AMI, 
our finding provides novel knowledge in this aspect and contributes to the understanding 
of the relationship between these two gasotransmitters. Firstly, we showed that 
exogenous NO and H2S are cardioprotective in this disease setting as marked 
improvements were noticed in the aspects of survival, infarct size and hypertrophy. 




Moreover, ECG charts revealed that cardiac functions were better-preserved in both 
groups. Next, we identified the presence of a crosstalk between NO and H2S in this 
pathological condition. Firstly, NaHS upregulated the gene and protein expressions of 
both eNOS and iNOS. In addition, there was a corresponding increase in NO amounts in 
both the LV and plasma. As such, NaHS, an exogenous source of H2S was demonstrated 
to upregulate the NO/NOS pathway. It is postulated that HIF-1α signaling may be 
involved, as its protein levels were elevated following drug treatment. Moreover, one of 
the downstream targets of HIF-1α activation is iNOS, which was shown to be 
upregulated earlier on. This discovery is fascinating and warrants further attention. 
 Secondly, PAG treatment led to an increase in eNOS and iNOS gene expressions with an 
accompanied increase in NO levels in both LV and plasma. Similarly, in the case of L-
NAME-treated rodents, there was an increase in CSE protein expression when NO 
production was inhibited. This increase in CSE protein correlated with a higher H2S 
production in the LV. In view that both H2S and NO share similar roles such as in the 
regulation of blood pressure, or as an anti-inflammatory agent in the physiological system, 
the redundancy in having two molecules serving similar functions may actually prove to 
be useful. A modulatory relationship appears to exist between these two gasotransmitters, 
such that when there is a blockade in the endogenous production of one gas, synthesis of 
the other gas will be stimulated. Hence, this ensures that vital physiological functions can 
still be maintained. In conclusion, this study has provided three distinct evidence for the 
crosstalk between NO and H2S in MI. However, the mechanisms (i.e HIF signaling 
system) governing the interaction in each instance is likely to be different, and awaits 
further clarification. 














RESULTS & DISCUSSION 
EXPERIMENTAL PROTOCOL 4 
Mechanisms of NaHS-mediated cardioprotection in myocardial ischemia 




H2S EXERTS CARDIOPROTECTION BY ENHANCING HIF-1α ACTIVATION 
AND iNOS EXPRESSION WITH THE INVOLVEMENT OF PI3K/AKT 
PATHWAY IN H9C2 AND CARDIOMYOCYTES 
6.1 RESULTS 
6.1.1 Optimization of Hypoxia Conditions 
6.1.1.1 Selection of Hypoxia Model 
Cells were subjected to hypoxia to simulate an ischemic condition in a cell culture setting. 
Hypoxia can be induced by the physical hypoxia method in which cells are placed in a 
hypoxic chamber and the amount of oxygen within the chamber controlled accordingly. 
Alternatively, hypoxia can be induced by treating cells with hypoxia-mimetic chemicals 
such as cobalt chloride (CoCl2) or desferrioxamine (DFX).  
Firstly, to select the most appropriate hypoxia model, h9c2 underwent hypoxia induced 
by three different models, namely, the hypoxic chamber, CoCl2 (100 and 200µM) and 
DFX (130 and 260µM). The concentrations of CoCl2 and DFX chosen for this 
preliminary investigation are based on existing literature (Chen et al., 2009b; Shu et al., 
2008; Montopoli et al., 2007; Chun et al., 2003; Namiki et al., 1995).  The duration of 
hypoxia in this initial experiment was 24h. Cell viability was assessed by the MTT assay 
and the results obtained are as illustrated in Figure 6.1.  Cell viability in the normoxic 
control (NC) group was set to be 100%, and results in other groups were expressed as a 
percentage of NC. 
Both DFX and the hypoxic chamber seemed to be ineffective in inducing hypoxia as cell 
viability was not drastically reduced in both models after the harsh ischemic insult 
(98.62±8.62% in 130µM DFX, 101.05±27.69 in 260µM DFX, and 105.73±24.78% for 




hypoxic chamber). On the contrary, CoCl2 appeared to be effective in inducing hypoxia 
in h9c2, as cell viability was reduced to 77.99±5.26% when h9c2 was exposed to 100µM 
CoCl2. Moreover, viability was further reduced to 47.53± 20.63% when 200µM CoCl2 




6.1.1.2 Optimization of CoCl2 Concentration 
To determine the optimal dose of CoCl2 to use in inducing hypoxia, h9c2 were grown in 
96-well plates and upon reaching 70% confluency, the cells were treated with different 
concentrations of CoCl2 for a period of 24h. Depletion of myoblastic population may 
occur if the cultures are allowed to become confluent as the myoblasts will initiate 
differentiation to become myocytes. Cells were exposed to 100µM, 200µM, 400µM, 
1000µM, 2000µM and 5000µM CoCl2 to determine the concentration-dependent trend of 
this chemical hypoxia model.  
Figure 6.1 Cell viability of h9c2 subjected to the various hypoxia models (CoCl2, DFX and 
hypoxic chamber) for 24h. NC, normoxic control. Results are expressed as a % of NC. Data 
shown are mean ± S.E.M. (n=6). *p<0.05 when compared to NC. 




It is observed that there is indeed a concentration-related decrease in cell viability as 
shown in Figure 6.2. Treatment with 100µM CoCl2 resulted in a slight but significant 
decrease in cell viability to 77.71±5.46% (p<0.05). Upon increasing CoCl2 concentration 
to 200µM, cell viability was further reduced to 43.65±5.57% which is statistically highly 
significant (p<0.01). Cell death induced with this condition is considered to be 
sufficiently high to evaluate if subsequent drug treatment is able to improve cell viability.  
By further increasing the concentration of CoCl2 to 400µM and 1000µM, cell viability 
was reduced to 31.00±4.17% and 28.80±15.6% respectively, which were not much 
different compared to that with 200µM CoCl2. Beyond this, hardly any viable cells were 





Figure 6.2 Cell viability of h9c2 subjected to different concentrations of CoCl2 for 24h. 
NC, normoxic control. Results are expressed as a % of NC. Data shown are mean ± S.E.M. 
(n=6). *p<0.05 when compared to NC. **p<0.01 when compared to NC. ***p<0.005 when 
compared to NC. 




6.1.1.3 Optimization of Hypoxic Duration 
After optimizing the concentration of CoCl2, the next logical step would be to establish 
the duration of hypoxia. A series of time points, namely 6h, 12h, 18h, 24h and 48h were 
investigated. According to data presented in Figure 6.3, there was a time-dependent 
reduction in cell viability. The decrease in viability (90.9±5.45%) was insignificant when 
cells were incubated with 200µM CoCl2 for 6h. Cell viabilities for 12h and 18h were 
75.7±6.90% and 61.6±9.2% respectively and both were significantly different compared 
to normoxic controls (p<0.05). In addition, when cells were subjected to a 24h incubation 
period with 200µM CoCl2, the cell viability was notably reduced to 43.7±5.57% (p<0.01) 
which was deemed best suited for the hypoxia model. For subsequent experiments, 24h 




Figure 6.3 Cell viability of h9c2 subjected to different durations of hypoxia using 200µM 
CoCl2. NC, normoxic control. Results are expressed as a % of NC. Data shown are mean ± 
S.E.M. (n=6). *p<0.05 when compared to NC. **p<0.01 when compared to NC.  




6.1.1.4 Optimization of NaHS Concentration 
As studies using NaHS to treat h9c2 under hypoxic conditions have not been conducted, 
the effective dosage of NaHS has to be ascertained. Cells were pre-treated with a series of 
NaHS concentrations (30µM — 1000µM) for 1h before hypoxia was initiated. The 
results in Figure 6.4 showed that there was a dose-dependent improvement in cell 
viability from 30µM to 300µM NaHS, with the 300µM dose being the most optimal as 
cell viability was restored to almost normoxic control values (84.04±1.86%, p<0.05 
compared to hypoxic controls). Higher doses of NaHS (1000µM) failed to further 
improve cell viability (47.95±6.55%, p>0.05 compared to hypoxic control) as this 
concentration was probably too high and may be toxic to the cells. As a consequence, in 
subsequent experiments, h9c2 was treated with 300µM NaHS.  
 
 
Figure 6.4 Cell viability of h9c2 treated with different concentrations of NaHS (30-
1000µM). NC, normoxic control; HC, hypoxic control; H30—H1000, hypoxia + 30—
1000µM NaHS. NaHS was administered to the cells 1h before the 24h hypoxic insult. 
Hypoxia was induced using 200µM CoCl2.  Results are expressed as a % of NC. Data shown 
are mean ± S.E.M. (n=6). *p<0.05 when compared to NC.  




6.1.2 Assessment of Cell Viability  
6.1.2.1 MTT Assay 
In this study, cell viability was assessed using the MTT assay. H9c2 was treated with 
300µM NaHS for 1h and subsequently incubated under hypoxic conditions (200µM 
CoCl2) for 24h. The relative cell viability in the normoxic control (NC) group is defined 
as 100%. The data in Figure 6.5 showed that in the hypoxic control (HC) group, cell 
viability was reduced to 43.83±11.55% (p<0.05). Upon treatment with 300µM NaHS, 
cell viability of hypoxic cells (H300) improved to 78.90±7.37% (p<0.05 compared to 
HC). There was no adverse reaction, i.e. reduction in cell survival, with cells treated with 
300µM NaHS under normoxic conditions as its viability is similar to NC (102.31±2.89%). 
 
Figure 6.5 Relative cell viability for NC, HC, N300 and H300. NC, normoxic control; HC, 
hypoxic control; N300, normoxia+300µM NaHS; H300, hypoxia+300µM NaHS. Cell viability 
in each treatment group is expressed as a percentage of that of normoxic control. The data 
shown are mean ± S.E.M. (n=6). * p<0.05 when compared to the normoxic control group. 
^p<0.05 when compared to the hypoxic control group. 




6.1.2.2 LDH Assay 
To further validate the credibility of the MTT results, LDH assay which measures the 
extent of cytotoxicity was performed. This assay is based on the principle that membrane 
integrity is compromised in damaged cells. As such, the release of LDH enzyme from 
these damaged cells into the culture medium is used as an index of cellular injury.  
Cells were treated to a range of NaHS concentrations under hypoxic conditions (30-
1000µM). Normoxic cells treated with NaHS had comparable levels of cell damage as 
normoxic controls. This is shown in Figure 6.6. It is apparent that cytotoxicity in hypoxic 
control (HC) group was much higher (186±6.2%, p<0.05) than NC. Cellular damage was 
reduced with NaHS treatment in a dose-dependent manner, with the lowest cytotoxicity 
observed in the group treated with 300µM (115±16.3%). With higher doses (600µM and 
1000µM), cell damage was increased to 145±20.3% and 135±20.6% respectively. The 
results are in agreement with that obtained from the MTT assay earlier on. 
 
 
Figure 6.6 LDH release for normoxic (in grey) and hypoxic (in black) groups treated 
with various concentrations of NaHS. NC, normoxic control; HC, hypoxic control. LDH 
release (cytotoxicity) in each treatment group is expressed as a percentage of that against the 
normoxic control. The data shown are mean ± S.E.M. (n=6). *p<0.05 compared to the 
normoxic control group. ^p<0.05 compared to the hypoxic control group. 




6.1.2.3 Trypan Blue Exclusion Assay  
6.1.2.3.1 H9C2 
Due to the paramount importance of ensuring that both the hypoxia model employed as 
well as the NaHS dosage used are the best suited, a third cell viability test (Trypan Blue 
Exclusion Assay) was carried out. The results in Figure 6.7 showed that cell viability was 
significantly reduced in HC to 79.99±0.90% of NC (p<0.05). In addition, when cells were 
treated with 300µM NaHS preceding hypoxic induction, cell viability was greatly 
ameliorated to 89.02±0.95% when judged against HC (p<0.05). Treatment of cells with 
300µM did not result in any cell death as demonstrated in the N300 group which had a 
cell viability of 96.30±0.47%. Results obtained from this Trypan Blue Exclusion assay 
was consistent with the data obtained from both MTT and LDH assays performed earlier.  
 
 
Figure 6.7 Cell viability test (Trypan Blue Exlusion assay) for NC, HC, N300 and H300. 
NC, normoxic control; HC, hypoxic control; N300, normoxia+300µM NaHS; H300, 
hypoxia+300µM NaHS. The data shown are mean ± S.E.M. (n=6). * p<0.05 when compared 
to the normoxic control group. ^p<0.05 when compared to the hypoxic control group. 





In cardiomyocytes, hypoxia was also induced using 200µM CoCl2 to maintain 
consistency with the conditions employed for h9c2. As cardiomyocyte is a more sensitive 
model compared to h9c2, the hypoxia duration is shortened to 1h as adopted from 
existing literature. Also, the dosage of NaHS employed is reduced to 100µM based on 
published studies (Pan et al., 2006; Perez-Severiano et al., 2004).  
From Figure 6.8, it is noted that cell viability of HC was 78.32±1.04%, which was 
statistically significant compared to NC (p<0.005). In addition, when myocytes were pre-
treated with NaHS for 1h before hypoxia, viability was greatly improved to 85.75±1.04% 
(p<0.01 vs. HC). Treatment with 100µM NaHS did not adversely harm the cells. Hence, 
in subsequent experiments using myocyte as a model, the cells were first treated with 
100µM NaHS for an hour before hypoxia induction with200µM CoCl2 for another hour. 
 
 
Figure 6.8 Cell viability test (Trypan Blue Exlusion assay) for NC, HC, N100 and H100. 
NC, normoxic control; HC, hypoxic control; N100, normoxia+100µM NaHS; H100, 
hypoxia+100µM NaHS. Cells were treated with 100µM NaHS for 1h, and hypoxia was 
induced with 200µM CoCl2 for another hour. The data shown are mean ± S.E.M. (n=6). 
***p<0.005 compared to the normoxic control group. ^^p<0.01 compared to the hypoxic 
control group. 




6.1.3 Involvement of HIF-1α/iNOS Pathway in H2S-Mediated Cardioprotection 
6.1.3.1 Protein Expression of HIF-1α in Total Cell Lysates 
After establishing the hypoxic conditions and showing that NaHS is able to confer 
protection to hypoxic cardiac cells, the next part of this study would be to explore the 
mechanism governing this H2S-mediated protection.  
Firstly, the protein expression of hypoxia-inducible factor-1α (HIF-1α) was quantified. 
HIF-1α is a transcription factor that governs the activation and regulation of a multitude 
of genes that are activated under hypoxic conditions. From Figure 6.9, it is apparent that 
the expression of HIF-1α was upregulated under hypoxic conditions as seen in both HC 
and H300 groups of h9c2. In HC, HIF-1α was upregulated to 1.37±0.09 (p<0.05) fold of 
NC. In the H300 group, HIF-1α was further increased to 1.95±0.30 (p<0.05), indicating 
that NaHS treatment brought about an enhancement of HIF-1α expression. On the other 
hand, NaHS had no influence on HIF-1α expression levels in normoxic cells. 
When HIF-1α expression was quantified in myocytes, it was noticeably stronger 
compared to h9c2. This is depicted graphically in Figure 6.10. Similar to that in h9c2, 
HIF-1α was upregulated in both HC and H100 (p<0.05), with the expression in H100 
being appreciably higher than that in HC (2.48±0.28 vs. 1.57±0.03, p<0.05). Similar to 
h9c2, cardiomyocytes treated with NaHS under normoxic conditions did not express the 
protein differently compared to NC. 









Figure 6.10 Protein expression of HIF-1α in myocytes. NC, normoxic control; HC, hypoxic 
control; N100, normoxic+100µM NaHS; H100, hypoxic+100µM NaHS. HIF-1α expression was 
normalized to that of α-tubulin in each group. Results are described as a fold difference over NC. 
Data are expressed as mean ± S.E.M. (n=4). *p<0.05 when compared to NC. ^p<0.05 when 
compared to HC. 
Figure 6.9 Protein expression of HIF-1α in h9c2. NC, normoxic control; HC, hypoxic 
control; N300, normoxic+300µM NaHS; H300, hypoxic+300µM NaHS. HIF-1α 
expression was normalized to that of β-tubulin in each group. Results are described as a 
fold difference over NC. Data are expressed as mean ± S.E.M. (n=4). *p<0.05 when 
compared to NC.  




6.1.3.2 Gene Expression of HIF-1α  
It was then examined to see whether hypoxia-induced upregulation of HIF-1α protein in 
h9c2 and myocytes was through the increase in mRNA levels. As depicted in Figure 6.11 
and Figure 6.12, hypoxia did not affect HIF-1α mRNA levels in both h9c2 and myocytes. 
Moreover, treatment with NaHS did not alter mRNA abundance, and expression levels 
were consistent in all groups.  








Figure 6.12 HIF-1α gene expression in NC, HC, N100 and H100 groups of 
cardiomyocytes. NC, normoxic control; HC, hypoxic control; N100, normoxic+100µM NaHS; 
H100, hypoxic+100µM NaHS. HIF-1α gene expression was normalized to that of GAPDH in 
each group. Results are described as a fold difference over NC. Data are expressed as mean ± 
S.E.M. (n=4). 
Figure 6.11 HIF-1α gene expression in NC, HC, N300 and H300 groups of h9c2. NC, 
normoxic control; HC, hypoxic control; N300, normoxic+300µM NaHS; H300, hypoxic 
+300µM NaHS. HIF-1α gene expression was normalized to that of GAPDH in each group. 
Results are described as a fold difference over NC. Data are expressed as mean ± S.E.M. (n=4). 




6.1.3.3 Protein Expression of HIF-1α in Nuclear and Cytoplasmic Fractions 
During hypoxia, HIF-1α is stably expressed in the cytoplasm and translocated into the 
nucleus where it functions as a transcription factor to bring about the activation of its 
downstream target genes. Thus, the expressions of HIF-1α in both the nuclear and 
cytoplasmic fractions were probed. Hypoxia enhanced the accumulation (Figure 6.13) of 
HIF-1α in the cytoplasm and its translocation (Figure 6.14) into the nucleus.  When cells 
were pretreated with NaHS (H300) prior to the hypoxia insult, the accumulation of HIF 
in the cytosol was enhanced (1.59±0.14 fold of NC, p<0.05). It was also observed that 
under normoxic conditions, HIF-1α expression levels in the cytoplasm were similar in 
both NC and N300 groups.  
Furthermore, from Figure 6.14, it was noted that HIF-1α was only translocated into the 
nucleus under hypoxic conditions as seen in both HC and H300. HIF-1α expression in the 
nucleus was barely detectable in the normoxic groups (ie. NC and N300). Once again, in 
cells treated with NaHS, nuclear translocation of HIF-1α was significantly enhanced 
(2.19±0.24 fold, p<0.005 vs. NC), suggesting that NaHS can augment HIF-1α activation 
under hypoxic situations. 
 








Figure 6.14 HIF-1α protein expression in nuclear fractions of various treatment groups 
of h9c2. NC, normoxic control; HC, hypoxic control; N300, normoxia +300µM NaHS; H300, 
hypoxia +300µM NaHS. HIF-1α expression was normalized to that of loading control histone 
in each group. Results shown are expressed as the fold difference over NC. Data are expressed 
as mean ± S.E.M. (n=6). *p<0.05 when compared to NC. ***p<0.005 compared to NC. 
 
Figure 6.13 HIF-1α protein expression in cytoplasmic fractions of various treatment 
groups of h9c2. NC, normoxic control; HC, hypoxic control; N300, normoxia+300µM 
NaHS; H300, hypoxia+300µM NaHS. HIF-1α expression was normalized to that of β-
tubulin in each group. Results shown are expressed as the fold difference over NC. Data 
are expressed as mean ± S.E.M. (n=4). *p<0.05 when compared to NC. 
 




6.1.3.4 Electrophoretic Mobility Shift Assay (EMSA) for HIF-1α Binding 
HIF-1α binding site in the 5’-flanking region of iNOS promoter was demonstrated to be 
involved in the regulation of iNOS gene expression. As such, EMSA was performed with 
a 30bp wild-type oligonucleotide containing the consensus HIF-1α binding site and 
nuclear extracts prepared from both h9c2 and myocytes. This is to examine if hypoxia 
exposure ensued in the binding of transcription factor HIF-1 to iNOS hypoxia response 
element (HRE) containing the HIF-1 binding site. DNA binding activity (indicated by 
arrows) was detected in hypoxic samples assayed with the wild type probes, with H300/ 
H100 showing the strongest binding intensity in both h9c2 (Figure 6.15) and myocytes 
(Figure 6.16) respectively. To ensure binding specificity, control experiments were 
performed using mutated probes and there was no detectable binding in these instances.  
In addition, negative control experiments which consist of substituting the biotin labeled 












Figure 6.16 Binding of HIF-1α protein from myocytes to HRE in iNOS gene promoter 
region. 5µg nuclear extracts from myocytes subjected to the various treatments were 
incubated with either the wild-type or mutated HIF-1α probes. Results are representative of 3 
independent experiments.  
Figure 6.15 Binding of HIF-1α protein from h9c2 to HRE in iNOS gene promoter region. 
5µg nuclear extracts from h9c2 subjected to the various treatments were incubated with either 
the wild-type or mutated HIF-1α probes. Negative control experiments were carried out by 
substituting the labeled probes with unlabeled ones. Results are representative of 3 
independent experiments.  




6.1.3.5 iNOS Gene Expression 
After validating that HIF-1α indeed binds to the iNOS promoter sequence in the nucleus, 
the next step would be to examine if the transcription of iNOS mRNA expression was 
effected. Indeed, the findings shown in Figure 6.17 showed that iNOS mRNA levels in 
h9c2 were upregulated in both HC and H300 (1.62±0.10 and 2.93±0.39 folds of NC 
respectively, p<0.05 and p<0.01 respectively). Moreover, the abundance of iNOS in 
H300 is significantly higher than that in HC (p<0.01), indicating that NaHS served to 
augment this activation. Cells treated with NaHS and placed under normoxic conditions 
displayed comparable expression levels as NC (1.26±0.17 fold, p>0.05). 
In myocytes, a similar observation was made as reported in Figure 6.18. In hypoxic 
controls, iNOS expression was upregulated by 2.07±0.24 fold when compared to NC 
(p<0.05). Upon NaHS treatment, iNOS level was upregulated in H100 to 5.07±0.67 fold 
of NC, which was statistically significant compared to HC (p<0.005). Normoxic groups 
had comparable amounts of iNOS expressed. From these two sets of results, it is apparent 
that iNOS is activated upon HIF-1α translocation into the nucleus and this can be further 
enhanced by treating cells with NaHS prior to hypoxia. 







Figure 6.18 iNOS gene expression in NC, HC, N100 and H100 groups of cardiomyocytes. 
NC, normoxic control; HC, hypoxic control; N100, normoxic+100µM NaHS; H100, hypoxic 
+100µM NaHS. iNOS gene expression was normalized to that of GAPDH in each group. 
Results are described as a fold difference over NC. Data are expressed as mean ± S.E.M. (n=4). 
*p<0.05 when compared to NC. ^^^p<0.005 when compared to HC. 
 
Figure 6.17 iNOS gene expression in NC, HC, N300 and H300 groups of h9c2. NC, 
normoxic control; HC, hypoxic control; N300, normoxic+300µM NaHS; H300, hypoxic 
+300µM NaHS. iNOS gene expression was normalized to that of GAPDH in each group. 
Results are described as fold difference over NC. Data are expressed as mean ± S.E.M. (n=3). 
*p<0.05 when compared to NC. **p<0.01 when compared to NC. ^^p<0.01 when compared to 
HC. 




6.1.3.6 iNOS Protein Expression 
To investigate if the observations made for iNOS mRNA transcripts were translated to 
the protein level, iNOS protein abundance was next analysed. The pattern of protein 
expression highly correlated to that of gene expression. With reference to Fig 6.19, iNOS 
was upregulated in HC by 1.55±0.05 fold of NC (p<0.05). Likewise, in H100, iNOS 
expression in myocytes was increased to 2.85±0.45 fold of NC, and this was significantly 






Figure 6.19 iNOS protein expression in NC, HC, N100 and H100 groups of 
cardiomyocytes. NC, normoxic control; HC, hypoxic control; N100, normoxia+100µM NaHS; 
H100, hypoxia+100µM NaHS. iNOS protein expression was normalized to that of α-tubulin in 
each group. Results are described as a fold difference over NC. Data are expressed as mean ± 
S.E.M. (n=4). *p<0.05 when compared to NC. ^^p<0.01 when compared to HC. 
 




6.1.3.7 NO Production 
After demonstrating that iNOS protein is upregulated under hypoxia and can be further 
enhanced by NaHS, the amount of NO produced in each treatment group was assessed. 
Nitrate/nitrite (NOx) is released into the cell medium upon formation and can thus be 
quantified. For NC of h9c2, the concentration of NOx produced is 26.45±2.37 µM 
(Figure  6.20). Upon treatment with NaHS, this amount was increased to 59.26±7.25 µM 
(p<0.05). In hypoxic controls, NO production was greatly augmented to 96.02±4.6 µM 
(p<0.005). As for hypoxic cells treated with NaHS, NO concentration was 107.46±6.85 
µM which is signficantly higher compared to NC (p<0.005).  
In the case of  cardiomyocytes, a trend similar to that seen in h9c2 was noted (Figure 
6.21). Following hypoxia, the amount of NO produced was greatly elevated to 
62.03±0.26 µM which is significantly different from that in NC (41.11±3.77µM, p<0.05). 
Likewise, this level was slightly higher in the hypoxic group treated with NaHS, with a 
concentration of 66.22±3.1µM (p<0.01 compared to NC). 
 
 








Figure 6.21 NO production in various treatment groups of cardiomyocytes. NC, 
normoxic control; HC, hypoxic control; N100, normoxic+100µM NaHS; H100, 
hypoxic+100µM NaHS. Results are expressed as µM NO produced per 106 cells. Data 
shown are mean ± S.E.M. (n=6). *p<0.05 when compared to NC. **p<0.01 when 
compared to NC. 
Figure 6.20 NO production in various treatment groups of h9c2. NC, normoxic 
control; HC, hypoxic control; N300, normoxic+300µM NaHS; H300, hypoxic+300µM 
NaHS. Results are expressed as µM NO produced per 106 cells. Data shown are mean ± 
S.E.M. (n=6). **p<0.01 when compared to NC. ***p<0.005 when compared to NC. 




6.1.4 Involvement of PI3K/Akt Pathway in H2S-Mediated Cardioprotection 
6.1.4.1 Protein Expression of Akt 
As several studies have implicated the involvement of PI3K/Akt pathway in hypoxia-
induced HIF-1α activation, the next part of the research was to examine if this pathway 
plays a part in the observed H2S-mediated cardioprotection. In addition to the four groups 
employed in the earlier studies, two additional groups with PI3K inhibitors wortmannin 
and LY294002 were added. In these groups, cells were pre-treated with the inhibitors for 
1h before NaHS treatment, and subsequently subjected to hypoxia simulation. Both 
inhibitors were tested in the two models (h9c2 and myocytes) at various concentrations. 
In preliminary studies, only wortmannin at 100nM and 200nM seemed to be effective in 
h9c2, while LY294002 was deemed ineffective (data not shown). On the other hand, both 
inhibitors were effective in myocytes, with wortmannin being employed at 100nM and 
LY294002 at 25µM. 
Firstly, the protein abundance of Akt was detected. As shown in Figure 6.22 and Figure 
6.23, Akt expression levels did not change between the various treatments in both h9c2 
and myocytes. No changes were brought about by hypoxia, NaHS treatment and/or PI3K 
inhibitors. 
 







Figure 6.23 Protein expression of Akt in the various treatment groups of myocytes.  
NC, normoxic control; HC, hypoxic control; N100, normoxia+100µM NaHS; H100, 
hypoxia+100µM NaHS; H100+W100, hypoxia+100µM NaHS+100nM wortmannin; 
H100+LY25, hypoxia+100µM NaHS+25µM LY294002. Akt protein expression was 
normalized to that of α-tubulin in each group. Results are described as a fold difference over 
NC. Data are expressed as mean ± S.E.M. (n=4).  
 
Figure 6.22 Protein expression of Akt in the various treatment groups of h9c2.  NC, 
normoxic control; HC, hypoxic control; N300, normoxia+300µM NaHS; H300, hypoxia 
+300µM NaHS; H300+W100, hypoxia+300µM NaHS +100nM wortmannin; H300+W200, 
hypoxia+300µM NaHS+200nM wortmannin. Akt protein expression was normalized to that 
of β-tubulin in each group. Results are described as a fold difference over NC. Data are 
expressed as mean ± S.E.M. (n=6).  
 




6.1.4.2 Protein Expression of p-Akt 
Next, the protein expression of phosphorylated Akt (p-Akt) was quantified as illustrated 
in Figure 6.24 (h9c2) and Fig 6.25 (myocytes). In h9c2, hypoxia elevated the expression 
of p-Akt, and this was significantly enhanced by treatment with 300µM NaHS (2.41±0.36 
fold vs. 1.49±0.10 fold, p<0.05 compared to HC). Additionally, when wortmannin was 
added to NaHS-treated cells under hypoxic conditions, there was a dose-dependent 
decrease in p-Akt expression. p-Akt was reduced from 2.41 fold prior to the addition of 
wortmannin, to 1.91 fold with 100nM wortmannin, and 1.17 fold (p<0.05 compared to 
H300) with 200nM wortmannin. These results verified that wortmannin inhibited PI3K 
activity, and Akt phosphorylation is chiefly dependent on PI3K activity. This in turn 
ensued in a reduction in phosphorylation levels of Akt in h9c2 in a dose-dependent 
manner.  
In myocytes, a similar trend was also noted as shown in Figure 6.25. Following hypoxia, 
p-Akt was upregulated compared to their normoxic counterparts (1.31±0.11 fold, p<0.05). 
This increase in expression was further escalated when treated with 100µM NaHS 
(2.62±0.39 fold, p<0.005 compared to HC). Similarly, treatments with both PI3K 
inhibitors wortmannin and LY294002 served to attenuate the increase in p-Akt observed 
in H100, bringing their levels down to 1.56±0.07 and 1.41±0.16 folds of NC respectively 
(p<0.01 compared to H300). Both wortmannin and LY294002 seemed to be equally 
effective in inhibiting PI3K activity as they reduced p-Akt to the same levels. 







Figure 6.25 Protein expression of p-Akt in the various treatment groups of myocytes.  
NC, normoxic control; HC, hypoxic control; N100, normoxia+100µM NaHS; H100, 
hypoxia+100µM NaHS; H100+W100, hypoxia+100µM NaHS+100nM wortmannin; 
H100+LY25, hypoxia+100µM NaHS+25µM LY294002. p-Akt protein expression was 
normalized to that of α-tubulin in each group. Results are described as a fold difference over 
NC. Data are expressed as mean ± S.E.M. (n=6).*p<0.05 when compared to NC. 
^^^p<0.005 when compared to HC. ##p<0.01 when compared to H100. 
 
 
Figure 6.24 Protein expression of p-Akt in the various treatment groups of h9c2.  NC, 
normoxic control; HC, hypoxic control; N300, normoxia+300µM NaHS; H300, hypoxia 
+300µM NaHS; H300+W100, hypoxia+300µM NaHS+100nM wortmannin; H300+W200, 
hypoxia+300µM NaHS+200nM wortmannin. p-Akt protein expression was normalized to that 
of β-tubulin in each group. Results are described as a fold difference over NC. Data are 
expressed as mean ± S.E.M. (n=6). ^p<0.05 compared to HC. #p<0.05 when compared to H300. 
 
 





The ratio of p-Akt/Akt was next analysed in both h9c2 and myocytes in order to establish 
the degree of Akt activation. As illustrated in Figure 6.26 and Figure 6.27, the status of 
Akt activation closely follows that of p-Akt expression as the amount of Akt in both h9c2 
and myocytes were similar between treatment groups. In h9c2, hypoxia promoted Akt 
activation (1.79±0.12 fold cf. NC, p<0.05), and this increase was further enhanced with 
NaHS treatment (3.10±0.24 fold, p<0.05 compared to HC) (Figure 6.26). Treatment with 
wortmannin attenuated Akt activation in a dose-dependent manner. When 200nM 
wortmannin was applied, the decrease was significant compared to H300 (1.36±0.23 
vs.3.10±0.24 fold, p<0.01). Normoxic groups had similar levels of Akt activation.   
The results obtained for myocytes is as illustrated in Figure 6.27. Similar to h9c2, Akt 
activation in hypoxic control group was significantly higher compared to normoxic 
control (1.68±0.19 fold, p< 0.05). This activation was dramatically increased in the 
hypoxic group treated with NaHS (3.07±0.32 fold vs. 1.68±0.19 fold in HC, p<0.005). 
Upon treatment with PI3K inhibitors wortmannin and LY294002, the increase in Akt 
activation observed in H300 group was abolished to levels comparable to HC (1.68±0.11 
and 1.61±0.27 fold respectively vs. 1.68±0.19 in HC, p>0.05). This reduction in Akt 
activation is significant compared to H300 in both groups (p<0.005). 







Figure 6.27 Akt activation (p-Akt/Akt) in the various treatment groups of myocytes.  NC, 
normoxic control; HC, hypoxic control; N100, normoxia+100µM NaHS; H100, hypoxia 
+100µM NaHS; H100+W100, hypoxia+100µM NaHS+100nM wortmannin; H100+LY25, 
hypoxia+100µM NaHS+25µM LY294002. Akt activation was quantified by normalizing 
corresponding p-Akt abundance over that of Akt for each treatment group. Results are 
described as a fold difference over NC. Data are expressed as mean ± S.E.M. (n=3). *p<0.05 
compared to NC. ^^^p<0.005 when compared to HC. ###p<0.005 when compared to H100. 
 
Figure 6.26 Akt activation (p-Akt/Akt) in the various treatment groups of h9c2.  NC, 
normoxic control; HC, hypoxic control; N300, normoxia+300µM NaHS; H300, hypoxia 
+300µM NaHS; H300+W100, hypoxia+300µM NaHS+100nM wortmannin; H300+W200, 
hypoxia+300µM NaHS+200nM wortmannin. Akt activation was quantified by normalizing 
corresponding p-Akt abundance over that of Akt. Results are described as a fold difference 
over NC. Data are expressed as mean ± S.E.M. (n=3). *p<0.05 when compared to NC. 
^p<0.05 when compared to HC. ##p<0.01 when compared to H300. 
 




6.1.4.4 Protein Expression of eNOS  
eNOS expression in the various treatment groups of h9c2 is shown in Figure 6.28. eNOS 
was upregulated in hypoxic groups, with both HC and H300 displaying comparable 
eNOS abundance. Upon treatment with wortmannin, the increase in eNOS was slightly 
reduced in a dose-dependent fashion. Next, eNOS expression was quantified in the 
treatment groups of myocytes and the data obtained is demonstrated in Figure 6.29. As 
shown, eNOS abundance was similar between the various treatment groups which were 
in contrast to that observed for h9c2. 








Figure 6.29 Protein expression of eNOS in the various treatment groups of myocytes.  
NC, normoxic control; HC, hypoxic control; N100, normoxia+100µM NaHS; H100, 
hypoxia+100µM NaHS; H100+W200, hypoxia+100µM NaHS+200nM wortmannin; 
H100+LY25, hypoxia+100µM NaHS+25µM LY294002. eNOS expression was normalized 
to that of loading control α-tubulin in each treatment group. Results are described as a fold 
difference over NC. Data are expressed as mean ± S.E.M. (n=6).  
 
Figure 6.28 Protein expression of eNOS in the various treatment groups of h9c2.  NC, 
normoxic control; HC, hypoxic control; N300, normoxia+300µM NaHS; H300, hypoxia 
+300µM NaHS; H300+W100, hypoxia+300µM NaHS+100nM wortmannin; H300+W200, 
hypoxia+300µM NaHS+200nM wortmannin. eNOS protein expression was normalized to that 
of β-tubulin in each group. Results are described as a fold difference over NC. Data are 
expressed as mean ± S.E.M. (n=6).*p<0.05 when compared to NC. #p<0.05 when compared to 
H300. 
 




6.1.4.5 Protein Expression of p-eNOS 
Expression levels of p-eNOS were next analysed in h9c2. As shown in Figure 6.30, there 
was a significant increase in p-eNOS in both HC and H300 groups (1.53±0.10 and 
1.84±0.21 fold respectively vs. NC; p<0.05). To add on, wortmannin treatment inhibited 
the upregulation seen in H300 to 1.34±0.15 fold in H300+W100 (p<0.01 vs.H300) and 
1.40±0.18 fold in H300+W200 (p<0.01 vs.H300). 
For myocytes, p-eNOS was quantified in the same set of samples used for eNOS 
quantitation and the results are as shown in Figure 6.31. There was a significant increase 
in p-eNOS in groups that underwent hypoxia. p-eNOS was upregulated by 1.72±0.11 fold 
in HC compared to NC (p<0.05). In addition, p-eNOS in H100 was also augmented and 
its expression was significantly enhanced compared to HC (2.55±0.30 fold, p<0.01). 
However, when myocytes were treated with PI3K inhibitors prior to NaHS treatment and 
hypoxia, the levels of p-eNOS was reduced drastically to 1.58±0.13 fold when treated 
with 100nM wortmannin and to 1.44± 0.10 fold when 25µM LY294002 was added. In 
contrast, in both normoxic groups, the levels were comparable to each other, implying 
that NaHS treatment per se did not bring about any changes in the eNOS phosphorylation 
status of the cells. 








Figure 6.31 Protein expression of p-eNOS in the various treatment groups of myocytes.  
NC, normoxic control; HC, hypoxic control; N100, normoxia+100µM NaHS; H100, hypoxia 
+100µM NaHS; H100+W100, hypoxia+100µM NaHS+100nM wortmannin; H100+LY25, 
hypoxia+100µM NaHS+25µM LY294002. p-eNOS expression was normalized to that of α-
tubulin. Results are described as a fold difference over NC. Data are expressed as mean ± 
S.E.M. (n=6). ).*p<0.05 compared to NC. ^^p<0.01 compared to HC. ##p<0.01 compared to 
H100. ###p<0.005 compared to H100. 
 
 
Figure 6.30 Protein expression of p-eNOS in the various treatment groups of h9c2.  
NC, normoxic control; HC, hypoxic control; N300, normoxia+300µM NaHS; H300, 
hypoxia+300µM NaHS; H300+W100, hypoxia+300µM NaHS+100nM wortmannin; 
H300+W200, hypoxia+300µM NaHS+200nM wortmannin. p-eNOS was normalized to that 
of β-tubulin in each group. Results are described as a fold difference over NC. Data are 
expressed as mean ± S.E.M. (n=6).*p<0.05 compared to NC. ##p<0.01 compared to H300. 
 




6.1.4.6 eNOS Activation 
The ratio of p-eNOS/eNOS in h9c2 is shown in Figure 6.32. Since the patterns of eNOS 
and p-eNOS expressions in the various treatment groups were largely similar, this 
translates to the groups having similar ratios of p-eNOS/eNOS, and there was no 
statistical significance between the different groups. 
 As illustrated in Figure 6.33, eNOS activation in myocytes was increased in both HC and 
H100, by 1.70±0.09 and 2.91±0.26 respectively and both were significantly different 
compared to NC (p<0.05). Additionally, when hypoxic cells were treated with 100µM 
NaHS, it greatly elevated p-eNOS/eNOS compared to HC (p<0.01). PI3K inhibitors 
reduced eNOS activation, indicating that the PI3K/Akt pathway is involved in governing 
H2S-mediated increase in eNOS activity. The reduction was observed to be significant 
compared to H100 when 25µM LY294002 was employed (1.47±0.27 fold, .p<0.005). 








Figure 6.33 eNOS activation in the various treatment groups of myocytes.  NC, normoxic 
control; HC, hypoxic control; N100, normoxia+100µM NaHS; H100, hypoxia+100µM 
NaHS; H100+W100, hypoxia+100µM NaHS+100nM wortmannin; H100+LY25, hypoxia+ 
100µM NaHS+25µM LY294002. eNOS activation was quantified by normalizing 
corresponding p-eNOS abundance over that of eNOS for each treatment group. Results are 
described as a fold difference over NC. Data are expressed as mean ± S.E.M. (n=3). *p<0.05 
when compared to NC. ^^p<0.01 when compared to HC. ###p<0.005 when compared to H100. 
 
Figure 6.32 eNOS activation (p-eNOS/eNOS) in the various treatment groups of h9c2.  
NC, normoxic control; HC, hypoxic control; N300, normoxia+300µM NaHS; H300, hypoxia 
+300µM NaHS; H300+W100, hypoxia+300µM NaHS+100nM wortmannin; H300+W200, 
hypoxia+300µM NaHS+200nM wortmannin. eNOS activation was quantified by normalizing 
corresponding p-eNOS abundance over that of eNOS for each treatment group. Results are 
described as a fold difference over NC. Data are expressed as mean ± S.E.M. (n=3).  
 




6.1.4.7 Nitrate/Nitrite Concentration  
Subsequently, the amount of NOx released into the medium of h9c2 treatment groups 
was measured. From Figure 6.34, it is noted that NOx levels were higher in groups that 
underwent the hypoxic insult. For instance, in the hypoxic control, there was an increase 
in NOx concentration from 31.75±5.28µM in NC to 69.29±4.50µM (p<0.01). Upon 
treatment with 300µM NaHS, this increase was further enhanced to 91.64±2.87µM 
(p<0.05 when compared to HC). In H300 groups with wortmannin added, a dose-
dependent decrease in NOx concentration was observed, but this was only significant in 
the group treated with 200nM wortmannin (64.94±4.52µM, p< 0.05 vs. H300). As such, 
from the results, it can be concluded that the PI3K/Akt pathway is involved in H2S-
induced NO production under hypoxic conditions in h9c2. 
NOx concentration was increased in myocytes treated with NaHS prior to hypoxia 
induction as shown in Figure 6.35. This amount was significantly higher than that 
measured in HC (84.16±2.06µM vs. 57.87±2.61µM, p<0.05). Following the addition of 
PI3K inhibitors, NOx concentrations were reduced to 65.86±3.93µM and 61.76±5.56 µM 
in H100+W100 and H100+LY25 groups respectively (p<0.05 compared to H100). 
 








Figure 6.35 NO production in various treatment groups of myocytes. NC, normoxic 
control; HC, hypoxic control; N100, normoxia+100µM NaHS; H100, hypoxia+100µM NaHS; 
H100+W100, hypoxia+100µM NaHS+100nM wortmannin; H100+ LY25, hypoxia+100µM 
NaHS+25µM LY294002. Results are expressed as µM NO produced per 106 cells. Data shown 
are mean ± S.E.M. (n=6). ^p<0.05 when compared to HC. #p<0.05 when compared to H100. 
Figure 6.34 NO production in various treatment groups of h9c2. NC, normoxic control; 
HC, hypoxic control; N300 normoxia+300µM NaHS; H300, hypoxia+300µM NaHS; 
H300+W100, hypoxia+300µM NaHS+100nM wortmannin; H300+W200, hypoxia+300µM 
NaHS+200nM wortmannin. Results are expressed as µM NO produced per 106 cells. Data 
shown are mean± S.E.M. (n=6). **p<0.01 when compared to NC. ^p<0.05 when compared to 
HC. #p<0.05 when compared to H300. 




6.1.5 Protein Expression of HIF-1α 
Now that the involvement of PI3K/Akt pathway has been established, the subsequent step 
would be to ascertain if this pathway lies upstream or downstream of HIF-1α activation.  
When wortmannin was added to h9c2 and subsequently treated with NaHS followed by 
hypoxia, there was a dose-dependent inhibition in the expression of HIF-1α compared to 
H300. HIF-1α expression levels were 1.44±0.07 fold in H300+W100 (p<0.05) and 
1.38±0.06 fold in H300+W200 (p<0.01), in contrast to 1.91±0.16 fold observed in H300. 
The results are as shown in Figure 6.36.  
Similar observations were also made for myocytes (Figure 6.37). It was noted that HIF-
1α was greatly enhanced in cells pre-treated with 100µM NaHS prior to hypoxia insult 
(1.90±0.16 fold vs. 1.33±0.10 fold in HC, p<0.01). Treatment with PI3K inhibitors 
brought about a decrease in this elevation. This reduction was more significant in cells 
treated with LY294002 (1.07±0.14 fold, p<0.005 compared to H300) compared to 
wortmannin (1.52±0.05 fold).  From these data, it can be concluded that HIF-1α lies 
downstream of the PI3K/Akt pathway as inhibition of PI3K prevented HIF-1α activation 
and returned HIF-1α expression levels to that comparable to hypoxic controls. 








Figure 6.37 Protein expression of HIF-1α in the various treatment groups of myocytes.  
NC, normoxic control; HC, hypoxic control; N100, normoxia+100µM NaHS; H100, hypoxia 
+100µM NaHS; H100+W100, hypoxia+100µM NaHS+100nM wortmannin; H100+LY25, 
hypoxia+100µM NaHS+25µM LY294002. HIF-1α was normalized to that of α-tubulin in each 
group. Results are described as a fold difference over NC. Data are expressed as mean ± 
S.E.M. (n=4). ^^p<0.01 compared to HC. ###p<0.005 compared to H100.  
 
Figure 6.36 Protein expression of HIF-1α in the various treatment groups of h9c2.  NC, 
normoxic control; HC, hypoxic control; N300, normoxia+300µM NaHS; H300, hypoxia 
+300µM NaHS; H300+W100, hypoxia+300µM NaHS+100nM wortmannin; H300+W200, 
hypoxia+300µM NaHS+200nM wortmannin. HIF-1α was normalized to that of β-tubulin in 
each group. Results are described as a fold difference over NC. Data are expressed as mean ± 
S.E.M. (n=4). **p<0.01 compared to NC. ^p<0.05 compared to HC. #p<0.05 compared to 
H300. ##p<0.01 compared to H300. 
 





6.2.1 Overview of HIF-1 
During hypoxia, cardiac cells are especially vulnerable as only limited reserves of high-
energy phosphates are maintained (Jennings et al., 1991). Hypoxia may arise in the 
myocardium due to myocardial ischemia after a major coronary artery occlusion or at 
high altitude. The severity and duration of this hypoxic insult will then determine the 
cardiac response to diminished oxygen supply. One of the key players that is mobilized 
under such circumstances is HIF-1 (Chi et al., 2004).  
HIF-1 is a master transcription factor, critical for the cellular response to hypoxia as it 
transactivates numerous genes responsible for cell survival (Semenza, 1998). Under 
conditions of low oxygen levels, HIF-1α is stabilized and translocates into the nucleus 
where it dimerizes with constitutively expressed HIF-1β to form a functional HIF-1 
complex. The paradigm for gene regulation in response to hypoxia involves oxygen 
sensing, followed by a series of signal transduction mechanisms that lead to induction or 
repression of transcription and changes in mRNA stability or the rate of protein 
translation (Bunn et al., 1996). More specifically, HIF-1 is involved in the upregulation 
of genes involved in angiogenesis, glycolytic energy metabolism, cell proliferation and 
survival (Semenza et al., 2006; Semenza et al., 1996).  
Downstream targets of HIF-1 include VEGF, glucose transporters, erythropoietin, and 
iNOS, which was first identified in pulmonary endothelial cells (Palmer et al., 1998). 
Subsequently, the relation between HIF-1 and iNOS was also proven in cardiac cells. 
This was demonstrated by Jung and colleagues who reported that hypoxia ensued in an 




increase in iNOS expression in cardiac myocytes and that HIF-1 is essential for the 
hypoxic regulation of iNOS gene expression (Jung et al., 2000). NO plays a prominent 
role in regulating the cardiovascular system. For instance, iNOS-derived NO contributes 
to vasodilation as well as a decrease in neutrophil adhesion and platelet aggregation in 
cardiac cells subjected to ischemia (Balligand et al., 1993). 
6.2.2 HIF-1 Involvement in NaHS-mediated Cardioprotection 
From the previous study in experiment 3, our results revealed that in the in vivo AMI rat 
model, NaHS consistently stimulated the NO/NOS pathway as depicted by enhanced 
eNOS and iNOS gene and protein expressions, together with elevated NO levels. 
Additionally, NaHS also triggered HIF-1α activation. As such, for this part of the thesis, 
the aim was to elucidate the mechanisms/pathways involved in NaHS-mediated increase 
in NO production observed in ischemic hearts.  
It was earlier hypothesized that NaHS further augmented hypoxia-induced HIF-1α 
activation, which then triggered the activation of downstream target iNOS. The increase 
in iNOS expression will then elevate endogenous NO production, hence justifying the 
increase in NO levels seen in LV and plasma. Furthermore, we also propose the 
involvement of pro-survival PI3K/Akt pathway in this mode of cardioprotection. It is 
suggested that NaHS may trigger the activation of PI3K and subsequently, Akt. Activated 
Akt will then phosphorylate downstream target eNOS, resulting in its activation and 
upregulation to ensue in enhanced NO production.  The increase in NO due to iNOS and 
eNOS will then bring about cardioprotection. 




As such, to test our hypothesis, HIF-1 expression and its transcriptional activity will be 
first assessed, and the subsequent effects on iNOS expressions and NO production will be 
determined. Next, the possible contribution of PI3K/Akt/eNOS pathway to H2S-induced 
cardioprotection will also be explored by determining the expression and activity levels 
of Akt and eNOS. Furthermore, should the PI3K/Akt pathway be implicated in this 
model of cardioprotection, it will be determined if this pro-survival pathway lies up- or 
downstream of HIF-1α.  
This discussion will start off with a rationalization of the hypoxia model selected together 
with the conditions utilized, and a justification of the concentration of NaHS employed. 
Following, the mechanism of NaHS-mediated cardioprotection and signaling pathways 
involved (HIF-1/iNOS and PI3K/Akt/eNOS) will be investigated. 
6.2.3 Optimization of Hypoxia Model and Conditions 
First and foremost, it is imperative that an appropriate hypoxia model was chosen for the 
in vitro cell culture models— h9c2 cardiac myoblast cell line and primary neonatal 
cardiomyocytes. As cardiomyocytes form the bulk of heart tissue, both models have been 
widely adopted in the study of diseases pertaining to the heart (Hakim et al., 2009; Singla 
et al., 2008; Bolshakova, 2008; Sekine et al., 2008; Yano et al., 2007; Crawford et al., 
2003; Bharadwaj et al., 2002). H9c2 underwent hypoxia stimulation by three of the most 
commonly used hypoxia models— (i) hypoxic chamber and treatment with hypoxia 
mimetics (ii) CoCl2 and (iii) DFX. These three models induce hypoxia via different 
mechanisms. Firstly, physical hypoxia was induced by equilibrating cells in a low oxygen 
environment in a hypoxic chamber. In cardiomyocytes, physical hypoxia-induced 




apoptosis is mainly mediated through a mitochondria-dependent apoptotic pathway, 
involving the release of cytochrome c and is tightly regulated by apoptotic-related 
proteins such as Bcl-2 and Bax (Shu et al., 2008). CoCl2 and iron chelator DFX in turn 
mimic hypoxia by stimulating HIF-1α stabilization and disrupting the association of 
molecular oxygen to heme-containing PHDs, a family of enzymes that play a key role in 
oxygen dependent degradation of HIF-1α (Wang et al., 1993b; Wang et al., 1993a). This 
limits prolyl hydroxylation and the subsequent degradation of HIF-1α, resulting in a well-
characterized ‘hypoxia-mimetic’ effect (Epstein et al., 2001; Bruick et al., 2001). 
Our findings uncovered that h9c2 responds best to hypoxia induction with CoCl2 which 
led to a significant portion of the cells dying. In contrast, both DFX and hypoxic chamber 
were shown to be less effective in causing cell death. CoCl2 has been employed 
extensively in the study of events and mechanisms underlying cellular death during 
hypoxia/ischemia conditions (Chen et al., 2009b; Jung et al., 2008; Montopoli et al., 
2007; Triantafyllou et al., 2006). As such, CoCl2 thus serves as a well-established and 
convenient model in the study of hypoxic cell damage (Jung et al., 2008). After 
identifying CoCl2 as the most suited hypoxia model, the next step would be to determine 
an optimal CoCl2 concentration to simulate hypoxia, which we identified to be 200µM 
after performing a series of dose-dependent experiments. 
Following, the duration of hypoxia was verified. H9c2 were treated with 200µM CoCl2 
for varying lengths and the percentage of cell death at the end of the experiments was 
examined. At the 24h hypoxia time-point, cell viability was significantly lowered when 
compared to normoxic controls. Hence, it was decided that the cells were to be incubated 
with 200µM CoCl2 for 24h for the induction of hypoxia. On the other hand, 




cardiomyocytes which are more sensitive to external stimuli were incubated with 200µM 
CoCl2 (to maintain consistency with h9c2) for 1h to induce hypoxia (Xu et al., 2008). 
6.2.4 Determination of NaHS Concentration 
After establishing the hypoxia conditions, the cells were pre-treated for an hour with 
various concentrations of NaHS to determine the most favorable concentration to use.  
The 1h pre-treatment is necessary as it allows the drug to be sufficiently taken up by the 
cells such that it can manifest its maximal protective effects when the cells are 
subsequently exposed to hypoxia. Our findings demonstrated that there is a 
concentration-dependent increase in cell viability when h9c2 was pre-treated with NaHS 
from 30µM to 300µM. Cell viability was significantly improved when 300µM NaHS was 
administered. On the other hand, higher NaHS doses noticeably reduced the cell viability, 
possibly due to high toxicity of NaHS at these concentrations. Hence, it was decided to 
treat h9c2 with 300µM NaHS. Due to the high cost and complexity in isolating 
cardiomyocytes, 100µM NaHS was chosen as the effective concentration to administer to 
cardiomyocytes based on existing literature (Pan et al., 2006).  
6.2.5 Cell Viabilities of H9c2 and Cardiomyocytes after Hypoxia 
Numerous studies have demonstrated the association and/or causation between the death 
of myocytes and progression of heart diseases, such as heart failure and MI in both 
human and animal models (Chen et al., 2009a; Hakim et al., 2009; Jin et al., 2009; Pyo et 
al., 2008; Iliodromitis et al., 2007; Krijnen et al., 2007; Haunstetter et al., 1998). As 
hypoxia is the key initiator to ensue in the loss of cardiomyocytes, arresting hypoxia-
mediated cell death may hence limit or even prevent the occurrence and progression of 




heart failure.  Thus, therapeutic strategies aimed at thwarting or minimizing hypoxia-
mediated cell death may be a reasonable choice for the treatment of these diseases.  
In the present study, cell survival is used as the sole functional indicator to determine if 
the drug of interest, NaHS, is able to successfully preserve cardiac function after hypoxia 
insult. Due to the paramount importance of this functional outcome, cell survival was 
evaluated by three different methods of cell viability/cell damage assays such that the 
results obtained can be validated. Cell survival was quantified using the MTT, LDH and 
Trypan Blue Exclusion assays. All three experiments gave consistent results— (i) cell 
viability was markedly decreased in hypoxic controls compared to normoxic untreated 
cells; (ii) pretreatment with 300µM NaHS (100µM NaHS for myocytes) for 1h prior to 
hypoxia significantly increased cell viability when compared to hypoxic controls; and (iii) 
treating normoxic cells with NaHS did not influence cell survival. This indicates that 
under normal physiological states, NaHS did not exert any deleterious effects on cell 
viability. 
The MTT assay is commonly used to reflect cell viability and is based upon the reduction 
of MTT into formazan pigment. Within the cells, this reaction is largely dependent on 
mitochondrial reductase activity and is coupled to NADPH and NADH-dependent redox 
systems. It is a relatively sensitive assay as alterations in MTT reductase activity are 
detectable even before membrane lysis (Liu et al., 2003). This is reflected in the results of 
this study as the cell viability of h9c2 dropped to approximately 40% of normoxic 
controls after undergoing hypoxia. Treatment with NaHS in turn restored cell viability to 
about 80% of NC. 




As for the second experiment, LDH assay which detects for cellular damage rather than 
cell viability is less sensitive than the former assay as the cells would have to be more 
severely damaged for LDH to escape through the leaky plasma membrane during cell 
lysis. Taking into consideration that CoCl2 was used to induce hypoxia in this study, the 
amount of LDH released during the hypoxic insult may have been potentiated as Marti 
reported that CoCl2 is capable of increasing intracellular LDH activity (Marti et al., 1994). 
This, coupled with the loss of membrane integrity during hypoxia-induced cell death may 
explain for the high LDH release in the cell medium. From the data, it is noted that LDH 
release was increased following hypoxic simulation by almost two fold. NaHS treatment 
in turn returned this to levels comparable to normoxic controls. 
The Trypan Blue dye is used to distinguish between live and dead cells. This method of 
cell viability detection has low sensitivity and is based on the principle that viable cells 
have intact membranes which can exclude the dye. On the contrary, cells undergoing 
either apoptosis or necrosis have compromised membrane integrity, and as such, they are 
able to take up the dye. For h9c2, our findings revealed that hypoxic controls have 80% 
viable cells, and this was increased to approximately 90% when pretreated with NaHS. 
From the data, this method of quantifying cell viability is evidently less sensitive as it 
samples only a portion of the cells compared to the two earlier assays. Likewise in 
cardiomyocytes, viability dropped to ~75% in myocytes that sustained the hypoxia insult 
and was markedly higher when pre-treated with 100µM NaHS. Therefore, these three 
assays which evaluate a common end-point provide convincing evidence that NaHS at 
our chosen dose is capable of mitigating cellular damage in the face of hypoxia, and 
confers protection in both our cardiac cell culture models. 




6.2.6 Effect of NaHS on HIF-1α Protein and Gene Expressions 
It is well-established that oxygen homeostasis represents a fundamental physiological 
process, requiring the coordinated regulation of an extensive array of genes, and 
deprivation of oxygen is a serious biological stress that compromises cell survival. In 
most cell types, transcription factor HIF-1 governs the expression of a wide range of 
hypoxia-sensitive genes in response to reduced oxygen tension. Much of the 
programmatic response directed by HIF-1 is involved in protecting cells against hypoxia, 
ischemic stress or injury. It is well established that HIF-1 activation and the upregulation 
of its target genes function to promote cell survival and restore tissue homeostasis under 
hypoxic conditions (Semenza, 2006).  
Findings from this study indicated that NaHS significantly enhanced the increase in HIF-
1α protein expression observed in hypoxic controls for both h9c2 and myocytes. This 
result is in agreement with that from the earlier in vivo study, which too demonstrated 
that NaHS can further elevate hypoxia-induced HIF-1α protein expression in MI rats. The 
increase in HIF-1α may hence bring about cardioprotection as demonstrated in earlier 
studies. Using rabbit MI/R models, isoflurane mediated the increase in HIF-1α, which 
then led to a reduction in infarct size and lowering of creatine kinase concentrations, thus 
conferring cardioprotection in the ischemic hearts (Raphael et al., 2008). Date and 
colleagues also reported that constitutive expression of HIF-1α effectively protected rat 
cardiomyocytes against ischemia injury (Date et al., 2005). Thus, this evidence supports 
our findings that the enhancement of HIF-1α expression by NaHS can ensue in 
cardioprotection. 




In addition, the upregulation of HIF-1α occurred at the post-transcriptional level as there 
was no change in HIF-1α gene expressions between the various treatment groups in both 
in vitro models. Similar observations were also made by other groups. Using h9c2, 
Bharadwaj reported that HIF-1α mRNA levels were similar between normoxic and 
hypoxic cells (Bharadwaj et al., 2002). This trend was not only limited to the 
cardiovascular system, as it was noted that mRNA transcript levels of HIF-1α remained 
unchanged after treatment and/or hypoxia in microglia too (Hwang et al., 2008a; Li et al., 
2008c; Lu et al., 2006). The metabolic turnover rates of proteins (ie. translation versus 
degradation rates) and their corresponding mRNAs (transcription versus degradation) do 
not necessarily change in concert, and are perhaps separately regulated depending on 
different stress conditions or signaling pathways (Gegelashvili et al., 1997). This may 
serve to explain the disparity observed in the results between gene and protein 
expressions.  
6.2.7 Effect of NaHS on HIF-1α Transcriptional Activity 
It was published that during hypoxia, both HIF-1α protein level and the activity of the 
HIF-1α transactivation domains increase (Jiang et al., 1996; Huang et al., 1996). As a 
consequence, we next went on to determine the transcriptional activity of HIF-1α in both 
h9c2 and myocytes. During hypoxia, limited oxygen levels prevented the activation of 
PHDs which require the presence of oxygen to hydroxylate HIF. Upon hydroxylation, 
HIF is subsequently ubiquitinated and degraded. As such, for the duration of hypoxia, 
HIF-1α is stabilized in the cytoplasm and its activation results in its translocation into the 
nucleus. NaHS potentiated this effect, as it was noted that in the nuclear extract, there 
was a further increase in HIF protein levels when compared to hypoxic controls. In the 




cytoplasmic fraction, inactivation of PHDs during hypoxia allows for HIF-1α 
accumulation and consequently, HIF-1α was increased in a similar fashion as that in the 
nucleus.  
This outcome was further ascertained by an increase in binding of transcription factor 
HIF to DNA in the nucleus of hypoxic cells. This binding was more pronounced when 
cells were pretreated with NaHS, enhancing the triggering of downstream 
cardioprotective genes such as iNOS to bring about beneficial effects in the ischemic 
heart. Hence, our study provided the first piece of evidence that NaHS mediated 
cardioprotection by increasing both HIF-1α expression and transcriptional activity. 
6.2.8 Effect of NaHS on iNOS Expressions and NO Production 
Stimulation of HIF-1 transcriptional activity promotes the activation of a wide range of 
downstream targets that may assist the cells in adapting to the hypoxic environment. In 
the heart, HIF participates in the induction of cardioprotective genes such as iNOS, heme 
oxygenase 1 and adrenomedullin which promote cell survival. Additionally, genes that 
improve oxygen-independent energy supply such as glucose transporter 1 and hexokinase 
2, or stimulate blood supply such as VEGF and erythropoietin may also be upregulated 
(Dendorfer et al., 2005). 
The possibility of iNOS as a downstream target of HIF-1 in the myocardium has been 
noted in several publications (Natarajan et al., 2006; Xi et al., 2004; Xi et al., 1999). 
Using a non-pharmacological approach, silencing of PHD2 which hydroxylates HIF-1α 
produced a time and concentration-dependent (i) stabilization of HIF-1α protein, (ii) 
increase in HIF-1 transcriptional activity and (iii) upregulation of iNOS mRNA steady-




state levels. This provides a straightforward evidence that iNOS is a HIF-1 driven gene. 
In the pioneer study by Jung and colleagues, it was reported that during hypoxia, the 
increased expression of HIF-1 ensued in the transcriptional activation of iNOS gene 
expression in myocardial cells (Jung et al., 2000). Hence, this demonstrated a specific 
mechanism for hypoxia-induced HIF-mediated iNOS expression in myocytes. However, 
in their study, the role(s) which NO played under conditions of low oxygen tension was 
not clarified. Nonetheless, it was suggested that iNOS is implicated in the late phase of 
ischemic and pharmacologic cardiac preconditioning (Xi et al., 1999). Subsequently, 
Date and colleagues showed that HIF-1 participated in the development of late-phase 
preconditioning in neonatal cardiomyocytes by inducing multiple protective genes such 
as VEGF, Glut-1, Glut-4, Hsp70 and iNOS (Date et al., 2005).  
In our study, hypoxia resulted in simultaneous peaks in HIF-1α protein and iNOS mRNA 
levels in both h9c2 and cardiomyocytes. These data were in line with an earlier study 
performed (Jung et al., 2000). Moreover, NaHS treatment further enhanced iNOS gene 
upregulation observed in hypoxic controls. The increase in iNOS gene transcripts was 
translated to an increase at the protein level. Next, when NO production was quantified, 
hypoxic cells had a noticeable increase in NO levels. Upon treatment with NaHS prior to 
the hypoxia insult, NO levels were further augmented. The data obtained for NO 
production is consistent with that of iNOS protein expression. Our results are in 
agreement with a study performed by Kitakaze, who demonstrated an increase in NO 
production when cardiac myocytes were exposed to short term hypoxia (Kitakaze et al., 
1995). However, this group did not address the mechanism, nor identify the NOS 
isoforms behind this increase.  




6.2.9 Involvement of PI3K/Akt Pathway in NaHS-mediated Cardioprotection 
A range of signaling molecules, including PI3K/Akt, extracellular signal-regulated kinase 
(ERK) and p38 mitogen-activated protein kinase (MAPK) are activated in response to 
hypoxia and mediate the stabilization of HIF-1α activation (Ryter et al., 2002; Lee et al., 
2000; Otterbein et al., 2000). Although it has not been demonstrated in the cardiovascular 
system, it is well documented that hypoxia induces iNOS expression through PI3K/Akt 
pathway and HIF-1α activation in the microglia (Hwang et al., 2008b; Lu et al., 2006).  
As a result, we next set out to investigate the possible involvement of this pathway in our 
model of cardioprotection.  
PI3K dependent signaling cascade is a ubiquitous pathway implicated in a wide range of 
physiological functions such as cell growth, proliferation, survival, migration and 
metabolism. In the myocardium, PI3K pathway exerts cardioprotection by activating key 
proteins including Akt, which prevents apoptosis induced by a multitude of pathological 
insults such as ischemia or hypoxia (Rubio et al., 2009). Findings in this study also 
showed that hypoxia activated Akt, exemplified by an increase in phosphorylated Akt 
levels and the ratio of p-Akt/Akt. These were further enhanced when the cells were pre-
treated with NaHS. PI3K activation is beneficial to the ischemic heart as it antagonized 
apoptosis in several cardiac cell types, including cardiomyocytes, cardiac fibroblast, 
VSMCs and endothelial cells by the modulation of Bax, caspase-3 and Forkhead 
transcription factors (Oudit et al., 2004). Consequently, activation of this pathway results 
in cardiomyocyte survival, ventricular remodeling and myocardial proliferation (Tsujita 
et al., 2006; Gude et al., 2006; Shiraishi et al., 2004). 




Furthermore, it is well-documented that one of the downstream targets of the PI3K/Akt 
pathway is eNOS (Namkoong et al., 2009; Liu et al., 2008; Zheng et al., 2008; Satake et 
al., 2008; Hashimoto et al., 2006; Bell et al., 2003). As such, the next step would be to 
assess if activation of Akt brought about any signal transduction to modulate eNOS 
activity. During hypoxia, eNOS expression was upregulated in h9c2 by a PI3K-
dependent mechanism. In contrast, eNOS levels were unaffected in cardiomyocytes. This 
dissimilarity may be partially explained by the difference in models (cell line vs. primary 
culture), as well as duration of hypoxia exposure (24h vs. 1h). When the abundance of 
phosphorylated eNOS was sought, it was determined to correlate with Akt activity. This 
is in agreement with an earlier report, which showed that wortmannin nullified the 
increase in p-eNOS expression while not affecting eNOS levels in an 
ischemic/reperfusion cardiomyocyte model (Li et al., 2008a). 
Our results revealed similar peaks between Akt activity and p-eNOS, implying that Akt 
was the kinase responsible for phosphorylating eNOS. Hypoxia stimulated an increase in 
eNOS phosphorylation, which was further enhanced with NaHS treatment. This 
escalation was PI3K dependent, as PI3K inhibitors attenuated this increase in a dose-
dependent manner. In summary, this, together with the seamless correlation with Akt 
activity, provides two convincing pieces of evidence that eNOS is a direct downstream 
target of PI3K/Akt cascade in NaHS-induced cardioprotection. 
NO production changed in tandem with eNOS activity, with hypoxic cells having higher 
NO levels. As NaHS promoted the activities of iNOS (via HIF-1α) and eNOS (via Akt), 
cells treated with this drug had the highest NO concentrations. The production of NO was 
verified to be dependent on the PI3K/eNOS signaling cascade, as there was a dose-




dependent reduction in NO synthesis when PI3K inhibitors were employed. However, in 
these groups, NO levels were still higher compared to hypoxic controls as the HIF-
1α/iNOS pathway also contributed partially to NaHS-mediated increase in NO 
biosynthesis. 
6.2.10 PI3K Lies Upstream of HIF-1α Signaling  
After establishing that both HIF-1α/iNOS and PI3K/Akt/eNOS pathways are involved in 
NaHS-mediated cardioprotection, the next logical step would be to resolve if HIF-1α lies 
upstream or below the PI3K/Akt pathway. Several studies have been designed to 
determine this, but were mostly carried out on neuronal systems. Hwang and co-workers 
reported that PI3K inhibitors wortmannin and LY294002, which were also utilized in our 
study, could successfully attenuate the increase in hypoxia-mediated HIF-1α in BV2 
microglia. This study hence provides evidence that HIF-1α lies below the PI3K/Akt 
cascade (Hwang et al., 2008b). In a separate study by Lu who also worked on microglia, 
it was shown that PI3K/Akt/mTOR signaling pathway is obligatory for the enhanced 
expression of HIF-1α and iNOS provoked by hypoxia, once again providing evidence 
that HIF-1α lies below PI3K in the signaling pathway (Lu et al., 2006). 
To date, no study has reported on the relationship between HIF-1α and PI3K/Akt 
signaling in the cardiovascular system. We are the first to do so. Our findings showed 
that the increase in HIF-1α observed in NaHS + hypoxia group was attenuated when 
either wortmannin or LY294002 was applied. This thus supports the notion that 
PI3K/Akt signaling pathway lies upstream of HIF-1, similar to that noted in microglia by 




other groups, as inhibition of PI3K prevented the upregulation of HIF which lies 
downstream of this cardioprotective pathway.  
HIF-1α induction brought about by stimulating PI3K/Akt is solely due to an increment in 
HIF-1α protein synthesis, and not related to an increase in steady-state HIF-1α mRNA 
level. Therefore, PI3K regulates HIF-1α mainly by altering either the stability of the HIF-
1α protein, or the efficiency of HIF-1α mRNA translation. Although not investigated in 
the present study, existing literature favors the former hypothesis. A study by Zundel 
offered convincing evidence that Akt stabilized HIF-1α, and that this is regulated by the 
proteasomal degradation pathway (Zundel et al., 2000). Furthermore, PI3K signaling was 
shown to target the 5’-untranslated region of HIF-1α mRNA which regulates HIF-1α 
translation (Laughner et al., 2001). However, this regulatory mechanism may differ under 
different experimental conditions (Kim et al., 2002).  
6.2.11 Summary of Findings for Experimental Protocol 4 
Taken together, the present study offers some answers to the mechanisms governing 
NaHS-mediated cardioprotection in AMI rats as observed earlier (in experiment 3). 
NaHS enhanced HIF-1α activation, which subsequently led to the upregulation of one of 
its downstream targets, iNOS. The increase in iNOS expression was then accompanied by 
an elevation in NO production. Similar observations were noted in both h9c2 cardiac 
myoblast and primary cardiomyocytes.  Moreover, the involvement of PI3K/Akt pathway 
was implicated in this mode of cardioprotection. During hypoxia, Akt activity was 
stimulated and it phosphorylated one of its downstream target genes, eNOS to yield an 
increase in its activity. NaHS potentiated this effect. The increase in eNOS was 




accompanied by an upregulation of PI3K-dependent NO synthesis. Furthermore, the 
findings in this study suggest that PI3K/Akt pathway acts upstream of HIF-1α by 
stabilizing its expression. Further clarification on the involvement of other HIF-1 
downstream targets (i.e. HO-1, VEGF), and the participation of additional signaling 
pathways (i.e Erk1/2 or JNK) remain a subject for further investigation. This may then 
contribute to a more complete understanding of the mechanisms governing H2S-mediated 
cardioprotection.














SUMMARY OF CONTRIBUTIONS  
&  
FUTURE DIRECTIONS 




7.1 Summary of Contributions 
The findings presented in this thesis provide substantial evidence for the cardioprotective 
roles of both endogenous gasotransmitters H2S and NO during MI. There was an 
attenuation of infarct size, amelioration of ventricular hypertrophy and a general 
improvement in survival when exogenous donors of these gasotransmitters were given. 
On the contrary, when endogenous synthesis of H2S and NO were blocked using PAG 
and L-NAME respectively, it aggravated the pathological situation in MI. 
The protection mediated was not only limited to classical and well-established donors of 
the gasotransmitters. To illustrate, in addition to the conventional H2S donor NaHS, it 
was demonstrated that novel H2S donor SAC also mediated cardioprotection. This may 
prove to be useful as SAC is an organosulfur-containing bioactive component of garlic, 
and as such, may be well-suited to serve as an adjuvant therapy to complement the 
primary treatment of MI. Corresponding to conventional NO donor molsidomine used 
clinically to treat MI patients, PDE-5 inhibitor sildenafil was shown to bring about 
cardioprotective benefits by prolonging cGMP action. Moreover, sildenafil may be 
proposed to be a novel NO donor as it stimulated the NO/NOS pathway by increasing 
protein expressions of NOS isoforms which enhanced NO production.  
As the relationship between H2S and NO has been demonstrated in several other models, 
the next objective of this thesis was to examine for possible interactions between these 
two gases in the context of MI. Our findings revealed that crosstalk is evident between 
H2S and NO. Firstly, exogenous H2S consistently stimulated NO/NOS pathway in the 
hearts of MI rats, supporting a synergistic relationship between the two gases. This was 




not limited to only NaHS, as SAC, the proposed novel H2S donor can also upregulate NO 
levels in the injured myocardium. Classical NO donor molsidomine can in turn bring 
about a slight increase in LV H2S production. Analogously, sildenafil also enhanced H2S 
production in the LV and increased plasma H2S concentration. Hence, a synergistic 
relationship between the two gasotransmitters is apparent when an exogenous source of 
the gas is introduced. 
On the contrary, the blockade of endogenous production of either gasotransmitter 
stimulated the other member’s production. To illustrate, PAG made up for the lack of 
H2S by stimulating NOS expressions to produce more NO. Likewise, when NO 
production was blocked by L-NAME, there was a corresponding increase in CSE 
expression to trigger more H2S production. As opposed to the observations made 
regarding the gaseous donors, this evidence thus support a modulatory relationship 
between H2S and NO when their inhibitors were employed. 
Due to the conflicting observations made when either donors or inhibitors were used, it 
would be imperative to individually explore the mechanisms/signaling pathways 
governing each of the interactions noted. This task would be exceedingly overwhelming 
if all interactions identified were examined for this thesis. As a consequence, the 
interplay between H2S and NO that gave the most promising data (NaHS persistently 
stimulated NO/NOS pathway with NO production) was selected for further investigation. 
From our findings, NaHS mediated cardioprotection through the HIF-1 signaling 
pathway with subsequent activation of iNOS. Additionally, it is conjectured that pro-
survival PI3K/Akt pathway participates to trigger the activation of downstream target 




eNOS. Both iNOS and eNOS stimulation may then account for the increase in NO levels 
observed in NaHS-mediated cardioprotection. 
More specifically, key contributions of this thesis include: 
1. SAC, a key bioactive constituent of garlic, served as a novel CSE substrate to 
increase H2S production, hence bringing about cardioprotection. It was shown to 
be more effective than NaHS in protecting against MI. Moreover, NO 
involvement was implicated in bringing about beneficial effects in the heart. This 
study is the first to offer an alternative mechanism in addition to the well-
established antioxidative roles of SAC in mediating cardioprotection during MI. 
 
2. Sildenafil exerted its cardioprotection via a NO-related pathway. For the first time, 
we reported that sildenafil could also upregulate nNOS protein (in addition to 
both eNOS and nNOS) to bring about cardiac benefits. More importantly, this 
study demonstrates the novel finding that sildenafil is capable of increasing H2S 
production to further confer cardioprotection. 
 
3. The interaction between H2S and NO is evident from our study. However, it 
appears that this crosstalk is differentially regulated when different 
pharmacological interventions were applied. Exogenous donors of H2S and NO 
seem to favor a synergistic relationship between the two gases. On the other hand, 
studies involving inhibitors of H2S/NO production suggest a modulatory 
relationship between the two molecules. 
 




4. The mechanism of NaHS-mediated cardioprotection was also elucidated. This 
involves the participation of the HIF-1/iNOS and PI3K/Akt pathways. 
Additionally, it was demonstrated that PI3K lies upstream of HIF-1 in NaHS-
mediated protection in myocardial cells.  
 
In conclusion, the observations made in this study contribute to the current knowledge on 
the roles and relationship of H2S and NO in myocardial infarction. Having identified one 
of the mechanisms which NaHS confers its beneficial effects in the heart, this may offer a 
potential therapeutic strategy in the treatment of MI. 
7.2 Future Directions 
The current study has provided new information on the roles of H2S and NO in a non-
reperfused model of MI. The interplay between H2S and NO in this disease state was also 
addressed to reveal that exogenous donors of these gases stimulated the biosynthesis of 
the other. To add on, the pathway for NaHS-mediated cardioprotection was also 
identified in this study. It was demonstrated that during MI, NaHS enhanced HIF-1α 
activation to bring about an upregulation of iNOS. Moreover, this cardioprotection 
involved the pro-survival PI3K pathway, which was shown to trigger downstream eNOS 
phosphorylation. Consequently, the stimulation of iNOS and eNOS brought about an 
increase in NO production. This pathway is illustrated below in Figure 7.1. 
However, this is only one of the several signaling mechanisms believed to be implicated 
in the interplay between H2S and NO during MI. Although several other evidence of 
crosstalk between H2S and NO has been identified in Chapter 5, it is beyond the scope of 
the current project to examine them all, and hence, may be the subject of future research. 




Furthermore, in addition to the PI3K/Akt pathway, several other pro-survival signaling 
mechanisms such as the MAPK, Erk1/2 and JNK pathways have been implicated in HIF-
1α activation during ischemic conditions in other disease states such as stroke. It is 
worthwhile to look into the involvement of these pathways in MI. Additionally, as the 
mechanism governing NaHS-mediated cardioprotection was only elucidated in in vitro 
studies, it can be considered to further this investigation in in vivo MI animal models. 
This would provide more information on functional outcomes such as cardiac functions, 
survival and infarct size which would bear more meaningful clinical implications.  
 
Figure 7.1 Schematic diagram illustrating the mechanism of NaHS-mediated 
cardioprotection during MI. NaHS enhances hypoxia-mediated stabilization and 
activation of HIF-1 which activates its downstream target iNOS. Additionally, this 
signaling mechanism involves the participation of pro-survival PI3K/Akt pathway, 
resulting in the concomitant activation of downstream eNOS. The upregulation of both 
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